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Die Nager […] sind […] höchst merkwürdig gebildet. Scharfes, aber geringes Erfassen, 
eilige Sättigung, auch nachher wiederholtes Abraspeln der Gegenstände, fortgesetztes, 
fast leidenschaftliches, absichtslos zerstörendes Knuspern, welches dann wieder in den 
Zweck, sich Lager und Wohnungen aufzubauen und einzurichten, unmittelbar eingreift 
und sich dadurch abermals bewährt: daß im organischen Leben selbst das Unnütze, ja 
das Schädliche selbst, in den notwendigen Kreis des Daseyns aufgenommen, ins Ganze 
zu wirken und als wesentliches Bindemittel disperater Einzelheiten gefordert wird. 
– Johann Wolfgang von Goethe: Die Skelette der Nagetiere – 
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1. Introduction and objectives 
Colorectal cancer constitutes a major cause of tumor-related morbidity and mortality in 
the industrialized world (Parkin et al., 2005; World Cancer Research Fund, 2007). To 
our current understanding, colorectal cancer develops from adenomatous precursor 
lesions by a multistep progress that involves multiple independent mutational events in 
oncogenes and tumor suppressor genes (Arnold et al., 2005; Fearon, 2011). In most 
cases of sporadic colon cancers, one allele of certain tumor suppressor genes becomes 
inactivated by loss of specific chromosomal regions (“loss of heterozygosity”, LOH), 
with particularly high frequencies on chromosome 17p (p53), 18q (DCC, SMAD4, 
SMAD2) and 5q (APC) (Fearon and Vogelstein, 1990; Arnold et al., 2005; Fearon, 
2011). The acquirement of an inactivating somatic mutation in the remaining wildtype 
allele promotes tumor development due to perturbation of critical signaling pathways 
controlling cellular metabolism, proliferation, differentiation; and survival (Fearon, 
2011; Hanahan and Weinberg, 2011).  
Previously, down-regulated by oncogenes 1 (DRO1) was noted to be down-regulated 
after neoplastic transformation of RK3E cells, in various colorectal and pancreatic 
cancer cell lines, in several primary colorectal cancer specimens (Bommer et al., 2005) 
and in thyroid neoplastic cell lines and tissues (Visconti et al., 2003). Moreover, re-
expression of DRO1 in several cancer cell lines reduced both colony formation and 
anchorage-independent growth (Bommer et al., 2005), and induced sensitization to 
various apoptotic stimuli (Bommer et al., 2005; Ferragud et al., 2011). Thus, DRO1 was 
proposed to be a putative tumor suppressor gene (Bommer et al., 2005). 
 
Obesity, characterized by excessive body fat accumulation, is known to be a major risk 
factor for the development of cardiovascular and metabolic disease (WHO, 2011). 
According to the WHO, obesity is a worldwide epidemic (WHO, 2011). White adipose 
tissue functions as an endocrine organ, secreting a variety of hormones and cytokines, 
so called adipokines, implicated in energy homeostasis and body weight regulation 
(Vazquez-Vela et al., 2008; Singla et al., 2010). Dysregulated production of adipokines, 
as in obesity, leads to the disruption of whole-body energy homeostasis and contributes 
to the development of metabolic disorders (Ailhaud et al., 2006; Ahima and Osei, 
2008). 
DRO1/Dro1 is known to be ubiquitously expressed, with highest levels in white adipose 
tissue (Aoki et al., 2002; Liu et al., 2004; Bommer et al., 2005; Okada et al., 2008; 
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Tremblay et al., 2009). Dro1 expression was also substantially decreased in epididymal 
white adipose tissue of several obese mouse models (Okada et al., 2008). Recent in 
vitro studies reported Dro1 to be a novel adipocyte-secreted protein that modulates 
adipocyte differentiation (Tremblay et al., 2009), a process involved in adipose tissue 
expansion (Hausman et al., 2001; Guilherme et al., 2008;).  
 
The aim of the present study was to elucidate the effects of Dro1 loss on colorectal 
carcinogenesis and body growth in vivo. We therefore generated the first constitutive 
Dro1 knockout mouse model (Dro1
-/-
) using a Cre/loxP strategy. To investigate the 
effect of Dro1 loss on colorectal tumorigenesis, Dro1
-/-
 mice were crossed into the 
Apc
+/Min
 background, a well established intestinal tumor mouse model (Moser et al., 
1990). Body weight, total body fat, lean mass, longitudinal growth, organ and fat pad 
weight as well as glucose and lipid metabolism were investigated under normal diet 
conditions and when maintained on a high-fat diet to evaluate a possible involvement in 
body growth. Moreover, the differentiation potential of primary mouse Dro1
-/-
 
preadipocytes was assessed in vitro to clarify the role of Dro1 in adipogenesis.
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2. Review of the literature 
2.1 Down-regulated by oncogenes 1 (DRO1/Dro1) 
2.1.1 Overview 
DRO1, also named, steroid-sensitive gene 1 (SSG1), up-regulated in bombesian receptor 
subtype 3 knockout mouse (URB), coiled-coil domain containing 80 (Ccdc80), CL2 and 
Equarin-L was first described in 2001 and to date is characterized in man, mouse, rat, 
chicken and Xenopus (Marcantonio et al., 2001; Aoki et al., 2002; Mu et al., 2003; 
Visconti et al., 2003; Bommer et al., 2005; Tremblay et al., 2009). Mouse Dro1 
comprises 57.744 bp and is encoded by 8 exons (Bommer et al., 2005; 
http://genome.ucsc.edu/). The start codon is located on exon 2 that also encodes most of 
the protein mass (http://genome.ucsc.edu/). DRO1/Dro1 was found to be ubiquitously 
expressed, with highest levels in white adipose tissue (Aoki et al., 2002; Liu et al., 
2004; Bommer et al, 2005; Okada et al., 2008; Tremblay et al., 2009). In chicken and 
man, two alternatively spliced transcripts were identified (Mu et al., 2003, Bommer et 
al., 2005; Cha et al., 2005; Trembay et al., 2009). Mouse DRO1 features a single long 
open reading frame of 949 amino acids, with an apparent molecular mass of 108 kDa 
(Mu et al., 2003; Liu et al., 2004; Bommer et al., 2005). Mouse, rat, chicken and human 
DRO1 show pronounced sequential and structural similarities (Mu et al., 2003; Liu et 
al., 2004; Bommer et al., 2005; Tremblay et al., 2009). The amino acid sequence 
exhibits 3 internal repeats which represent the most highly conserved (93 to 97%) 
regions between mouse, rat, chicken and man (Aoki et al., 2002; Liu et al., 2004; 
Bommer et al., 2005; Tremblay et al., 2009). Moreover, it shows homology to the 
putative tumor suppressor sushi repeat-containing protein, X chromosome (SRPX) 
(Aoki et al., 2002; Visconti et. al., 2003; Liu et al., 2004; Bommer et al., 2005; 
Tremblay et al., 2009). Within the cell, DRO1 was found to be located in the cytosol 
(Marcantonio et al., 2001; Bommer et al., 2005), the nucleus/nucleolus (Visconti et. al., 
2003), the Golgi apparatus and at the cytoplasmic membrane (Ferragud et al., 2011). A 
hydrophobic N-terminal signal peptide suggests DRO1 to be a secretory protein (Mu et 
al., 2003; Visconti et al., 2003; Liu et al., 2004; Bommer et al., 2005). Secretion of full-
length forms as well as cleaved fragments was reported for adipose tissue-derived 
stromal cells (Okada et al., 2008) and several cell lines ectopically expressing 
DRO1/Dro1, namely 3T3-L1 fully differentiated adipocytes (Tremblay et al., 2009), 
COS7 (Liu et al., 2004), Flp293 (Okada et al., 2008) and MCF-7-TetOn cells (Ferragud 
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et al., 2011). By contrast, it was not detected to be a secretory protein in transfected 
HEK293T and COS cells (Bommer et al., 2005). In vivo DRO1 was identified to be a 
secreted cartilage protein since it localized to the extracellular matrix of post-natal 
mouse femoral head cartilage (Wilson et al., 2011), the hyperthrophic cartilage region 
of facial, axial and appendicular developing mouse skeleton (Liu et al., 2004) and 
mouse embryonic rib cartilage (Manabe et al., 2008). 
In rat mammary tissue Dro1 expression was identified to be tightly regulated by 
estrogen and it was proposed that its over-expression is associated with mammary 
carcinogenesis (Marcantonio et al., 2001). High DRO1 expression was shown in human 
bone marrow stromal cells, with a drastically decrease during osteoblastic 
differentiation. As temporal and spatial expression patterns correlate with the timing 
and sites of cartilage development in skeleton element formation in mouse embryos, 
Dro1 was implicated in skeletogenesis (Liu et al., 2004). Consistently, recent findings 
suggest a role for Dro1 within the extracellular matrix during mouse post-natal cartilage 
development prior to bone formation (Wilson et al., 2011). DRO1 was also identified as 
an extracellular matrix component that promotes cell attachment and matrix assembly in 
vitro (Manabe et al., 2008). In chicken eye development Dro1 was demonstrated to be 
expressed in the lens with a high-dorsal-to-low-ventral gradient at the equatorial region 
from the early embryonic stage until the postnatal period (Mu et al., 2002). 
Microinjection of DRO1 mRNAs into 4-8 cell stage Xenopus embryos caused abnormal 
eye formation, thus it was proposed to play an important role in eye development (Mu 
et al., 2002). Dro1 was also implicated in hair development due to the fact that it is 
over-expressed in hair follicle dermal papilla cells as compared to dermal fibroblasts 
(Cha et al., 2005). Furthermore, in hair follicle dermal papilla cells DRO1 expression 
was found to be androgen responsive (Cha et al., 2005). The putative function of DRO1 
in adipose tissue as well as its proposed tumor suppressor gene role are presented in the 
following in more detail.  
 
2.1.2 The putative tumor suppressor role 
DRO1 was found to be down-regulated in RK3E epithelial cells neoplastically 
transformed by β-catenin stabilization as well as by various oncogenes. Also, DRO1 
expression is considerably reduced in several colon and pancreatic cancer cell lines, in 
the majority of primary colorectal cancers samples (Bommer et al., 2005) and in human 
thyroid neoplastic cell lines and tissues (Visconti et al., 2003). DRO1 down-regulation 
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is presumably mediated by transcriptional repression through trans-acting repressors 
binding to the promoter. Recent findings demonstrated down-regulation of DRO1 by 
amplified in breast cancer 1 (AIB1) (Ferragud et al., 2011), an oncogene that acts as a 
transcriptional co-activator in the nucleus and is implicated in cancer development 
(Gojis et al., 2010). Furthermore, DRO1 sensitizes cells to different apoptotic stimuli in 
vitro and re-expression in cancer cell lines results in a reduction of their malignant 
growth properties. DRO1 was therefore postulated to be a candidate tumor suppressor 
gene that may play a crucial role in both intestinal tissue homeostasis and 
carcinogenesis (Bommer et al., 2005). Repression of DRO1 by the AIB1 oncogene 
contributes to inhibition of apoptosis, confirming the role of DRO1 in facilitating the 
apoptotic cascade (Ferragud et al., 2011). 
 
2.1.3 Putative functions in adipose tissue 
DRO1/Dro1 is a gene predominantly expressed in white adipose tissue with 
considerably lower levels in other tissues (Aoki et al., 2002; Liu et al., 2004; Bommer 
et al., 2005; Okada et al., 2008; Tremblay et al., 2009). Thus, it was often supposed to 
play important roles in energy storage and metabolism (Aoki et al., 2002; Okada et al., 
2008; Tremblay et al., 2009). In mildly obese bombesin receptor subtype-3 mice, a 
mouse model of obesity and metabolic syndrome, Dro1 was shown to be up-regulated 
in brown adipose tissue and was therefore hypothesized to have a unique function in 
thermogenesis (Aoki et al., 2002). Furthermore, Dro1 expression was demonstrated to 
be down-regulated in epididymal white adipose tissue of several obese mouse models, 
an effect probably induced by obesity-related low-grade inflammation as treatment of 
3T3-L1 adipocytes with insulin, tumor necrosis factor-alpha (TNF-α), H2O2 and 
hypoxia resulted in reduced Dro1 mRNA levels (Okada et al., 2008). In vitro studies 
reported DRO1 to be an adipocyte secreted protein and it was proposed to be a novel 
adipokine, which might influence whole-body energy homeostasis and contribute to 
metabolic disorders in obesity (Okada et al., 2007; Tremblay et al., 2009).  
Recent findings indicate that Dro1 plays an important role during adipogenesis, as Dro1 
knockdown in preadipocyte clonal cells (3T3-L1) significantly impaired their ability to 
differentiate into adipocytes and accumulate lipids. During adipocyte differentiation 
Dro1 was found to be expressed in a biphasic manner. While proliferating 3T3-L1 
preadipocytes show relatively low Dro1 mRNA levels, expression increases 
dramatically when cells reach postconfluency. Dro1 expression is highly reduced during 
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early differentiation but increases again in the late stage of adipocyte differentiation 
(Tremblay et al., 2009). The transition from undifferentiated preadipocytes into lipid-
filled fat cells is hallmarked by a series of transcriptional changes. CCAAT/enhancer 
binding protein alpha (C/EBPα), a basic leucine-region zipper protein and the nuclear 
receptor peroxisome proliferator activated receptor gamma (PPARγ), both master 
regulators of adipogenesis, promote transcription of early adipogenetic genes that are 
required for fatty acid uptake, triglyceride formation and lipid metabolism (Ross et al., 
2000; Vázquez-Vela et al., 2008). It was postulated that DRO1 indirectly induces 
C/EBPα and PPARγ expression by repression of canonical Wnt/ß-catenin signaling 
pathway (Tremblay et al., 2009). 
The canonical Wnt/ß-catenin pathway plays a crucial role during cell proliferation, cell 
differentiation and embryonic development and is considered the predominant regulator 
of adipogenesis (Ross et al., 2000; Bennet et al., 2002; Clevers, 2006). In short, in the 
absence of a Wnt signal, β-catenin becomes phosphorylated by glycogen synthase 
kinase-3 (GSK-3) which results in ubiquitination and subsequent destruction of β-
catenin by the proteasome. Binding of secreted Wnt to the Frizzled-receptor inhibits the 
destruction complex, thus leading to the stabilization and accumulation of β-catenin in 
the cytoplasm and its translocation to the nucleus. Once there, it binds to transcription 
factors of the T-cell factor/lymphoid enhancing factor (TCF/LEF) family, leading to the 
transcriptional activation or repression of target genes (Logan and Nusse et al., 2004; 
Clevers, 2006).  
In 3T3-L1 cells depleted for Dro1 the activity of the Wnt signaling pathway was 
actually increased compared to controls. Interestingly, over-expression of Dro1 also 
impaired adipocyte differentiation by a mechanism that does not influence canonical 
Wnt signaling and which still remains to be determined (Tremblay et al., 2009). This 
phenomenon - inhibition of adipogenesis upon over-expression and knockdown of the 
same gene - is already known for other modulators of adipogenesis (Ross et al., 2000; 
Wang et al., 2006; Cheung et al., 2007).  
 
2.2 Intestine 
2.2.1 Overview 
The intestine comprises two anatomically and functionally distinct segments, the small 
intestine and the large intestine. Both sections share a general structure in the 
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organization of the gut wall constituted by several tissue layers, including, from within 
outwards, the tunica mucosa, tela submucosa, tunica muscularis and tunica serosa. 
The tunica mucosa, adjoining the gut lumen, is subdivided into the lamina epithelialis 
mucosae, composed of a columnar epithelium, lamina propria mucosae, comprising 
connective tissue, vasculature and lymphatic tissue, and lamina muscularis mucosae, 
constituted by a thin smooth muscle layer. To increase the absorbent capacity of the gut, 
the columnar epithelial cells are fitted with microvilli.  
The tela submucosa is represented by connective tissue, blood vessels, nerves and 
vegetative ganglion cells (plexus submucosus). 
Throughout the whole intestine, lymphoid tissue is scattered in the lamina propria 
mucosae and tela submucosa, referred to as the gut-associated lymphatic tissue (GALT). 
The tunica muscularis comprises two smooth muscle layers, a circularly arranged inner 
layer (stratum circulare) and a longitudinally arranged outer layer (stratum 
longitudinale). Between those layers lies a varying amount of connective tissue, 
containing vegetative nerve cells (plexus myentericus). 
The tunica serosa includes a single-layered epithelium and a small amount of 
connective tissue (Hees and Sinowatz, 2000; Hedrich et al., 2004).   
 
2.2.2 Small intestine 
The main function of the small intestine is to digest and reabsorb nutrients with the aid 
of bile from the liver and enzymes from the pancreas. The small intestine is divided into 
three sections, duodenum, jejunum and ileum. In the small intestine the absorbent 
surface is enlarged by alternating fingerlike protrusions (villi) which are composed of 
lamina epithelialis mucosae and lamina propria mucosae. Villi, projecting into the 
intestinal lumen, alternate with invaginations called crypts of Lieberkühn. The length of 
the intestinal villi decreases from the duodenum to the ileum. The lamina epithelialis 
mucosae consists of four differentiated cell types: absorbent epithelial cells, 
representing the predominant cell type, goblet cells, enteroendocrine cells and Paneth 
cells (Hees and Sinowatz, 2000). Goblet cells, named after their characteristic cup-like 
shape, are exocrine cells displaying many secretory granules and are found regularly at 
the bottom of the crypts. They secrete high-molecular-weight glycoproteins called 
mucins which form a protective mucus blanket overlaying the intestinal surface (Hees 
and Sinowatz, 2000; Specian et al., 1991). A small number of the epithelial surface 
lining cells is represented by enteroendocrine cells which secrete various hormones, e.g. 
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serotonin and secretin (Hees and Sinowatz, 2000; Schonhoff et al., 2004). In the small 
intestine, in contrast to the large intestine, a fourth type of epithelial cells is present, the 
Paneth cell. These cells are located at the base of the crypt and secrete lysozyme, 
antimicrobial peptides and growth factors (Porter et al., 2002; Yeung et al., 2011). The 
lamina propria mucosae comprises solitary lymph nodes and large amounts of 
lymphocytes, plasma cells and granulocytes. Duodenal tubuloalveolar glands 
(Brunner`s glands), located in the lamina propria mucosae and tela submucosa, secrete 
alkaline mucus which forms a protective blanket against the acidic content of the gastric 
juice. Aggregated lymph nodes (Peyer`s patches) of the tela submucosa are 
characteristic for the ileum (Hees and Sinowatz, 2000). The surface of the Peyer`s 
patches features M-cells which serve to sample antigens (Hedrich et al., 2004).       
Every day, more than 10
11
 enterocytes are shed into the gut lumen, thus the intestinal 
epithelium has to undergo continuous replacement (Potten and Loeffler, 1990). The 
cells composing the columnar single layer intestinal epithelium derive from a 
multipotent stem cell population located basolaterally in the crypts. These stem cells 
divide and give rise to transient progenitor cells which proliferate in the lower third of 
the crypt (“transit-amplifying” crypt compartment), migrate upwards towards the tip of 
the villus, and differentiate along the way into the different mature cell types. Fully 
differentiated mouse enterocytes reach the surface epithelium after a journey of three to 
five days where they undergo apoptosis and are shed into the gut lumen (Giles et al., 
2003; Sancho et al., 2003, Schonhoff et al., 2004; Simons and Clevers, 2011). Paneth 
cells also derive from the stem cells residing at the bottom of the crypt, however, 
differentiation of progenitor cells takes place during a downward migration towards a 
Paneth cells compartment at the base of the crypt, where they reside for about 20 d, 
after which they are phagocytosed (Sancho et al., 2003; Buske et al., 2011; Simons and 
Clevers, 2011; Yeung et al., 2011). Proliferation, migration and differentiation in the 
intestinal epithelium are regulated by the canonical Wnt signaling pathway. 
Proliferating and undifferentiated stem and precursor cells at the bottom of the crypt 
exhibit high nuclear β-catenin levels allowing for the expression of β-catenin/TCF target 
genes. During migration towards the surface of the epithelium Wnt signaling decreases, 
resulting in cell cycle arrest and differentiation (Stappenbeck et al., 1998; Radtke and 
Clevers, 2005; Clevers, 2006; Yeung et al., 2011). On the contrary, in Paneth cells Wnt 
signaling promotes terminal differentiation (Clevers, 2006).  
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2.2.3 Large intestine 
The large intestine is subdivided into three segments, the caecum, the colon and the 
rectum. The main function of this compartment lies in its capacity to reabsorb water, 
electrolytes, and vitamins. In the large intestine the mucous membrane forms crypts of 
Lieberkühn, but no villi. The lamina epithelialis mucosae comprises absorbent epithelial 
cells, enteroendocrine and mucin-secreting goblet cells, but no Paneth cells are found. 
The number of goblet cells is increased in comparison to the small intestine 
(Stappenbeck et al., 1998; Hees and Sinowatz, 2000; Hedrich et al., 2004; Simons and 
Clevers, 2011). 
In the mouse, the ascending and transverse parts of the colon exhibit transverse folds, 
whereas the descending colon and rectum have longitudinal folds (Hedrich et al., 2004). 
The assertions made above for the small intestine relating to the epithelial renewal also 
largely apply to the large intestine (Hees and Sinowatz, 2000; Hedrich et al., 2004).   
 
2.2.4 Genetics of colorectal cancer 
Colorectal cancer is the major cause of non-smoking-related cancer mortality in the 
Western World (Parkin et al., 2005; World Cancer Research Fund, 2007). In the general 
population the lifetime risk of colorectal cancer is about 5 to 6% (Hawk and Levin, 
2005). Approximately 95% of colorectal cancers are adenocarcinomas (in the following 
referred to as colorectal cancer) (World Cancer Research Fund, 2007).  
Eighty percent of all colorectal malignancies develop spontaneously, only 20% being 
due to a hereditary cancer syndrome (Kerber et al., 2005).  Colorectal carcinomas 
evolve from preexisting adenomatous lesions of the intestinal glandular epithelium 
(Fearon and Vogelstein, 1990; Bienz and Clevers, 2000; Fearon, 2011). The adenoma-
carcinoma sequence is a progressive multistep process involving the sequential 
accumulation of genetic alterations that account for novel or increased function of 
oncogenes and inactivation of tumor suppressor genes (Fearon and Vogelstein, 1990; 
Arnold et al., 2005; Fearon, 2011). Oncogenes are always activated by somatic 
alterations, that is, the mutation arises in non-germ cells during lifetime, in consequence 
of specific point mutations, gene rearrangements, chromosome rearrangements or 
amplifications (Fearon, 2011). Defects of tumor suppressor genes can be caused by both 
inherited and somatic alterations and result from localized mutations, complete loss of 
the gene or epigenetic alterations, e.g. transcriptional silencing due to promoter 
hypermethylation (Arnold et al., 2005, Fearon, 2011; Curtin et al., 2011). A substantial 
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fraction of colorectal carcinomas display microsatellite instability, i.e. mutations in 
microsatellite sequences caused by mutations in the DNA mismatch-repair system, 
which can initiate and promote tumor formation when oncogenes and/or tumor 
suppressor genes are involved (Arnold et al., 2005, Fearon, 2011). In most cases of 
sporadic colon cancers, loss of specific chromosomal regions affecting one allele of 
certain tumor suppressor genes (“loss of heterozygosity” (LOH)) occurs, with 
particularly high frequencies on chromosome 17p (protein 53 (p53)), 18q (deleted in 
colorectal cancer (DCC), mothers against decapentaplegic homolog 2 (SMAD2), 
mothers against decapentaplegic homolog 4 (SMAD4)) and 5q (adenomatous polyposis 
coli (APC)) (Fearon and Vogelstein, 1990; Arnold et al., 2005; Fearon, 2011). The 
acquirement of an inactivating somatic mutation in the remaining wildtype allele 
promotes tumor development due to perturbation of critical signaling pathways 
controlling cellular metabolism, proliferation, differentiation and survival (Fearon, 
2011; Hanahan and Weinberg, 2011). Inactivation of the APC tumor suppressor gene as 
a consequence of mostly truncating mutations and LOH, respectively, plays a leading 
role in the initiation of sporadic colorectal neoplasms and is present in about 80% of 
colorectal adenomas and carcinomas (Nishisho et al., 1991; Powell et al., 1992; Polakis, 
1999; Fearon 2011). In familial adenomatous polyposis (FAP), an inherited form of 
colorectal cancer, a germline mutation within the APC gene promotes the development 
of a multitude (hundreds to thousands) of adenomatous polyps in the large intestine 
(Lynch, 2003; Logan and Nusse, 2004; Arnold et al., 2005; Fearon, 2011). In the 
majority of sporadic colorectal tumors as well as tumors from FAP patients, both APC 
alleles are inactivated (Bienz and Clevers, 2000). APC is part of a multiprotein 
destruction complex which plays a crucial role in Wnt signaling by the regulation of 
intracellular β-catenin levels. APC dysfunction leads to the stabilization and 
accumulation of β-catenin that translocates into the nucleus, complexes with DNA-
binding proteins of the TCF/LEF family and activates the transcription of genes 
regulating cell proliferation, migration and differentiation (Bienz and Clevers, 2000; 
Giles et al., 2002; Arnold et al., 2005; Aoki et al., 2007). The disruption of the Wnt 
signaling pathway perturbs normal intestinal homeostasis and finally triggers adenoma 
development (Bienz and Clevers, 2000; Giles et al., 2002; Arnold et al., 2005). In the 
intestinal epithelium, stabilized β-catenin is supposed to impair enterocyte 
differentiation and migration, implicating an expansion of the “transit-amplifying” crypt 
compartment (Bienz and Clevers, 2000). In the murine intestine, loss of APC was found 
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to induce hyperproliferation in the crypt compartment, to abrogate cell migration and to 
interfere with differentiation (Sansom et al., 2004; Andreu et al., 2005). Colorectal 
adenomas may progress stepwise to carcinomas through the accumulation of multiple 
independent somatic alterations in further tumor suppressor genes (e.g. p53, SMAD4, 
SMAD2) and oncogenes (e.g. KRAS, BRAF) (Arnold et al., 2005).  
 
2.3 Adipose tissue 
2.3.1 Overview 
Adipose tissue is a multi-depot organ comprising several subcutaneous and visceral 
sites that are distributed over the body (Gesta et al., 2007; Cinti, 2009). In addition to 
mature adipocytes, which represent the major cell type, adipose tissue includes 
fibroblasts, macrophages, vascular cells, preadipocytes, and nerves, collectively referred 
to as the stromal vascular fraction (Hausman et al., 2001, Gesta et al., 2007; Vazquez-
Vela et al., 2008). According to their unique morphology and distinct function, two 
different types of adipocytes, brown and white, are distinguishable and organized in two 
tissues, the white adipose tissue and the brown adipose tissue. Both cell types are able to 
store triglycerides and release fatty acids (Cinti, 2005). In rodents, adipose tissue was 
found to exhibit pronounced plasticity as white adipocytes have the ability to 
transdifferentiate into brown adipocytes and vice versa, according to biological 
requirements (Cinti, 2005; Cinti, 2009). During embryogenesis, adipose tissue origins 
from mesenchymal stem cells. These cells give rise to undifferentiated preadipocytes 
which differentiate into adipocytes (Gregoire et al., 1998; Gesta et al., 2007). 
Preadipocytes are fibroblast-like cells which reside in adipose tissue and bear the ability 
to proliferate and differentiate into mature adipopcytes (Gregoire et al., 1998; Hausman 
et al., 2001). It remains unknown whether brown and white adipocytes and adipocytes 
from different fat depots evolve from the same type of preadipocytes (Gesta et al., 
2007). After birth, adipose tissue grows rapidly, due to both an increase in fat cell size 
(adipocyte hypertrophy) and the addition of new adipocytes (adipocyte hyperplasia), a 
process collectively termed adipogenesis (Hausman et al., 2001; Vazquez-Vela et al., 
2008). As mature adipocytes are postmitotic, additional adipocytes can only origin from 
preadipocytes (Hausman et al., 2001). Adipogenesis is mediated by hormones, 
cytokines, and growth factors and implicates down-regulation of the canonical Wnt 
signaling pathway and expression of transcription factors of the C/EBP and PPAR 
families, especially C/EBPα and PPARγ (Gregoire et al., 1998; Ross et al., 2000; 
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Kennel et al., 2005; Christoduolides et al., 2006; Gesta et al., 2007; Hausman et al., 
2001). Adipogenesis takes place within cell clusters and is closely interrelated with 
angiogenesis (Nishimura et al., 2007). Most likely the proliferation of preadipocytes is 
induced by circulating factors and neuronal inputs as well as paracrine and autocrine 
factors secreted from the various cells composing adipose tissue (Lau et al., 1996; 
Serrero and Lepak, 1996; Hausman et al., 2001). 
 
2.3.2 White adipose tissue 
White adipocytes are spherical cells which store triglycerides in a single large lipid 
droplet that accounts for more than 90% of the cell’s volume. A single fat pad contains 
adipocytes of variable size, ranging from 10 μm to 100 μm, depending on the size of the 
fat vacuole. White adipose tissue is the primary site for the storage of dietary energy in 
the form of triglycerides (Cinti, 2005). Dietary lipids are enzymatically hydrolyzed in 
the proximal intestinal lumen by lipases leading to the production of non-esterified fatty 
acids which are taken up by the enterocytes (Bamba and Rader, 2007). In the 
enterocyte, free fatty acids are re-esterified to triglycerides and packaged with 
apolipoprotein B-48 and other lipids to form so-called chylomicrons. Chylomicrons are 
secreted into the intestinal lymph and reach the systemic circulation via the thoracic 
duct. In the capillaries of adipose tissue, hydrolysis of chylomicron-triglycerides into 
non-esterified fatty acids is mediated by lipoprotein lipase which is synthesized by 
adipocytes, anchoraged to proteoglycans on the endothelial surface and dependent on its 
cofactor apoC-II, an integral part of chylomicrons. The non-esterified fatty acids are 
taken up by adipocytes where they are re-esterified into triglycerides for energy storage 
(Bamba und Rader, 2007). In times of energy deprivation, free fatty acids and glycerol 
are generated by lipolysis of triglycerides and released into the circulation, thereby 
providing an energy source for other tissues, mainly the skeletal muscle (Ahima and 
Osei, 2008; Bays et al., 2008; Guilherme et al., 2008 Karpe et al., 2011). Uptake of 
circulating free fatty acids by adipocytes plays only a minor role compared to fatty acid 
uptake from hydrolysis of chylomicron-triglycerides (Bamba and Rader, 2007). 
Furthermore, white adipose tissue functions as an endocrine organ because of its 
capacity to secrete a variety of hormones and cytokines, so called adipokines (Vazquez-
Vela et al., 2008; Singla et al., 2010). Adipokines not only participate in the control of 
energy metabolism (e.g. leptin, adiponectin, resistin, visfatin), they also play a role in 
immunological responses (TNF-α, monocyte chemotactic protein-1 (MCP-1)) and the 
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regulation of blood pressure (e.g. apelin) (Gregoire et al., 1998; Ailhaud, 2006; 
Vazquez-Vela et al., 2008; Bays et al., 2008). Leptin was the first adipokine described 
and constitutes an important regulator of energy homeostasis and body weight as it 
provides a satiety signal to the central nervous system. After food intake leptin is 
secreted from adipocytes into the blood circulation and binds to receptors expressed by 
hypothalamic neurons. Thereby a signal transduction cascade is activated that results in 
a decrease in energy consumption and an activation of energy expenditure pathways. 
Moreover, leptin, together with adiponectin, enhances insulin sensitivity (Gregoire et 
al., 1998; Ahima and Osei, 2008; Guilherme et al., 2008; Morris and Rui, 2009; Singla 
et al., 2010). There is also strong evidence that autocrine and paracrine signaling 
pathways as well as neuronal influences play an important role in the maintenance of 
adipose tissue homeostasis (Ahima and Osei, 2008).    
 
2.3.3 Brown adipose tissue 
Brown adipocytes store triglycerides in the form of many lipid droplets, thus showing a 
multilocular appearance. Brown adipose tissue is more densely vascularized and 
innervated than white adipose tissue, and brown adipocytes possess large characteristic 
mitochondria containing the protein uncoupling protein 1 (UCP1), a member of the 
mitochondrial carrier family. Brown adipose tissue is primarily located in the 
intrascapular region and is most abundant at birth as it is replaced by white adipose 
tissue during aging (Gesta et al., 2007). The main function of brown adipose tissue is 
the generation of body heat from triglycerides and fatty acids in a process called (non-
shivering) thermogenesis. Combustion of fatty acids in the respiratory chain results in 
an electrochemical proton gradient between the outer and inner mitochondrial 
membrane. In brown fat mitochondria UCP1, the equivalent of an H
+
 transporter, is able 
to release the energy stored in this proton gradient in the form of heat (Cannon and 
Nedergaard, 2004; Gesta et al., 2007; Ravussin and Galgari, 2011). Thermogenesis is 
under the control of the sympathetic nervous system and is activated by a temperature 
below thermoneutrality. Under conditions of increased thermogenetic demand, new 
brown adipocytes can either derive from preadipocytes by adipogenesis or by direct 
transformation of white into brown adipocytes (Cinti, 2009).  
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2.3.4 Obesity 
Obesity (also termed adiposity) is characterized by an excessive growth of white 
adipose tissue caused by an increase in energy uptake and a decrease in energy 
expenditure. Obesity is defined in humans by a body mass index (body weight (kg) 
divided by (body height (m))
2
; BMI) greater than 30. In industrialized countries obesity 
is a major health problem (World Health Organization (WHO), 2011). In 2008, 
according to the WHO, 1.5 billion adults were overweight (BMI greater than 25), of 
these 200 million men and 300 million women were considered obese. Moreover, 
nearly 43 million children under the age of five were overweight in 2010.  
In times of positive caloric balance, adipose tissue expands due to a rising deposit of 
triglycerides. This is accomplished through increases in adipocyte size (adipocyte 
hypertrophy) as well as increases in adipocyte number (adipocyte hyperplasia) 
(Hausman et al., 2001; Vazquez-Vela et al., 2008). During the development of obesity 
in young animals (early-onset obesity), adipogenesis contributes far more to the 
increase of fat mass than in older animals (late-onset obesity) as the capacity of 
preadipocytes to become fully functional mature adipocytes declines in adult life 
(Lemonnier, 1972; DiGirolamo et al., 1998; Hausman et al., 2001; Vazquez-Vela et al., 
2008). In times of positive energy balance, storage of excess energy is initially 
accomplished by adipocyte hyperthrophy (Guilherme et al., 2008; Hausman et al., 
2001). Adipocytes, however, possess only a restricted capacity for cell expansion, hence 
if adipocytes reach a critical cell size further energy can only be stored by an increase in 
adipocyte number. This critical cell size is assumed to be genetically determined and 
specific for each fat depot that means some fat depots are more prone to undergo 
hyperplasia than other (Hausman et al., 2001). In rodents, for example, perirenal and 
inguinal fat pads have a high tendency to hyperplasia whereas hypertrophy is more 
characteristic for epididymal and mesenteric fat depots (DiGirolamo et al., 1998). 
Hyperthrophic adipocytes are more prone to undergo necrotic-like cell death than non-
hypetrophic adipocytes (up to 30-fold), thus it was suggested that with increasing 
obesity only the switch from adipocyte hyperthorphy to hyperplasia is able to further 
increase the lipid storage capacity of adipose tissue (Cinti et al., 2005). Moreover, 
adipocyte hyperthrophy was linked to adipocyte dysfunction given that a high degree of 
hyperthrophy in comparison to hyperplasia is related with the risk to develop metabolic 
disease (Ravussin and Smith, 2002; Bays et al., 2008). Obesity is strongly associated 
with a number of chronic diseases such as coronary atherosclerotic heart disease, gout, 
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restrictive lung disease, gall bladder disease, some forms of cancer, degenerative 
arthritis, infertility, and sleep apnoea (Montague and O'Rahilly, 2000; Hausman et al., 
2001; Singla et al., 2010). There are also several metabolic complications of obesity 
(termed metabolic syndrome), including impaired glucose tolerance, insulin resistance, 
often giving way to β-cell failure, type 2 diabetes, dyslipidemia, hypertension, and 
premature heart disease (Bays et al., 2008; Singla et al., 2010). In humans, visceral 
adipose tissue accumulation is supposed to be associated with increased mortality and a 
higher risk to develop metabolic disease (Montague and O'Rahilly, 2000; Bays et al., 
2008; Singla et al., 2010).  
Excess body fat storage is often accompanied by insulin resistance that is characterized 
by decreased insulin-stimulated glucose uptake and metabolism in adipocytes and 
skeletal muscle and by impaired suppression of hepatic glucose output. There is strong 
evidence that these changes in glucose metabolism are due to defective signaling from 
the insulin receptor and down-regulation of the glucose transporter type 4 (GLUT-4) 
(Singla et al., 2010). Furthermore, adiposity leads to a rise in basal lipolysis in adipose 
tissue and impaired trapping of fatty acids in adipocytes implicating elevated circulating 
free fatty acids. Elevated circulating fatty acid levels result in ectopic lipid accumulation 
in the pancreas, muscle and liver and strongly influences cellular glucose uptake, thus 
being one of the main factors causing insulin resistance (Boden, 2008; Guilherme et al., 
2008; Vazquez-Vela et al., 2008; Singla et al., 2010).  
The endocrine function of adipose tissue is highly impaired in obesity. With increasing 
body fat mass the release of adipokines from adipose tissue becomes more and more 
dysregulated, thus disrupting physiological whole-body energy homeostasis (Ahima and 
Osei, 2008). Most adipokines (e.g. leptin, TNF-α, interleukin-6 (IL-6) and resistin) are 
upregulated in obesity, however, adiponectin levels are inversely related to adiposity 
(Ahima and Osei, 2008; Vazquez-Vela et al., 2008). Hyperthrophic adipocytes secrete 
high amounts of leptin, however, in adiposity non-adipose tissues have developed leptin 
resistance and high circulating leptin levels promote insulin resistance (Ahima and Osei, 
2008; Vazque-Vela et al., 2008; Morris et al., 2009).  
Given that adipose tissue contains all the components of the renin-angiotensin system 
and constitutes a major source of extra-hepatic angiotensinogen, it is supposed that 
adipose tissue directly contributes to obesity-related hypertension (Ailhaud, 2006).  
Moreover, obese adipose tissue develops a chronic low-inflammatory state that is due to 
an increase in the secretion of pro-inflammatory factors (e.g. TNF-α, IL-6, MCP-1) 
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from and a decreased production of anti-inflammatory factors (e.g. transforming growth 
factor- β (TGF-β)) by adipocytes. Thereby, immunoreactive cells, primarily bone-
marrow derived macrophages, are attracted and accumulate in adipose tissue in an 
amount that is positively correlated with adipocyte size and BMI (Bays et al., 2008; 
Singla et al., 2010; Guilherme et al., 2008; Weisberg et al., 2003; Wellen and 
Hotamisligil, 2003). Macrophages were found to be predominantly localized around 
dead adipocytes, hence it was supposed that necrotic-like cell death of hyperthrophic 
adipocytes contributes to the aggregation of macrophages in adipose tissue (Cinti et al., 
2005). Activated macrophages secrete a plethora of inflammatory cytokines, especially 
TNF-α, which strongly enhances lipolysis and impairs triglyceride deposition in 
adipocytes, thus contributing to excess blood levels of free fatty acids and triglycerides 
and finally to insulin resistance, type 2 diabetes and ectopic lipid deposition (Guilherme 
et al., 2008; Weisberg et al., 2003). 
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3. Animals, Materials and Methods 
3.1 Animals 
3.1.1 Dro1 constitutive knockout mice (Dro1
-/-
) 
Dro1 constitutive knockout mice (in the following designated as knockouts or Dro1
-/-
 
mice) were generated by gene targeting using a Cre-loxP-mediated recombination 
system (Fig. 3.1). For generation of the targeting construct, the essential exon 2 of the 
Dro1 gene and 5’ and 3’ homology arms were amplified by PCR from genomic DNA of 
E14 mouse embryonic stem cells. In doing so, a loxP site was added to the end of the 5’ 
homology arm. A targeting vector was created by insertion of the PCR products into the 
multiple cloning site of the pPNT4 (Conrad et al., 2003) cloning vector that also carried 
a neomycin resistance gene, a thymidine kinase gene and another loxP sequence. The 
construct was linearized by SalI restriction digest and electroporated into E14 mouse 
embryonic stem cells. An embryonic stem cell line that had integrated the construct 
correctly by homologous recombination was identified by Southern blot analysis and 
microinjected into blastocysts of C57BL/6N mice. Blastocysts were transferred into the 
uteri of pseudopregnant synchronized foster mothers and the resulting chimeric progeny 
were intercrossed with C57BL/6N mice to establish a mouse line with floxed Dro1 
alleles (Dro1
fl/fl
). Dro1
fl/fl
 females were mated to transgenic males expressing Cre 
(causes recombination) recombinase, a type 1 topoisomerse from P1 bacteriophage that 
catalyzes recombination between loxP sites, under control of the cytomegalovirus 
(CMV) promoter (Schwenk et al., 1995). The heterozygous Dro1
+/-
 offspring was bred 
to obtain Dro1
-/- 
mice. In the present study Dro1
fl/fl
 mice were used as control animals, 
in the following referred to as “controls”. Dro1fl/fl mice were generated by PD Dr. 
Marlon R. Schneider and were made available for the present studies. 
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Fig. 3.1 Schematic representation of the strategy employed to generate Dro1
-/-
 mice. The 
essential exon 2 of the Dro1 gene was flanked by 2 loxP sequences. Cre-recombinase-
mediated recombination between loxP sites results in deletion of exon 2 and Dro1 
knockout. Black boxes: exons; White arrows: loxP sites; PGK-neo: phosphoglycerine 
kinase neomycin resistance cassette. 
3.1.2 B6.C-Tg(CMV-cre)1Cgn/J mice 
B6.C-Tg(CMV-cre)1Cgn/J mice (Schwenk et al., 1995) were kindly donated by Prof. 
Dr. Irmgard Förster, Heinrich-Heine-University, Düsseldorf. In this mouse strain the 
Cre gene is under transcriptional control of a human CMV minimal promoter and is 
expressed during early embryogenesis in all tissues including germ cells. Thus Cre-
mediated deletion of the loxP-flanked DNA sequence is ubiquitously present and the 
acquired mutation is transmitted through the germ-line. The transgene was observed to 
be linked to the X chromosome (Schwenk et al., 1995). 
 
3.1.3 C57BL/6J-Apc
Min
/J mice 
C57BL/6J-Apc
Min
/J mice (in the following referred to as Apc
+/Min
 mice) were purchased 
from the Jackson Laboratory (Bar Harbor, USA). Apc
+/Min
 mice were established from 
an ethylnitrosourea-treated C57BL/6J male mouse and carry a single autosomal 
dominant germ-line nonsense mutation at nucleotide 2549 (codon 850) in the Apc tumor 
suppressor gene (Moser et al., 1990; Su et al., 1992). Somatic allelic loss of the 
remaining Apc wild-type locus leads to dysregulation of the Wnt signaling pathway 
(Levy et al., 1994; Luongo et al., 1994). The resulting phenotype is characterized by a 
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high predisposition to develop a multitude of tumors of the intestinal tract. Therefore 
the mutant gene was named multiple intestinal neoplasia (Min) (Moser et al., 1989). 
Apc
+/Min
 mice develop, on average, 30 tumors throughout the entire length of the 
intestinal tract, though the majority of neoplastic lesions are distributed to the small 
bowel and few occur in the colon (Moser et al., 1990; Shoemaker et al., 1997; Boivin et 
al., 2003). Apc
+/Min
 mice die, on average, at 120 d of age in consequence of secondary 
effects of tumor growth, mainly intestinal bleeding and obturation (Moser et al., 1990; 
Shoemaker et al., 1997). On the C57BL/6 background all intestinal tumors are 
adenomas which may, especially in older animals, occasionally progress to 
adenocarcinomas (Moser et al., 1990; Shoemaker et al., 1997; Boivin et al., 2003). 
Invasion of tumors into the tela submucosa is uncommon (McCart et al., 2008) and 
adenocarcinomas possess no metastatic properties (Boivin et al., 2003). Spontaneous 
colonic ACF formation is rare or absent (Reitmair et al., 1996; Song et al., 2000; Boivin 
et al., 2003). Tumor burden was observed to be strongly affected by the genetic 
background due to the presence or absence of genetic modifiers, so called modifiers of 
Min (Mom) (Shoemaker et al., 1997; Halberg et al., 2000; McCart et al., 2008). Since 
mutant homozygotes die early in embryogenesis (Moser et al., 1990; Moser et al., 
1995), all studies were conducted in heterozygote mice of both genders. Considering the 
fact that Apc
+/Min 
females are seldom healthy enough to maintain a pregnancy and feed 
an eventual litter (Moser et al., 1990), only heterozygote males were used for breeding. 
Apc
+/Min
 males were mated to Dro1
-/- 
females and the resulting male Dro1
+/-
;Apc
+/Min
 
offspring was intercrossed with Dro1
-/-
 females to obtain Dro1
-/-
;Apc
+/Min
 progeny. 
Dro1
fl/fl
;Apc
+/Min
 mice were used as control animals to Dro1
-/-
;Apc
+/Min
 mice and were 
bred as described for Dro1
-/-
;Apc
+/Min
 mice. In the following, Dro1
fl/fl
;Apc
+/Min
 mice are 
entitled as “Apc+/Min controls”. Mice on the Apc+/Min background were inspected on a 
daily basis and sacrificed when moribund. 
To investigate Mom1 allele status of Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 control mice, a 
500 bp region of the Mom1 allele was amplified by PCR using primers Mom1#1 and 
Mom1#2 (see below for general PCR conditions). PCR products were digested with 
BamHI (MBI Fermentas, St. Leon-Rot) for 1 h at 37°C and separated along with a 
molecular weight marker (pUC mix molecular weight marker, MBI Fermentas, St. 
Leon-Rot) on a 1.5% Tris-acetate-EDTA buffer (TAE) agarose (Invitrogen, Karlsruhe) 
gel containing ethidium bromide (Roth, Karlsruhe). Electrophoresis was carried out in 
an agarose gel electrophoresis chamber (MWG-Biotech, Ebersberg) at 120 V for 45 min 
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in a TAE running buffer. DNA band patterns were visualized with ultraviolet light at 
254/366 nm. 
 
Restriction digest: 
PCR product  20 µl 
BamHI buffer (MBI Fermentas, St. Leon-Rot)  5 µl 
BamHI restriction enzyme 1 µl 
Bidistilled water  24 µl 
 
50x TAE running buffer 
Tris (Roth, Karlsruhe) 242.0 g 
Glacial acetic acid (Roth, Karlsruhe) 57.1 ml 
Ethylenediaminetetraacetic acid (EDTA), 0.5 M, pH 8.0  100 ml 
(VWR International, Darmstadt)   
Bidistilled water up to  1 l 
 
3.1.4 Animal maintenance 
Animals were maintained under specific pathogen free conditions in a closed barrier 
system in the facilities of the Gene Center. They were housed separated by sex in type 2 
and type 3 Makrolon cages, with a 12 h light cycle at 22°C and 40% humidity. Food and 
water were provided ad libitum and mice were either fed a chow diet (V1536, Ssniff, 
Soest, Germany; 13.0 MJ/kg, with 9% energy derived from fat, 33% from protein, and 
58% from carbohydrate) or, to induce obesity, a high fat diet (D12492 mod., Ssniff, 
Soest, Germany; 25.2 MJ/kg, with 60% energy derived from fat, 19% from protein, and 
21% from carbohydrate). Mice were weaned at an age of 3 weeks and earmarked. In 
case studies were conducted in mice younger than 3 weeks, foot tattooing was used to 
identify animals. Cervical dislocation was applied for killing.  
Experiments were carried out in accordance with the German Animal Protection Law 
and were officially sanctioned by the local authorities (AZ 55.2-1-54-2531-126-09).   
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3.2 Materials and Methods 
3.2.1 Mouse Genotyping 
3.2.1.1 Sample collection 
Samples were collected when mice were 3 to 4 weeks of age by clipping 0.5 mm of the 
tail tip with a pair of scissors (Aesculap, Tuttlingen). The wound was blotted dry from 
blood on absorbent paper and closed with Histoacryl
® 
liquid skin glue (B. Braun, 
Melsungen). Samples were immediately frozen on dry ice, transferred to a 1.5 ml 
centrifuge tube (Eppendorf, Hamburg), and stored at -80°C to prevent DNA 
degradation. 
 
3.2.1.2 Extraction of DNA from mouse tail tips 
Digestion buffer (620 µl) was added to the centrifuge tubes containing the frozen tail 
tips and the samples were incubated at 56°C overnight with gentle shaking. 
 
Digestion buffer: 
Nuclei Lysis Solution (Promega, Mannheim)   500 µl 
EDTA, 0.5 M, pH 8.0  120 µl 
Proteinase K, 20 mg/ml (Roche, Mannheim)  17.5 µl 
 
The next day 3 µl of RNase (Roche, Mannheim) were added and samples incubated at 
37°C for 20 min to degrade RNA. Thereafter 200 µl Protein Precipitation Solution 
(Promega, Mannheim) were added and the samples were vortexed vigorously at high 
speed for 20 s. After chilling on ice for 5 min, samples were centrifuged at 14.000 x g 
for 4 min to pelletize precipitated proteins at the bottom of the tube. The supernatant 
containing the DNA was carefully transferred to a clean 1.5 ml centrifuge tube 
containing 600 µl of room temperature isopropanol (Merck, Darmstadt) and the solution 
was gently mixed by inverting the tubes until white strands of precipitated DNA were 
visible. To pelletize DNA, samples were centrifuged at 14.000 x g for 1 min. After 
carefully removing the isopropanol, 600 µl of room temperature 70% ethanol (Merck, 
Darmstadt) were added to the pellet and the tubes were inverted several times to wash 
the DNA. Samples were again centrifuged for 1 min at 14.000 x g, the ethanol carefully 
removed using a pipette and the pellet air-dried for 10 min. To rehydrate DNA, 50 µl of 
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DNA Rehydration Solution (Promega, Mannheim) were added and samples incubated 
for 1 h at 65°C. 
 
3.2.1.3 PCR analysis 
PCR reactions were prepared on ice using the Taq DNA polymerase Kit (Qiagen, 
Hilden) and were carried out in a reaction volume of 20 μl in DNase-, RNase and 
pyrogen-free 100 μl PCR-reaction-tubes (G. Kisker GbR, Steinfurt). 
 
Mastermix preparation (per sample):  
PCR buffer, 10x (Qiagen, Hilden)  2.00 μl 
dNTPs, 1 mM (MBI Fermentas, St. Leon-Rot) 2.00 μl 
Q-Solution (Qiagen, Hilden) 4.00 μl 
MgCl2, 25mM (Qiagen, Hilden)  1.25 μl 
Sense primer, 2 µM  1.00 μl 
Antisense primer, 2 µM   1.00 μl 
Bidistilled H2O  7.65 μl 
Taq Polymerase, 5U/µl (Qiagen, Hilden)  0.10 μl 
Template DNA, about 50 ng/µl  1.00 μl 
 
Mastermix preparation using primers Apc33, Apc34 and Apc758 to genotype Apc
+/Min
 
mice (per sample):  
PCR buffer, 10x  2.00 μl 
dNTPs, 1 mM  4.00 μl 
Q-Solution  4.00 μl 
MgCl2, 25 mM  1.25 μl 
Primer Apc33 2.00 μl 
Primer Apc34 2.00 μl 
Primer Apc758 2.00 μl 
Bidistilled H2O 1.65 μl 
Taq Polymerase, 5U/µl  0.10 μl 
Template DNA, about 50 ng/µl  1.00 μl 
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The reaction took place in a thermal cycler (Biometra, Göttingen) according to the 
following protocol: 
Step 1: 94°C – 4 min  (DNA denaturation) 
Step 2: 94°C – 1 min  (DNA denaturation) 
Step 3: Annealing temperature  (primer annealing) 
Step 4: 72°C – 2 min  (elongation) 
Step 5: 72°C – 10 min  (elongation) 
Step 6: 4°C  (cooling) 
 
Step 2 to 4 were repeated 35 times (36 amplification cycles in total), thereafter the 
program continued with step 5. Amplified products and a molecular weight marker were 
loaded into the slots of 1.5% agarose TAE gels containing ethidium bromide and 
electrophoresis was carried out in an electrophoresis chamber at 120 V for 45 min in a 
TAE running buffer. DNA band patterns were visualized with ultraviolet light at 
254/366 nm. 
 
3.2.2 Identification of knockout mice by non-radioactive Southern blot 
3.2.2.1 Digest, electrophoresis and transfer of DNA 
DNA was extracted from liver samples as described above (Chapter 3.2.1.2) and DNA 
concentration was measured with a spectrophotometer (Beckman, Palo Alto, USA) at 
260 and 280 nm. 10 μg of genomic DNA were restriction digested with PstI (MBI 
Fermentas, St. Leon-Rot) over night at 37°C in a centrifuge tube. 
 
Restriction digest:  
Liver genomic DNA, 10 μg  15.0 μl 
PstI restriction enzyme    3.0 μl 
Buffer PstI (MBI Fermentas, St. Leon-Rot)   4.0 μl 
Spermidine, 0.1 M (Sigma-Aldrich, Deisenhofen)    1.0 μl 
Bidistilled water  17.0 μl 
 
The next day 10 μl of 6x loading dye (MBI Fermentas, St. Leon-Rot) were added to 
each sample and DNA fragments were separated by electrophoresis on a 0.9% agarose 
TAE gel containing ethidium bromide for 6 h at 60 V using a TAE running buffer. DNA 
fragments were visualized by ultraviolet light at 254/366 nm and photographed together 
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with a ruler. For DNA denaturation, the gel was placed in buffer I (1.5 M NaCl (Roth, 
Karlsruhe), 0.5 M NaOH (Roth, Karlsruhe)) for 45 min by gently shaking. The gel was 
rinsed with bidistilled water and transferred to buffer II (1.5 M NaCl, 1.0 M Tris-HCl 
(Roth, Karlsruhe)) for 30 min to depurinate DNA. In the meantime a nylon membrane 
(Pall Corporation, Pensacola, USA) was cut to the size of the gel, wetted in bidistilled 
water for 10 min and incubated in 10x saline-sodium citrate buffer (SSC) until needed. 
For transfer of DNA, the gel was placed upside down on a piece of filter paper (GE 
Healthcare, Munich) whose ends were dipped into a 10x SSC reservoir. The gel was 
carefully covered with the membrane, wetted filter paper, and a stack of tissue towels 
(both cut to the size of the membrane), and a burden of approximately 1 kg was placed 
on top. Air bubbles were removed with a glass pipette after each step. Blotting took 
place over night, so that the buffer was drawn from the buffer reservoir through the gel, 
the nylon membrane and the filter paper to the stack of dry paper tissues by capillary 
force. Thereby the DNA fragments were carried to the nylon membrane on which they 
were immobilized. The next day the membrane was removed and washed in 6x SSC for 
5 min. Thereafter it was illuminated with ultraviolet light (120 J/cm
2
) for 60 s to cross-
link DNA covalently to the membrane. 
 
20x SSC: 
NaCl  175.3 g 
Sodium citrate (Merck, Darmstadt)    88.2 g 
Bidistilled water up to  1 l 
Adjusted to pH 7.0 
 
3.2.2.2 Non-radioactive probe labeling 
The digoxigenin (DIG) labeled hybridization probe was generated by PCR from 
C57BL/6N mice genomic DNA using the DIG Probe Synthesis kit (Roche, Mannheim). 
The dNTP mixture contains DIG labeled uridine nucleotides, in consequence DIG is 
incorporated into the nucleic acid probe by the DNA polymerase. Preparation of the 
PCR reaction was accomplished in 100 µl PCR tubes on ice using primers Dro3’end#1 
and Dro3’end#2. 
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Master mix (per sample): 
PCR buffer with MgCl2, 10x (Roche, Mannheim)   5.00 μl 
PCR DIG Probe Synthesis mix (Roche, Mannheim)   5.00 μl 
Forward primer, 2 µM    5.00 μl 
Reverse primer, 2 µM    5.00 μl 
Enzyme mix (Roche, Mannheim)   0.75 μl 
Bidistilled water  28.25 μl 
Template DNA, about 50 ng/µl    1.00 μl 
 
Thermic cycling was carried out in a thermal cycler according to the following protocol: 
Step 1: 94°C – 4 min  (DNA denaturation) 
Step 2: 94°C – 1 min  (DNA denaturation)  
Step 3: 58°C – 1 min  (primer annealing)  
Step 4: 72°C – 2 min  (elongation) 
Step 5: 72°C – 10 min  (elongation) 
Step 6: 4°C  (cooling) 
 
Steps 2 to 4 were repeated 44 times before the program continued with step 5 (45 
amplification cycles in total). 5 µl of the amplified product were transferred to a clean 
100 µl tube containing 15 µl bidistilled water and 4 µl 6x loading dye. The aliquot was 
run on a 0.9% agarose TAE gel containing ethidium bromide along with a DNA 
molecular weight marker. DNA band patterns were visualized by ultraviolet light. The 
remaining probe was stored at -20°C until needed. 
 
3.2.2.3 Hybridization, washing and detection 
For hybridization, washing and detection, the DIG Block and Wash Buffer Set (Roche, 
Mannheim) was used and all necessary solutions were prepared following the 
manufacturer`s manual. All washing and incubation steps were performed with gentle 
agitation at room temperature if not stated differently. 
The nylon membrane was placed in a glass hybridization tube (Bachofer, Reutlingen) 
and incubated in pre-heated DIG Easy Hyb buffer (Roche, Mannheim) for 30 min. 30 µl 
of the DIG labeled probe were transferred to a 1.5 ml centrifugation tube, heated at 
95°C for 5 min, cooled on ice for 2 min and added to the DIG Easy Hyb buffer in the 
hybridization tube. Hybridization took place over night at 39°C. The next day non-
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bound probes were removed by washing the membrane 2 times for 5 min in 2x SSC 
containing 0.1% sodium dodecyl sulfate (SDS; Merck, Darmstadt) and 2 times for 15 
min in 0.5x SSC containing 0.1% SDS at 65°C. Thereafter the membrane was incubated 
in Washing buffer (Roche, Mannheim) for 5 min, in Blocking solution (Roche, 
Mannheim) for 1 h and finally treated for 30 min with alkaline phosphatase conjugated 
Anti-DIG-AP Fab fragments (Roche, Mannheim) diluted 1: 10.000 in Blocking 
solution. Unbound Anti-DIG-AP Fab fragments were eliminated by rinsing the 
membrane 2 times for 15 min with Washing buffer. Next, the membrane was removed 
from the hybridization tube, placed with the DNA side facing up in a hybridization bag 
and 2 ml of CSPD ready-to-use detection solution (Roche, Mannheim) were applied and 
spread evenly and without air bubbles over the membrane. After 5 min, excess liquid 
was removed from the hybridization bag, the edges were heat-sealed and the membrane 
was exposed to a chemiluminiscence film (GE Healthcare, Munich) until the required 
signal strength was achieved.  
 
3.2.3 Evaluation of gene expression at the RNA level  
3.2.3.1 Extraction of RNA from tissues 
Mice were killed by cervical dislocation and tissue samples (liver, muscle, heart, white 
adipose tissue and brown adipose tissue) excised immediately. The intestine was 
excised and the faecal content rinsed out with 1x phosphate buffered saline (PBS) using 
cannula (B.Braun, Melsungen) and syringe (Codan Medical ApS, Roedby, Denmark). 
The intestine was opened longitudinally, laid open and small intestinal epithelium and 
colon epithelium were scraped off with cover glass slides (VWR International, 
Darmstadt) and transferred to 1.5 ml centrifuge tubes. Samples were frozen on dry ice 
and stored at -80°C. For RNA isolation, frozen tissue samples (~50-100 mg) were 
transferred to 5 ml plastic tubes (Greiner Bio-One, Frickenhausen) containing 1 ml of 
Trizol reagent (Invitrogen, Karlsruhe) and homogenised for 60 s using a homogenizer 
(ART Labortechnik, Müllheim) at 23500 rpm. To avoid cross-contamination the tip of 
the homogenizer was cleaned with diethylpyrocarbonate-treated (DEPC; Sigma-
Aldrich, Deisenhofen) water and 0.2 M NaOH between samples. The lysate was 
centrifuged at 12.000 x g for 10 min at 4°C and the supernatant was transferred to a 
clean 2 ml centrifuge tube (Eppendorf, Hamburg). Samples were incubated for 5 min at 
room temperature, 0.2 ml chloroform (Merck, Darmstadt) were added and the solution 
shaken vigorously by hand for 15 s. Phase separation was achieved by incubating 
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samples for 3 min at room temperature and centrifugation at 12.000 x g for 15 min at 
4°C. The upper clear, aqueous phase which contains the RNA fraction was transferred 
to a clean 1.5 ml centrifuge tube. To precipitate RNA, 0.5 ml isopropanol was added 
and the tubes were inverted several times. Incubation was carried out for 10 min at 
room temperature and RNA was pelletized by centrifugation at 12.000 x g for 10 min at 
4°C. After decantation of the supernatant, the RNA was washed with 0.5 ml of ice-cold 
75% ethanol and samples centrifuged at 7.500 x g for 5 min at 4°C. The ethanol was 
carefully removed with a pipette, the pellet air-dried for 3 min and resuspended in 
100 µl DEPC-treated water. For RNA cleanup the RNeasy Mini kit (Quiagen, Hilden) 
was used according to the manufacturer`s manual. RNA was finally dissolved in 50 µl 
DEPC-treated water and stored at -80°C. 
 
10x PBS: 
NaCl  80.0 g 
Na2HPO4 (Merck, Darmstadt) 14.7 g 
KCl (Merck, Darmstadt)   2.0 g 
KH2PO4 (Merck, Darmstadt)   2.4 g 
Bidistilled water up to  1 l 
Adjusted to pH 7.4 
 
3.2.3.2 cDNA synthesis 
RNA concentration was measured with a spectrophotometer and samples diluted in 
DEPC-treated water to a final RNA concentration of 0.5 µg/µl. Genomic DNA was 
removed from the RNA preparation using DNase I, Amplification Grade (Invitrogen, 
Karlsruhe). 
 
DNaseI digest (per sample): 
DNase I reaction buffer, 10x (Invitrogen, Karlsruhe). 2 µl 
DNase I Amp Grade, 1U/ µl (Invitrogen, Karlsruhe). 2 µl 
DEPC-treated water 8 µl 
RNA preparation, 0.5 µg/µl 8 µl 
 
After an incubation for 15 min at room temperature, the DNase I was inactivated by the 
addition of 2 µl of 25 mM EDTA solution (Invitrogen, Karlsruhe) to the reaction 
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mixture and heating for 10 min at 65°C. cDNA was synthesized using the SuperScript 
First Strand cDNA Synthesis System (Invitrogen, Karlsruhe) in a final reaction volume 
of 55 µl. PCR reactions were prepared in DNase-, RNase and pyrogen-free 0.5 ml 
centrifuge tubes (Eppendorf, Hamburg) on ice as follows: 
 
RNA/ primer mixture (per sample): 
dNTPs, 10 mM  2.75 µl 
Random hexamer primer (Invitrogen, Karlsruhe) 2.75 µl 
Template RNA, 4 µg  22.0 µl 
 
cDNA synthesis mix (per sample):  
RT buffer, 10x (Invitrogen, Karlsruhe)   5.5 µl 
MgCl2, 25 mM (Invitrogen, Karlsruhe) 11.0 µl 
DTT, 0.1 M (Invitrogen, Karlsruhe)   5.5 µl  
RNaseOUT, 40 U/ µl (Invitrogen, Karlsruhe) 2.75 µl 
Superscript III RT, 200 U/ µl (Invitrogen, Karlsruhe) 2.75 µl 
 
The RNA/ primer mixture was incubated at 65°C for 5 min and chilled on ice for 1 min. 
The cDNA synthesis mix was intermixed and reverse transcription was carried out as 
follows: 
 
Step 1: 25°C  – 10 min  
Step 2: 42°C  – 50 min  
Step 3: 70°C  – 15 min  
Step 4: 4°C  –   1 min  
 
Finally RNA was degraded by addition of 2.75 µl of RNase H (Invitrogen, Karlsruhe) 
and incubation at 37°C for 20 min.  
 
3.2.3.3 Quantitative real-time PCR (RT-PCR) 
PCR reactions were prepared in 96 well real-time PCR plates (Eppendorf, Hamburg) in 
a total reaction volume of 20 µl using the Taq DNA polymerase Kit and HotStar Taq 
polymerase (Quiagen, Hilden). The intercalating dye SYBR
®
 Green (Lonza, Basel, 
Switzerland) was used as fluorescent reporter in the reaction. 
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Mastermix (per reaction): 
PCR buffer, 10x 2.0 µl 
MgCl2, 25 mM 1.0 µl 
Q-Solution 4.0 µl 
dNTPs,10mM 0.5 µl 
Forward primer, 10 µM 1.0 µl 
Reverse primer, 10 µM 1.0 µl 
SYBR
®
 Green, 1: 2000 0.8 µl 
HotStar Taq, 5 U/ µl 0.2 µl 
Bidistilled water 7.5 µl 
cDNA 2.0 µl 
 
Real-time PCR plates were sealed using a heat sealing foil (Eppendorf, Hamburg) and 
DNA was amplified and quantified in a Mastercycler
®
 ep realplex PCR machine 
(Eppendorf, Hamburg) according to the following protocol: 
 
Step 1: 95°C  – 15 min (DNA denaturation) 
Step 2: 95°C  – 30 s (DNA denaturation) 
Step 3: 55°C  – 30 s (primer annealing) 
Step 4: 72°C  – 30 s (elongation) 
Step 5: 82°C  – 20 s (DNA quantification) 
Step 6: 95°C  – 15 s (DNA denaturation) 
Step 7: 60°C  – 15 s 
Step 8: Heating to 95°C  – 20 min (melting curve determination) 
Step 9: 95°C  – 15 s 
 
Steps 2 to 5 were repeated 55 times (56 amplification cycles in total) whereupon the 
program continued with step 6. The amount of Dro1 cDNA was compared to the 
amount of the housekeeping gene Gapdh and each sample was normalized on the basis 
of its Gapdh content. 
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3.2.4 Evaluation of gene expression at the protein level  
3.2.4.1 Extraction of proteins from tissues 
Tissue samples (heart, lung, liver, spleen, kidney, intestine, white adipose tissue, 
skeletal muscle) were frozen on dry ice and stored at -80°C until needed. 
Approximately 50 mg of frozen tissue samples were transferred to a 5 ml plastic tube 
containing 400 µl of protein extraction buffer and homogenized at 23500 rpm for 30 s. 
To avoid protein carryover between samples the homogenizer was rinsed with 
bidistilled water after each sample. The homogenate was transferred to a 1.5 ml 
centrifuge tube, incubated for 5 min at 95°C, cooled down on ice for 5 min, and 
centrifuged for 5 min at 4°C and 13.000 x g. The supernatant containing the proteins 
was transferred to a fresh 1.5 ml centrifuge tube and samples were stored at -20°C until 
needed. 
 
Protein extraction buffer: 
Tris, 1M, pH 7.5        2 ml 
Triton X-100 (Roth, Karlsruhe)        2 ml 
Laemmli buffer, 5x      20 ml 
Bidistilled water      76 ml 
 
5x Laemmli buffer: 
Tris, 1M, pH 6.8   65.5 ml 
Glycerol (Roth, Karlsruhe) 100.0 ml 
EDTA, 0.5M, pH 8.0     2.0 ml 
SDS     20.0 g 
Bromphenol blue (Serva, Heidelberg)       0.1% 
Bidistilled water up to  200 ml 
 
3.2.4.2 Determination of protein concentration 
To determine the protein content of the samples, a bicinchoninic acid (BCA) protein 
assay was performed. For generation of a standard curve, serial dilutions of a bovine 
serum albumin (BSA; Roth, Karlsruhe) stock solution (4 mg/ml) were prepared. 10 µl 
of the samples of unknown protein concentration and of the standards were added into 
the wells of a 96-well plate (Becton Dickinson, Heidelberg) individually and intermixed 
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with 200 µl CuSO4-BCA solution and 40 µl 1x PBS. The reaction was incubated for 
30 min at 37°C and the absorbance was measured at 562 nm in a micro-plate reader 
(Tecan, Männedorf, Switzerland). For generation of a standard curve, protein 
concentrations of standards were plotted versus their absorbance. To obtain protein 
concentration in the unknown samples their absorbance was applied to the standard 
curve.  
 
CuSO4-BCA solution: 
CuSO4 solution (Sigma-Aldrich, Deisenhofen)      70 µl 
BCA (Sigma-Aldrich, Deisenhofen) 3430 µl 
 
3.2.4.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein separation was performed using the Mini Protean
®
 3 cell system (Bio-Rad, 
Munich). Preparation of the separating gel was accomplished in a 50 ml glass beaker 
under continuous agitation and poured into the space between the glass plates of the 
system, leaving space for the stacking gel. To ensure a plain surface the gel was covered 
with bidistilled water. After polymerization for 1 h the stacking gel was prepared 
accordingly, poured on top of the separating gel and a comb was inserted. After 
polymerization, the plates were implanted into the electrophoresis chamber filled with 
SDS-PAGE electrophoresis buffer and the comb was removed. Prior to loading, 20 µg 
of each protein sample was transferred to a fresh 1.5 centrifuge tube, filled up with 1x 
Laemmli buffer to 30 µl, incubated at 95°C for 5 min and chilled on ice. In some 
experiments 5% 2-mercaptoethanol (Merck, Darmstadt) was added to the protein 
samples. Samples were loaded into the wells of the gel along with a molecular weight 
marker (PageRuler
TM
Prestained Protein Ladder, MBI Fermentas, St. Leon-Rot) and 
separated by electrophoresis on the stacking gel at 100 V for 15 min and on the 
separating gel at 140 V until the dye front run off the bottom of the gel. 
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Separating gel (12%):  
Tris, 0.5 M, pH 8.8    2.5 ml 
Acrylamide, 30% (Bio-Rad, Munich)   4.0 ml 
SDS, 10%    100 µl 
Ammonium persulfate, 10% (Bio-Rad, Munich)     50 µl 
Temed (Bio-Rad, Munich)       5 µl 
Bidistilled water  3.35 ml 
 
Stacking gel (5%): 
Tris, 0.5 M, pH 6.8  1.25 ml 
Acrylamide, 30%    1.5 ml 
SDS, 10%    100 µl 
Ammonium persulfate, 10%    100 µl 
Temed        5 µl 
Bidistilled water  3.35 ml 
 
SDS-PAGE electrophoresis buffer: 
Tris  30.3 g 
Glycine (Merck, Darmstadt)  144 g 
SDS     10 g 
Bidistilled water up to  1 l 
 
3.2.4.4 Blotting 
Transfer of the separated proteins was performed using a semidry electroblotting 
apparatus (Bio-Rad, Munich). A polyvinylidene difluoride (PVDF) membrane 
(Millipore, Billerica, USA) was cut the size of the gel and kept in methanol (Merck, 
Darmstadt) until needed. Two sheets of blotting paper (Bio-Rad, Munich) were soaked 
in 200 ml of 1x transfer buffer containing 40 ml methanol. One sheet of blotting paper 
was placed onto the semidry blotter and covered with the membrane. The gel was taken 
out of the electrophoresis apparatus, placed on top of the membrane and covered with 
another sheet of blotting paper. Between each step air bubbles were removed by use of a 
pipette. The upper electrode was put onto the blotting apparatus and blotting was carried 
out at 15 mA for 1 h. 
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10x transfer buffer: 
Tris  58.2 g 
Glycine  29.2 g 
SDS    3.7 g 
Bidistilled water up to  1 l 
 
3.2.4.5 Detection 
After blotting, the PVDF membrane was placed in a glass hybridization tube and 
incubated in 1x Tris buffered saline Tween20 (TBST) containing 5% instant skimmed 
milk powder (Roth, Karlsruhe) for 60 min, washed 2 times with 1x TBST for 5 min and 
treated with the primary antibody diluted in 1x TBST containing 1% milk powder for 
60 min. The membrane was washed 3 times for 5 min with 1x TBST, incubated with the 
secondary antibody diluted 1: 10.000 in 1x TBST containing 1% milk powder for 
60 min and washed 2 times with 1x TBST for 20 min. For detection, the membrane was 
treated with 2 ml ECL Western blotting Detection Reagent (GE Healthcare, Munich), 
enveloped in plastic foil and exposed to a chemiluminiscence film until the required 
signal strength was achieved. All incubation steps were carried out at room temperature 
with gentle agitation. 
To remove primary and secondary antibodies the membrane was treated with Restore 
Western Blot Stripping Buffer (Thermo Scientific, Rockford, USA) for 10 min, washed 
3 times for 1 min with bidistilled water and washed 2 times for 5 min with 1x TBST. 
 
25x TBS:  
Tris    60 g 
NaCl   200 g 
HCl, 12 N (Merck, Darmstadt) 7.9 ml 
Bidistilled water up to  1 l 
Adjusted to pH 7.6  
 
1x TBST: 
25x TBS  40 ml 
Tween
®
20 (Sigma-Aldrich, Deisenhofen)     2 ml 
Bidistilled water up to  1 l 
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Primary antibodies:  
Mouse anti-actin antibody (MP Biomedicals, Solon, USA), diluted 1: 1000 
Rabbit anti-CCDC80 antibody (Acris, Herford), diluted 1: 5000  
Rabbit anti-CCDC80 antibody (Sigma-Aldrich, Deisenhofen), diluted 1: 1000 
 
Secondary antibodies:  
Donkey anti-rabbit antibody (GE Healthcare, Munich), diluted 1: 10.000 
Goat anti-mouse antibody antibody (MP Biomedicals, Solon, USA), diluted 1: 10.000 
 
3.2.5 Histological analysis 
3.2.5.1 Hematoxilin and eosin (H&E) staining 
Heart, lung, liver, spleen, kidney, intestine and the cranial tip of the epididymal white 
adipose tissue depot were dissected, the intestine processed as described in Chapter 
3.2.6.1, samples placed in a histology cassette (Medite, Burgdorf) and fixed in 4% 
buffered formaldehyde solution at 4°C for a minimum of 24 h. Samples were 
dehydrated, embedded in paraffin, and 4 μm tissue sections were cut and mounted on 
glass microscope slides (Menzel-Gläser, Braunschweig). After the sections dried for 3 d 
at room temperature they were deparaffinized in Roti
®
-Histol (Roth, Karlsruhe) for 
40 min and rehydrated in a descending graded alcohol series (100% ethanol, 90% 
ethanol, 80% ethanol, 70% ethanol, 50% ethanol) down to bidistilled water. They were 
stained in hematoxylin solution according to Mayer (Sigma-Aldrich, Deisenhofen) for 2 
min, rinsed under running tap water for approximately 10 min and counterstained in 
eosin solution (Medite, Burgdorf) for 2.5 min. Next, slices were rinsed in bidistilled 
water, dehydrated in an ascending graded alcohol series (50% ethanol, 70% ethanol, 
80% ethanol, 90% ethanol, 100% ethanol) to Roti
®
-Histol and mounted with mounting 
medium (VWR International, Darmstadt) and cover glass slides. Histopathologic 
analysis of H&E-stained tissue sections was performed in a blinded manner by Dr. Jens 
Neumann, Institute of Pathology, University of Munich. 
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4% buffered formaldehyde solution: 
Paraformaldehyde (Sigma-Aldrich, Deisenhofen)  40 g 
10x PBS  100 ml 
NaOH, 5 M  250 µl 
Bidistilled water up to  1 l 
Adjusted to pH 7.4 
 
3.2.5.2 Periodic acid Schiff (PAS) staining  
Intestines were processed, formaldehyde fixed and paraffin embedded as described in 
Chapter 3.2.6.1. PAS staining was performed according to a standard protocol at the 
Institute of Pathology, University of Munich. The number of PAS-positive cells per 
total cells in the crypt-villus axis of the small intestine was counted in 20 crypts per 
mouse. 
 
3.2.5.3 Elastic van Gieson (EvG) staining 
Livers were formaldehyde fixed and paraffin embedded as described in Chapter 3.2.5.1. 
EvG staining was performed according to a standard protocol at the Institute of 
Pathology, University of Munich. Histopathologic examination of EvG-stained tissue 
sections was performed in a blinded manner by Dr. Jens Neumann, Institute of 
Pathology, University of Munich. 
 
3.2.6 Immunohistochemistry (IHC) 
3.2.6.1 Bromodeoxyuridine (BrdU) staining 
BrdU is a proliferation marker that is incorporated, instead of thymidine, into the newly 
synthesized DNA of cycling cells. To analyse cell proliferation in the intestine, mice 
were injected intraperitoneally with BrdU (30 mg/kg body weight; Roche, Mannheim) 
1 h prior to sacrifice. Mice were killed and the intestine excised immediately. The 
caecum was discarded and the colon and small intestine rinsed with 1x PBS to remove 
fecal material. The small intestine was cut equally into 3 pieces. Each intestine section 
was curled up in a histology cassette and fixed in 4% buffered formaldehyde solution at 
4°C for 48 h. After the samples were dehydrated and embedded in paraffin, 4 μm tissue 
sections were sliced and mounted on superfrost glass microscope slides (Menzel Gläser, 
Braunschweig). Slices were dried for 1 week at room temperature, and baked at 45°C 
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for 1 h to improve the adherence of the tissue to the glass microscope slides and to melt 
the paraffin. They were deparaffinised and rehydrated as described above (Chapter 
3.2.5.1) and heat-induced epitope retrieval was performed by cooking in Target 
Retrieval Solution (Dako, Hamburg) at 99°C for 40 min. Cooled slices were washed 2 
times in 1x TBS for 2 min, incubated in rabbit serum (PromoCell, Heidelberg) diluted 
1: 10 in 1x TBS for 30 min and treated with rat anti-BrdU primary antibody (Serotec, 
Düsseldorf) diluted 1: 50 in 1x TBS for 1 hour. The slices were washed 2 times for 
2 min in 1x TBS and incubated in 3% H2O2 (Roth, Karlsruhe) for 10 min. The samples 
were then washed 3 times in 1x TBS for 2 min and incubated in rabbit anti-rat 
secondary antibody (Serotec, Düsseldorf) diluted 1: 50 in 1x TBS for 30 min. They 
were washed again 3 times for 2 min in 1x TBS and subsequently treated with 
diaminobenzidine solution (Sigma-Aldrich, Deisenhofen) until the required staining 
strength was achieved. The staining reaction was stopped by washing in 1x TBS. Next, 
slices were stained in hematoxylin solution according to Mayer for 30 s, rinsed under 
running tap water for approximately 10 min, dehydrated to Roti
®
-Histol as described 
above (Chapter 3.2.5.1) and mounted with mounting medium and cover glass slides. All 
incubation, washing and staining steps were carried out at room temperature. To 
evaluate intestinal proliferation the number of BrdU-stained cells was counted in 20 
crypts of the small intestine and 20 crypts of the colon per mouse.  
 
10x TBS: 
NaCl  80.0 g 
Tris  30.0 g 
Bidistilled water up to  1 l 
Adjusted to pH 7.4 
 
3.2.6.2 Matrix metalloproteinase-7 (MMP-7) staining 
MMP-7 staining was performed to identify Paneth cells. Intestines were processed, 
formaldehyde fixed and paraffin embedded as described above (Chapter 3.2.6.1) and 
4 μm tissue sections were cut, mounted on superfrost microscope glass slides and dried 
at 37°C for 3 d. For antigen unmasking, deparaffinised sections were sub-boiled at 95°C 
for 40 min in 10 mM sodium citrate buffer (pH 6.0). Cooled sections were incubated in 
methanol containing 3% H2O2 for 30 min, washed 3 times for 5 min in 1x PBS, treated 
with 0.5% BSA dissolved in 1x PBS for 30 min and incubated overnight at 4°C in goat 
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anti-MMP-7 (Santa Cruz Biotechnology, Heidelberg) primary antibody diluted 1: 100 in 
1x PBS. Next day sections were washed 3 times for 5 min in 1x PBS and incubated in 
donkey anti-goat biotinylated secondary antibody (Santa Cruz Biotechnology, 
Heidelberg) diluted 1: 200 in 1x PBS for 30 min. After being treated with avidin-biotin-
peroxidase complexes (Vector Laboratories, Burlingame, USA) for 30 min, the sections 
were washed 3 times for 5 min in 1x PBS and incubated in diaminobenzidine solution 
for 10 min. The staining reaction was stopped by washing for 5 min in 1x PBS. Finally, 
the sections were washed for 5 min in bidistilled water, stained in hematoxylin solution 
according to Mayer for 30 s, rinsed under running tap water for approximately 10 min, 
dehydrated to Roti
®
-Histol as described above (Chapter 3.2.5.1) and mounted with 
mounting medium and cover glass slides. Incubation, washing and staining steps were 
performed at room temperature if not differently stated.    
 
3.2.6.3 Cleaved caspase-3 staining  
To identify apoptotic cells, cleaved caspase-3 staining was performed on intestinal 
tissue sections. Intestines were processed, formaldehyde fixed and paraffin embedded as 
described above (Chapter 3.2.6.1), and 4 μm tissue sections were cut, mounted on 
superfrost microscope glass slides and dried at 37°C overnight. Sections were 
deparaffinised in Roti
®
-Histol for 10 min, incubated in ethanol for 10 min and treated 
with 96% ethanol for 2 min before being transferred to methanol containing 3% H2O2. 
For antigen retrieval, slices were cooked in 1x TBS containing 0.001% Tween
®
20 in a 
pressure cooker. After incubation in 1x TBS containing 5% goat serum (Sigma-Aldrich, 
Deisenhofen), the sections were treated with avidin blocking reagent (Vector 
Laboratories, Burlingame, USA) for 15 min, washed in 1x TBS for 1 min, and treated 
with biotin blocking reagent (Vector Laboratories, Burlingame, USA) for 15 min. After 
being incubated with primary rabbit anti-cleaved caspase-3 antibody (Cell Signaling, 
Danvers, USA) diluted 1: 200 in 1x TBS, sections were washed 3 times for 5 min in 1x 
TBS and incubated with goat anti-rabbit secondary antibody (DAKO, Hamburg) diluted 
1: 200 in 1x TBS. Sections were then treated with avidin-biotin-peroxidase complexes 
for 30 min, washed 2 times in 1x TBS for 5 min and incubated with diaminobenzidine 
solution for 5 min. Thereafter slices were processed as described above (Chapter 
3.2.6.2). The number of cleaved caspase-3-positive cells was counted in 50 crypt-villus 
units in the small intestine and in 100 crypts in the colon per mouse. 
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3.2.6.4 β-catenin staining 
Intestines were processed, formaldehyde fixed and paraffin embedded as described 
above (Chapter 3.2.6.1). Immunohistochemistry of β-catenin in the intestine was 
performed by the Institute of Pathology, University of Munich. β-catenin-stained 
intestinal sections were evaluated for the accumulation of nuclear β-catenin by 2 
investigators who were blinded to the experimental groups. Within neoplastic tissue the 
percentage of nuclear β-catenin-positive cells was estimated. 
 
3.2.6.5 Ki-67 staining 
Intestines were processed, formaldehyde fixed and paraffin embedded as described 
above (Chapter 3.2.6.1). Immunohistochemistry of Ki-67 in the intestine was performed 
by the Institute of Pathology, University of Munich. The percentage of Ki-67-positive 
cells within neoplastic tissue was estimated by 2 investigators who were blinded to the 
experimental groups.  
 
3.2.7 Analysis of body and organ growth 
Body weight of mice was recorded using a laboratory scale (BP4100S, Sartorius, 
Göttingen). Nose-rump-length (NRL), defined as the distance from the tip of the nose to 
the base of the tail, was measured under anesthesia with the aid of a ruler. Anesthesia 
was induced by intraperitoneal injection of ketamine (100 mg/kg body weight, Bremer 
Pharma, Warburg) and xylazine (5 mg/kg body weight, Selectavet, Munich). To 
determine organ weight, the animals were killed, the organs (heart, lungs, liver, spleen, 
kidneys) immediately excised, blotted dry from blood on absorbent paper and weighted 
to the nearest mg with a laboratory scale (BP221S, Sartorius, Göttingen). For bilateral 
organs the paired weight was recorded. Carcass weight was determined after the 
removal of organs, fat pads, skin and head. For long bone size analysis, femora were 
dissected, coarsely freed from surrounding tissue, incubated in 1x PBS at 80°C for 2 h, 
and maintained in 1% papain (Merck, Darmstadt) at 37°C overnight. After the bones 
were cleaned with water and dried at 37°C overnight, their length was determined with 
a slide rule. 
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3.2.8 Analysis of adipose tissue parameters 
3.2.8.1 Total body fat content 
Total body fat content and lean mass were analyzed in live mice by magnetic resonance 
imaging (MRI) using the Minispec LF50 (Bruker, Karlsruhe). After recording their 
body weight, the mice were placed in a perforated plastic cylinder (Bruker, Karlsruhe), 
carefully restrained with the aid of a plastic plunger (Bruker, Karlsruhe) and inserted 
into the Minispec LF50 for a 2 min lasting measurement. Total body fat and lean mass 
values in percent were converted to fat in g. To guarantee accurate measurement and to 
reduce stress in animals, analyses did not start before the mice were 4 weeks of age.    
  
3.2.8.2 Fat pad weight 
Mice were sacrificed, and the epididymal, abdominal and subcutaneous white fat pads 
were excised and weighted to the nearest mg using a laboratory scale. 
 
3.2.9 Analysis of liver triglyceride content 
At necropsy the liver was resected, frozen on dry ice and stored at -80°C until needed. 
50 mg of frozen tissue were transferred to a 5 ml tube containing 500 μl of 0.9% NaCl 
solution and homogenized at 23500 rpm for 60 s. To avoid sample carryover the tip of 
the homogenizer was rinsed with 0.9% NaCl for 30 s after each sample. The 
homogenate was centrifuged at 14.000 x g for 1 min to pelletize tissue debris and the 
supernatant containing the triglycerides was transferred to a clean centrifuge tube. The 
triglyceride content of the supernatant was determined by use of the Triglyceride FS Kit 
(DiaSys, Holzheim). The principle of this test involves enzymatic hydrolysis of 
triglycerides by lipase into glycerol and free fatty acids. The glycerol produced is then 
measured in a series of enzymatic reactions by the formation of a quinoneimine dye. To 
create a standard curve for triglyceride concentration, a dilution series of the 
Triglyceride FS standard (200 mg triglycerides/dl; DiaSys, Holzheim) was prepared. 
10 μl of the supernatant or standard were pipetted in duplicate into the wells of a 96-
well plate, treated with 10 μl of 1% dioxycholic acid (Merck, Darmstadt) and incubated 
for 5 min at 37°C with gentle agitation. 200 μl of Triglyceride FS reagent (DiaSys, 
Holzheim) were added to each well, incubated for 20 min at 37 °C with gentle shaking 
and absorbance was measured in a micro-plate reader at 495 nm against blank. A 
standard curve was generated by plotting absorbance of standards versus their 
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triglyceride concentration. Triglyceride content of samples was calculated with the aid 
of the standard curve. 
 
3.2.10 Evaluation of serum parameters 
3.2.10.1 Blood collection 
Blood was drawn from the retro-orbital sinus with heparinized capillary tubes (Brand, 
Gießen) under ketamine and xylazine injection narcosis (Chapter 3.2.7) and collected in 
a 1.5 ml centrifugation tube. Blood samples were centrifuged at 7.000 x g for 10 min at 
4°C to isolate serum. Serum was stored in aliquots of 50 μl at -80°C until use.  
 
3.2.10.2 Serum free fatty acids 
Free fatty acids were determined in 10 μl of serum using the Free Fatty Acid 
Quantification Kit (Abcam, Cambridge, United Kingdom) according to the 
manufacturer`s manual. The principle of the assay is the conversion of fatty acids to 
their CoA derivatives, which are subsequently oxidized with the concomitant generation 
of color.  
 
3.2.10.3 Serum triglycerides 
Serum triglycerides were measured with the Triglyceride FS Kit. For information on the 
principle of the test and preparation of the standard curve see above (Chapter 3.2.9). 10 
μl of serum and 200 μl of Triglyceride FS reagent were intermixed in the wells of a 96-
well plate in duplicate, incubated for 20 min at 37°C with gentle shaking and 
absorbance was measured in a micro-plate reader at 495 nm against blank. Triglyceride 
concentration of serum samples was calculated using a standard curve.  
 
3.2.11 Analysis of glucose tolerance and insulin tolerance 
After mice were fasted for 16 h (5 pm to 9 am), blood glucose level was measured in a 
drop of blood from the tail vein using a glucometer (Abbot, Ludwigshafen). 
Subsequently mice were injected intraperitoneally either with glucose solution (1.5 g/kg 
body weight; B. Braun, Melsungen) for glucose tolerance test or with insulin (0.75 U/kg 
body weight; B. Braun, Melsungen) for insulin tolerance test. In both assays blood 
glucose levels were determined 20, 40, 60 and 120 min after administration of glucose 
or insulin.  
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3.2.12 Evaluation of preadipocyte differentiation in primary cell culture 
Stromal vascular (SV) cells were isolated, cultured and differentiated according to 
Hausman et al., 2008. 
 
3.2.12.1 Isolation of SV cells 
For isolation of SV cells, inguinal fat pads of 5 mice were pooled. Mice were killed by 
cervical dislocation, the lower abdominal area disinfected with isopropanol and the 
abdominal skin incised in the mid-line. Inguinal fat pads were dissected using sterile 
instruments and transferred to a 10 cm Petri dish (Becton Dickinson, Heidelberg) filled 
with 20 ml prewarmed DMEM/F12 medium (PAA Laboratories GmbH, Pasching, 
Austria) containing 100 units penicillin (Sigma-Aldrich, Deisenhofen) and 0.1 mg 
streptomycin (Sigma-Aldrich, Deisenhofen) per ml (in the following referred to as 
DMEM/F12 medium). Inguinal fat pads were transferred to a sterile 100 ml glass 
beaker, and minced with sterile pointed scissors. After adding 10 ml of digestion buffer, 
the beaker content was transferred to a 100 ml Erlenmeyer flask.  
 
Digestion buffer: 
HEPES (Sigma-Aldrich, Deisenhofen) 0.1 M 
NaCl 0.12 M 
KCl 50 mM 
D-glucose (Sigma-Aldrich, Deisenhofen) 5 mM 
BSA 1.5% 
Calcium chloride (Merck, Darmstadt) 1 mM 
Collagenase type I (Sigma-Aldrich, Deisenhofen)  10.000 U 
Dissolved in bidistilled water  
 
Following incubation in a rotating shaker (Infors AG, Bottmingen) for 60 min at 37°C 
and 115 rpm, the undigested tissue was removed by pouring the solution through a 
100 μm nylon cell strainer (Becton Dickinson, Heidelberg) into a 50 ml centrifugation 
tube (Becton Dickinson, Heidelberg). Additional 20 ml of DMEM/F12 medium were 
added and the cell suspension centrifuged at 200 x g for 10 min at room temperature to 
pelletize SV cells. The supernatant was removed and cells resuspended in 30 ml of fresh 
DMEM/F12 medium containing 10% fetal bovine serum (FBS; Biochrom AG, Berlin). 
To remove cell clumps, the cell suspension was filtered through a 40 μm nylon cell 
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strainer (Becton Dickinson, Heidelberg) into a 50 ml centrifugation tube. After 
centrifugation at 200 x g for 10 min at room temperature, the supernatant was discarded, 
cells resuspended in 7.5 ml of DMEM/F12 medium containing 10% FBS and plated in 
12 well cell culture plates (Becton Dickinson, Heidelberg) at a density of 4.8 x 10
3 
cells/cm
2
. 
 
3.2.12.2 Maintenance and differentiation of SV cells 
One day after plating, the medium was replaced with DMEM/F12 medium containing 
5% FBS and exchanged every 2 d until the cells became confluent. Differentiation of 
preadipocytes was induced by incubating confluent cells with induction medium for 
72 h.  
 
Induction medium: 
Dexamethasone (Sigma-Aldrich, Deisenhofen)  0.1 μM 
IBMX (Sigma-Aldrich, Deisenhofen) 250 μM 
Insulin   17 nM 
Dissolved in DMEM/F12 medium containing 5% FBS 
 
The induction medium was exchanged for DMEM/F12 medium containing 10% FBS 
and 17 nM insulin. The insulin containing medium was removed after 72 h and replaced 
with DMEM/F12 medium containing 10% FBS. Every other day 70% of the medium 
was substituted with fresh DMEM/F12 medium containing 10% FBS until cells were 
filled with lipid droplets. 
 
3.2.12.3 Oil red O staining 
Adipocyte lipid droplets were identified by oil red O staining. The medium was 
removed, each well rinsed with 500 μl 1x PBS and cells fixed by addition of 1 ml 4% 
buffered formaldehyde solution. After 10 min the fixative was removed, cells rinsed 
with 60% isopropanol for 30 s and oil red O stain (0.34 mM oil red O (Sigma-Aldrich, 
Deisenhofen), dissolved in 60% isopropanol) applied 1 ml per well for 10 min. Cells 
were rinsed again with 60% isopropanol for 30 s and 500 μl 1x PBS were added to each 
well. Oil red O staining was accomplished according to Ramírez-Zacarías et al., 1992. 
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3.2.12.4 Differentiation scoring 
To evaluate differentiation properties of SV cells the number and size of oil red O-
stained lipid droplets were counted by computer image analysis. Oil red O-stained wells 
were viewed under a light microscope (Olympus, Hamburg) at 100x magnification and 
areas showing a high density of lipid droplets were photographed with a digital camera 
(Olympus, Hamburg). Images were processed with GIMP Portable (Freeware, 
Copyright by John T. Haller) so that all colors, except red, were removed. The 
following commands were used for the conversion: Color saturation (All: -100, Red: 
+100), Transparency, New layer (Layer fill type: White), Lower layer. An accurate 
conversion was ensured by comparing the converted images to the original images. 
Photos were converted into black and white and the quantity and mean area of black 
particles were analyzed with Image J (Freeware) using the following commands: Image 
(8-bit), Threshold (Default, Red), Analyze Particles (Size: 10-Infinity; Circularity: 0.00-
1.00). To minimize incorrectness caused by staining artifacts values less than 10
2
 pixel 
were excluded from analysis. An example of digital image processing is shown in Fig. 
3.2.  
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Fig. 3.2 Oil red O-stained differentiated SV cells were photographed at 100x 
magnification (A). All colors except red were erased by digital image processing (B) 
and photos converted into black and white (C). The number and mean area of black 
particles were counted by computer image analysis.   
3.2.13 Analysis of aberrant crypt foci (ACF) 
3.2.13.1 Tissue collection 
Mice were sacrificed at the age of 5 and 10 weeks, respectively. The colon was excised 
and rinsed with 1x PBS to remove fecal content. After the colon was cut into 2 equal 
sections, each segment was put on a Super Frost microscope glass slide, opened 
longitudinally and laid open. A piece of filter paper cut the size of the glass slide was 
placed on the top and attached by the aid of paper clips. Samples were fixed in 4% 
buffered formaldehyde solution at 4°C for a minimum of 24 h. 
 
3.2.13.2 Methylene blue staining 
The formaldehyde-fixed intestinal sections on the microscope glass slides were washed 
2 times for 10 min in 1x PBS. Filter paper and paper clips were removed and samples 
stained in 0.1% methylene blue staining solution (Sigma-Aldrich, Deisenhofen) for 
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3 min. The colon was mounted with liquid gelatin (Merck, Darmstadt) and a cover glass 
slide, and the samples were stored at 4°C until the gelatin solidified. Methylene blue 
staining was accomplished according to Bird, 1987. 
 
3.2.13.3 ACF scoring 
Whole-mount colonic samples were placed under a dissecting microscope (Zeiss, Jena) 
and examined at 25x magnification. The criteria used to identify ACF were increased 
crypt size (in comparison to most crypts in the field), round or elongated luminal 
openings and a thickened layer of epithelial cells that stain more intensely with 
methylene blue (Bird, 1987; Fenoglio-Preiser and Noffsinger, 1999; Boivin et al., 2003; 
Gupta et al., 2008). 
 
3.2.14 Analysis of weight and length of the intestine  
Mice were sacrificed and the intestine excised immediately. The caecum was discarded 
and the small intestine and colon rinsed with 1x PBS to remove fecal material. Small 
intestine and colon were weighted to the nearest mg with a laboratory scale and their 
length was measured with a ruler. 
 
3.2.15 Analysis of intestinal neoplastic lesions 
3.2.15.1 Tissue collection 
Mice were killed, the intestine dissected and transferred to a plastic dish containing 1x 
PBS. The caecum was discarded and the colon and small intestine rinsed with 1x PBS 
to remove fecal material. The small intestine was cut into 3 equal segments and each 
intestinal section was placed on a piece of filter paper, opened longitudinally, laid open 
and fixed in 4% buffered formaldehyde solution at 4°C for a minimum of 24 h.  
 
3.2.15.2 Tumor scoring  
Formaldehyde-fixed intestinal sections were placed under running water for 10 min to 
remove excess formaldehyde. The intestine was detached from the filter paper and 
tumor number and their maximum diameter were determined under a dissecting 
microscope at 10x magnification. Depending on their size, tumors of the small intestine 
were classified into the categories “≤ 2 mm” and “> 2.5 mm”. Because of uncertainty 
about the precise anatomic demarcation, the colon and rectum were scored as “colon”. 
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A quantity of small intestinal lesions and all colonic tumors sized ˃ 2 mm in diameter 
were resected including adjacent normal tissue, dehydrated and embedded in paraffin. 4 
µm tissue sections were cut in parallel with the mucosal surface, mounted on glass 
microscope slides and stained with H&E. Histopathologic analysis of neoplastic lesions 
was performed in a blinded manner by Dr. Jens Neumann, Institute of Pathology, 
University of Munich, using standard criteria for the classification of human adenomas 
of the colon and the assessment of the degree of dysplasia. The diagnosis intramucosal 
adenocarcinoma was made for lesions with high grade dysplasia/IEN in combination 
with focal invasion of the lamina propria mucosae. Adenocarcinomas invading through 
the lamina muscularis mucosae into the tela submucosa were termed invasive 
adenocarcinoma.      
 
3.2.16 Statistical analysis 
All data are displayed as means ± standard deviation. All data were analyzed for normal 
distribution using Kolmogorov-Smirnov test with Dallal-Wilkinson-Lilliefor P value 
(GraphPad Prism version 4.00 for Windows, GraphPad software, San Diego, USA). To 
analyze significance of differences, two-tailed Student`s t-test (normally distributed 
data) or two-tailed Mann Whitney U test (not normally distributed data) were performed 
(GraphPad Prism version 4.00 for Windows). Body weight gain, total body fat gain and 
lean mass gain were evaluated by 2-factorial ANOVA (GraphPad Prism version 4.00 
for Windows). P values < 0.05 were considered to be statistically significant.   
 
3.2.17 Primer sequences 
Sequences of the primers used in the experiments are the following: 
 
Name Sequence 
β-actinFW 5’-GGCATCGTGATGGACTCC-3’ 
β-actinRV 5’-GTCGGAAGGTGGACAGGG-3’ 
Apc33 5’-GCCATCCCTTCACGTTAG-3’ 
Apc34 5’-TTCCACTTTGGCATAAGGC-3’ 
Apc758 5’-TTCTGAGAAAGACAGAAGTTA-3’ 
Cre1 5’-AATCGCCATCTTCCAGCAGG-3’ 
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Name Sequence 
Cre2 5’-GATCGCTGCCAGGATATACG-3’ 
Dro3’end#1 5’-GCA AAG CTC TAG ATA AGC CAG-3’ 
Dro3’end#2 5’-ACT CCT GTT CAT AAT GGC CAG-3’ 
Dro1homo1 5’-TTCTTTAACTATCTCCTGCCC-3’ 
Dro1homo2 5’-CATCATTGTATTATCCACTTGG-3’ 
Dro1rec 5’-ACGTGTCTCTGAGTTTCACAAC-3’ 
mDro1FW 5’-CTTCCTCCTGCTCCAGTCAC-3’ 
mDro2RV 5’-CTGGATAGGCAGTGGTGGTT-3’ 
mGapdhFW 5’-TCATCAACGGGAAGCCCATCAC-3’ 
mGapdhRV 5’-AGACTCCACGACATACTCAGCACCG-3’ 
Mom1#1 5’-GTC-CAA-GGG-AAC-ATT-GCG-3’ 
Mom1#2 5’-AGA-ACA-GGT-GAT-TTG-GCC-C-3’ 
 
3.2.18 Materials 
3.2.18.1 Machines  
Agarose gel electrophoresis chamber   MWG-Biotech, Ebersberg 
Analytical balance   Sartorius, Göttingen 
Benchtop 96 tube working rack   Stratagene, La Jolla, USA 
Blunt forceps   Aesculap, Tuttlingen 
Digital camera  Olympus, Hamburg 
Dissecting microscope   Zeiss, Jena 
Fine scissors   Aesculap, Tuttlingen 
Gel documentation system   Intas, Göttingen 
GIMP Portable  Freeware, Copyright by John T.  
  Haller 
Glucometer Precision   Abbott, Ludwigshafen 
GraphPad Prism version 4.00 for Windows  GraphPad software, San Diege, USA 
Heating plate with magnetic stirrer   IKA process Equipment, Staufen 
Homogenizer   ART Labortechnik, Müllheim 
Hybridization oven  Saur, Reutlingen 
Hybridization tube   Bachofer, Reutlingen 
Image J  Freeware  
Incubator   Heraeus, Munich 
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Laboratory scale, BP221S  Sartorius, Göttingen 
Laboratory scale, BP4100S  Sartorius, Göttingen 
Light microscope   Olympus, Hamburg 
Mastercycler
®
 ep realplex PCR machine  Eppendorf, Hamburg 
MicroPlate reader  Tecan, Männedorf, Switzerland 
Microwave   Siemens, Munich 
Mini Protean
®
 3 cell system   Bio-Rad, Munich 
Minispec LF50   Bruker, Karlsruhe 
Mouse restrainer   Bruker, Karlsruhe 
Pointed scissors   Aesculap, Tuttlingen 
Rotating shaker   Infors AG, Bottmingen  
Semidry electroblotting apparatus   Bio-Rad, Munich  
Spectrophotometer   Beckman, Palo Alto, USA 
Table centrifuge (5417R)  Eppendorf, Hamburg 
Thermal cycler   Biometra, Göttingen 
Thermomixer 5436   Eppendorf, Hamburg 
UV-Crosslinker   Biometra, Göttingen 
 
3.2.18.2 Consumables 
Blotting paper   Bio-Rad, Munich 
Cannulas   B.Braun, Melsungen 
Centrifugation tube (15 ml, 50 ml)   Becton Dickinson, Heidelberg 
Centrifuge tube (0.5 ml, 1.5 ml, 2.0 ml)   Eppendorf, Hamburg 
Chemoilluminiscence film   GE Healthcare, Munich 
Cover glass slides   VWR International, Darmstadt 
Disposable syringes (2, 5, 10, 20 ml)  Codan Medical ApS, Roedby,  
 Denmark 
Filter paper   GE Healthcare, Munich 
Glass microscope slides   Menzel-Gläser, Braunschweig 
Heat sealing foil   Eppendorf, Hamburg 
Heparinized capillary tubes  Brand, Gießen 
High fat diet  ssniff, Soest 
Histology cassettes  Medite, Burgdorf 
Multi-well cell culture plates   Becton Dickinson, Heidelberg 
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Nylon cell strainer (40 μm, 100 μm)   Becton Dickinson, Heidelberg 
Nylon membrane  Pall Corporation, Pensacola, USA 
PCR-reaction-tubes   G. Kisker GbR, Steinfurt 
Petri dishes (diameter 10 cm)   Becton Dickinson, Heidelberg  
Plastic tubes (5 ml)   Greiner Bio-One, Frickenhausen 
PVDF membrane   Millipore, Billerica, USA 
Real-time PCR plates (96 well)  Eppendorf, Hamburg 
Standard chow  ssniff, Soest  
Super Frost microscope glass slides  Menzel Gläser, Braunschweig 
 
3.2.18.3 Chemicals 
2-mercaptoethanol  Merck, Darmstadt 
Acrylamide, 30%   Bio-Rad, Munich 
Agarose    Invitrogen, Karlsruhe 
Ammonium persulfate, 10%   Bio-Rad, Munich 
Anti-DIG-AP Fab fragments   Roche, Mannheim 
Avidin blocking reagent   Vector Laboratories, Burlingame, 
USA 
Avidin-biotin-peroxidase complexes   Vector Laboratories, Burlingame, 
USA 
BamHI buffer   MBI Fermentas, St. Leon-Rot 
BamHI restriction enzyme  MBI Fermentas, St. Leon-Rot 
Bichinonic acid   Sigma-Aldrich, Deisenhofen 
Biotin blocking reagent   Vector Laboratories, Burlingame, 
USA 
Blocking solution  Roche, Mannheim 
BrdU  Roche, Mannheim 
Bromphenol blue Serva, Heidelberg 
BSA   Roth, Karlsruhe 
Buffer PstI   MBI Fermentas, St. Leon-Rot 
Calcium chloride  Merck, Darmstadt 
Chloroform  Merck, Darmstadt 
Collagenase type I  Sigma-Aldrich, Deisenhofen 
CSPD ready-to-use detection solution Roche, Mannheim 
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CuSO4   Sigma-Aldrich, Deisenhofen 
DEPC  Sigma-Aldrich, Deisenhofen 
D-Glucose  Sigma-Aldrich, Deisenhofen 
Diaminobenzidine   Sigma-Aldrich, Deisenhofen 
Diethylpyrocarbonate  Sigma-Aldrich, Deisenhofen 
DIG Block and Wash Buffer Set Roche, Mannheim 
DIG Easy Hyb buffer  Roche, Mannheim 
DIG Probe Synthesis kit  Roche, Mannheim 
DMEM/F12 cell culture medium PAA Laboratories GmbH, Pasching, 
Austria 
DNA Rehydration Solution  Promega, Mannheim 
DNase I Amp Grade, 1U/ µl  Invitrogen, Karlsruhe. 
DNase I reaction buffer, 10x  Invitrogen, Karlsruhe 
DNase I, Amplification Grade  Invitrogen, Karlsruhe 
dNTPs (DATP, dTTP, dCTP, dGTP)  MBI Fermentas, St. Leon-Rot 
Donkey anti-goat biotinylated antibody  Santa Cruz Biotechnology, 
Heidelberg  
DTT, 0.1 M  Invitrogen, Karlsruhe 
ECL Western blotting detection reagent  GE Healthcare, Munich 
EDTA solution, 25 mM   Invitrogen, Karlsruhe 
EDTA  VWR International, Darmstadt 
Enzyme mix  Roche, Mannheim 
Eosin solution   Medite, Burgdorf 
Ethanol  Merck, Darmstadt 
Ethidium bromide  Roth, Karlsruhe 
FBS   Biochrom AG 
Free Fatty Acid Quantification Kit  Abcam, Cambridge, United Kingdom 
Gelatin  Merck, Darmstadt 
Glacial acetic acid   Roth, Karlsruhe 
Glucose solution   B. Braun, Melsungen 
Glycerol  Roth, Karlsruhe 
Glycine   Merck, Darmstadt 
Goat anti-MMP-7 antibody Santa Cruz Biotechnology, 
Heidelberg 
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Goat anti-mouse antibody antibody   MP Biomedicals, Solon, USA 
Goat serum   Sigma-Aldrich, Deisenhofen  
Goat-anti-rabbit antibody   DAKO, Hamburg 
H2O2   Roth, Karlsruhe 
HCl Merck, Darmstadt)  
Hematoxylin solution according to Mayer   Sigma-Aldrich, Deisenhofen 
HEPES  Sigma-Aldrich, Deisenhofen 
Hot-start Taq, 5 U/ µl  Quiagen, Hilden 
IBMX  Sigma-Aldrich, Deisenhofen 
Isopropanol  Merck, Darmstadt 
KCl  Roth, Karlsruhe 
Ketamine  Bremer Pharma, Warburg 
KH2PO4  Merck, Darmstadt 
Loading dye (6x)  MBI Fermentas, St. Leon-Rot 
Methanol  Merck, Darmstadt 
Methylene Blue  Sigma-Aldrich, Deisenhofen 
MgCl2, 25 mM   Invitrogen, Karlsruhe 
MgCl2, 25mM   Qiagen, Hilden 
Milk powder   Roth, Karlsruhe 
Molecular weight marker  MBI Fermentas, St. Leon-Rot 
Mounting medium VWR International, Darmstadt 
Mouse anti-actin antibody  MP Biomedicals, Solon, USA 
Na2HPO4   Merck, Darmstadt 
NaCl  Roth, Karlsruhe 
NaOH  Roth, Karlsruhe  
Nuclei Lysis Solution  Promega, Mannheim 
Oil red O   Sigma-Aldrich, Deisenhofen 
PageRuler
TM
Prestained Protein Ladder SM0671 MBI Fermentas, St. Leon-Rot 
Papain  Merck, Darmstadt 
Paraformaldehyde   Sigma-Aldrich, Deisenhofen 
PCR buffer with MgCl2, 10x   Roche, Mannheim 
PCR buffer, 10x   Qiagen, Hilden 
PCR DIG Probe Synthesis mix   Roche, Mannheim 
Penicillin   Sigma-Aldrich, Deisenhofen 
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Protein Precipitation Solution   Promega, Mannheim 
Proteinase K  Roche, Mannheim 
PstI restriction enzyme  MBI Fermentas, St. Leon-Rot  
pUC mix molecular weight marker  MBI Fermentas, St. Leon-Rot 
Q-Solution Qiagen, Hilden 
Rabbit anti-CCDC80 antibody  Acris, Herford 
Rabbit anti-CCDC80 antibody  Sigma-Aldrich, Deisenhofen 
Rabbit anti-cleaved caspase-3 antibody  Cell Signaling, Danvers, USA 
Rabbit anti-rat antibody  Serotec, Düsseldorf 
Rabbit serum  PromoCell, Heidelberg 
Random hexamer primer  Invitrogen, Karlsruhe 
Rat anti BrdU primary antibody Serotec, Düsseldorf 
Restore Western Blot Stripping Buffer  Thermo Scientific, Rockford, USA 
RNase   Roche, Mannheim 
RNase H  Invitrogen, Karlsruhe 
RNaseOUT, 40 U/ µl  Invitrogen, Karlsruhe 
RNeasy Mini kit  Quiagen, Hilden 
Roti
®
-Histol   Roth, Karlsruhe 
RT buffer, 10x   Invitrogen, Karlsruhe 
SDS  Merck, Darmstadt 
Sodium citrate   Merck, Darmstadt  
Spermidine (0.1 M)   Sigma-Aldrich, Deisenhofen 
Streptomycin   Sigma-Aldrich, Deisenhofen 
SuperScript First Strand cDNA Synthesis  Invitrogen, Karlsruhe 
Superscript III RT, 200 U/ µl  Invitrogen, Karlsruhe 
SYBR
®
 Green   Lonza, Basel, Switzerland 
Taq DNA polymeras Kit   Quiagen, Hilden 
Taq Polymerase, 5U/µl  Quiagen, Hilden 
Target Retrieval Solution  Dako, Hamburg 
Temed   Bio-Rad, Munich 
Triglyceride FS Kit  DiaSys, Holzheim 
Triglyceride FS reagent  DiaSys, Holzheim 
Triglyceride FS standard,200 mg/dl  DiaSys, Holzheim 
Tris  Roth, Karlsruhe 
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Tris-HCl   Roth, Karlsruhe 
Triton X-100   Roth, Karlsruhe 
Trizol  Invitrogen, Karlsruhe 
Tween
®
20   Sigma-Aldrich, Deisenhofen 
Washing buffer   Roche, Mannheim 
 
3.2.18.4 Drugs 
Dexamethasone   Sigma-Aldrich, Deisenhofen 
Insulin rapid  B. Braun, Melsungen 
Histoacryl
®
 iquid skin glue  B. Braun, Melsungen 
Xylazine  Selectavet, Munich 
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4. Results 
4.1 Generation of Dro1
-/-
 mice 
4.1.1 Establishment of Dro1
-/-
 mice 
One of the embryonic E14 stem cell clones identified for correct construct integration 
into the Dro1 allele was injected into blastocysts from C57BL/6N mice. Transplantation 
of blastocysts into the uteri of pseudopregnant foster mothers resulted in the birth of 14 
mice of which 8 were identified as being chimeric. Crossing of chimeras into the 
C57BL/6N background and screening of the progeny by PCR identified 3 animals to 
transmit a loxP-flanked Dro1 allele through the germ-line. A Dro1
-/-
 line was 
established by intercrossing mice carrying loxP-flanked Dro1 alleles homozygously to 
mice expressing Cre-recombinase under control of the CMV promoter. Dro1
-/-
 mice 
were viable and fertile, showed no increased morbidity or mortality, and litters from 
Dro1
-/-
 parents were similar in number of progeny (Fig. 4.1A) and gender distribution 
(Fig. 4.1B) as compared to litters from control
 
mice. Genotyping was performed by 
PCR analysis from genomic tail tip DNA using primers Dro1homo1 and Dro1homo2 to 
detect the wildtype and floxed Dro1 locus and primers Dro1homo1 and Dro1rec to 
detect the deleted Dro1 locus (Fig. 4.2). Primers Cre1 and Cre2 were employed to 
identify Cre transgenic mice (Fig. 4.2).  
 
 
 
 
 
 
 
 
 
Fig. 4.1 Litter size (A) and gender distribution (B) in litters from Dro1
-/-
 (knockout) 
parents (n=18 litters) and control animals (n=15 litters).    
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Fig. 4.2 PCR analysis of the Dro1, Cre and β-actin locus. Primers Dro1homo1 and 
Dro1homo2 were derived from sequences upstream of exon 2 and on exon 2 resulting in 
a 173 bp fragment for the wildtype and a 211 bp fragment for the floxed Dro1 locus. To 
detect the deleted Dro1 locus primers Dro1homo1 and Dro1rec were derived from 
sequences upstream and downstream of exon 2, resulting in a 272 bp product for the 
deleted locus. Primers Cre1 and Cre2 were employed to identify Cre transgenic mice. 
PCR for the housekeeping gene β-actin was used as loading control.  
4.1.2 Analysis of genomic recombination 
To verify Cre-recombinase-mediated deletion of Dro1, Southern blot analysis with liver 
genomic DNA from 8-week-old Dro1
fl/fl
, Dro1
-/-
 and wildtype mice was performed. As 
expected, digest with PstI resulted in restriction fragments of 7.6 kb (genomic locus), 
7.0 kb (floxed locus), and 6.4 kb (deleted locus) (Fig. 4.3B). PstI restriction sites and 
calculated restriction fragment sizes are displayed in Fig. 4.3A. Deletion of exon 2 on 
the Dro1 gene was also confirmed by PCR analysis from genomic tail tip DNA using 
primers Dro1homo1 and Dro1rec. Primers were derived from sequences upstream and 
downstream of exon 2, resulting in a 272 bp product for the deleted locus (Fig. 4.2). 
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Fig. 4.3 (A) Schematic representation of the strategy employed for Southern blot 
analysis of the Dro1 locus. PstI restriction sites, the probe binding site and expected 
restriction fragment sizes are indicated. Black boxes: Exons; White box: Probe binding 
site; Shaded box: PGK-neo; White arrows: loxP sequences. (B) Southern blot analysis 
of genomic liver DNA digested with PstI from wildtype (+/+), Dro1
fl/fl
 (fl/fl) and Dro1
-/-
 
(-/-) mice.   
4.1.3 Expression analysis 
To investigate Dro1 expression in Dro1
-/-
 mice RNA was extracted from liver, heart, 
muscle, white adipose tissue, brown adipose tissue, small intestinal epithelium and 
colon epithelium of Dro1
-/-
 and control animals at 4 month of age (n=3/ group). 
Quantitative RT-PCR analysis from cDNA using primers mDro1#1 and mDro1#2 failed 
to detect any significant Dro1 expression in tissues of Dro1
-/- 
mice, confirming the 
genetic deletion of Dro1 (Fig. 4.4A). Moreover, PCR analysis from cDNA using 
primers Dro1homo1 and Dro1homo2 detected a 211 bp fragment in several tissues of 
control (Dro1
fl/fl
) animals that is absent in Dro1
-/-
 mice (Fig. 4.4B). 
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Fig. 4.4 (A) Dro1 expression was evaluated by quantitative RT-PCR analysis from 
cDNA in various tissues of Dro1
-/-
 and control animals (n=3/ group). Shown is one 
representative data set (n=1/ group, analyses done in duplicates) and Dro1 expression is 
presented relative to controls. Primers mDro1#1 and mDro1#2 were derived from 
sequences on exon 2. WAT: White adipose tissue; BAT: Brown adipose tissue; SI: 
Small intestine. (B) Gel electrophoresis of Dro1 PCR products using primers 
Dro1homo1 and Dro1homo2 from cDNA detected a 211 bp fragment in several tissues 
of control (Dro1
fl/fl
) animals that is absent in Dro1
-/-
 mice. PCR of Gapdh demonstrates 
that equal amounts of cDNA were employed. 
 
4.1.4 Protein analysis 
For further investigation of Dro1 expression, Western blot analysis of heart, liver, 
muscle, white adipose tissue and intestinal epithelium from 4-month-old Dro1
-/-
 and 
control mice was performed. It was not possible to detect the mouse DRO1 protein 
using antibodies raised against human DRO1, indicating antigenic differences between 
mouse and human DRO1 (data not shown). 
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4.2 Effects of Dro1 loss on intestinal tumor formation 
DRO1 has been identified in in vitro studies as a putative tumor suppressor gene with 
particular relevance for colorectal carcinogenesis (Bommer et al., 2005). In the 
following the effect of Dro1 deficiency on intestinal epithelium homeostasis and 
intestinal tumor formation was investigated in vivo. 
 
4.2.1 Anatomy and histology of the intestine 
4.2.1.1 Weight and length of the intestine 
To detect changes in intestinal growth, Dro1
-/-
 and control mice (n=3/ group) were 
sacrificed at 2.5 months of age and both the small intestine and colon were weighted 
and measured. Intestinal length was similar in Dro1
-/-
 and control mice and no 
significant differences in wet weight were observed (Table 4.1). 
 
Table 4.1 Mean intestinal length and wet weight of the small intestine and colon in 
Dro1
-/-
 (knockout) and control mice at the age of 2.5 months (n=3/ group). Values are 
presented as means and corresponding standard deviations are presented in brackets.  
Genotype Control Knockout
 
Length (cm)   
Small intestine 45.6 (2.3) 46.1 (3.6) 
Colon 9.9 (0.4) 9.9 (0.1) 
Wet weight (g)   
Small intestine 1.17 (0.11) 1.27 (0.25) 
Colon 0.29 (0.03) 0.28 (0.01) 
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4.2.1.2 Intestinal epithelium 
Studies in colorectal cancer cell lines suggested DRO1 to be involved in detachment-
induced apoptosis (Bommer et al., 2005), a phenomenon essential for the maintenance 
of the intestinal epithelium (Grossmann et al., 2002). To determine the consequences of 
Dro1 loss on the architecture of the intestinal epithelium, well oriented histological 
sections of intestinal rolls of 16-week-old Dro1
-/-
 and control mice were investigated for 
pathologic changes. Microscopic analysis of H&E-stained histological sections showed 
no changes in the intestinal epithelium architecture in Dro1
-/-
 mice (n=3; Fig. 4.5A). 
Evaluation of PAS-stained histological sections of the intestine (n=2/ group) revealed a 
normal distribution of mucus-producing goblet cells (Fig. 4.5A). The ratio of PAS-
positive cells per total cells in the crypt-villus axis of the small intestine, counted in 20 
crypts per mouse, was unchanged in Dro1
-/- 
mice as compared to controls (n=2/ group; 
Fig. 4.5C). Loss of Dro1 had no influence on the positioning of Paneth cells at the 
bottom of the small intestinal crypts as demonstrated by MMP-7 staining (n=2/ group; 
Fig. 4.5B). To evaluate intestinal cell proliferation, 16-week-old Dro1
-/-
 and control 
mice (n=3 /group) were subjected to a single intraperitoneal injection of BrdU 1 h 
before sacrificed. Immunohistochemical detection of BrdU-labeled cells failed to 
demonstrate an abnormal proliferation rate in the small intestine and colon of Dro1
-/-
 
mice, as the mean number of BrdU-positive cells, counted in 20 crypts per mouse and 
intestinal segment, was not significantly different from control mice (Fig. 4.6). 
Moreover, the positioning of BrdU-positive cells in the crypt was similar in Dro1
-/- 
and 
control mice (Fig. 4.6). As demonstrated by cleaved caspase-3 staining, no significant 
differences in the mean number of apoptotic cells in the intestinal epithelium of the 
small intestine (counted in 50 crypt-villus units per mouse) and colon (counted in 100 
crypts per mouse) were recorded between control and Dro1
-/-
 mice (n=3/ group; Fig. 
4.6).  
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Fig. 4.5 (A) Representative H&E- and PAS-stained intestinal sections from small 
intestine and colon of 16-week-old Dro1
-/-
 (knockout) and control mice. (B) 
Immunohistochemical detection of MMP-7 in the small intestine of 16-week-old Dro1
-/-
 
(knockout) and control mice. Black arrowheads indicate localization of MMP-7 positive 
cells. (C) Ratio of PAS-positive cells per total cells in the crypt-villus axis of the small 
intestine in 16-week-old Dro1
-/-
 (knockout) and control mice, counted in 20 crypts per 
mouse (n=2/ group).  
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Fig. 4.6 Immunohistochemical detection of BrdU and cleaved caspase-3 in the small 
intestine and colon of 16-week-old Dro1
-/-
 (knockout) and control mice. (B) Mean 
number of BrdU-positive cells, counted in 20 crypts per mouse and intestinal segment, 
in the small intestine and colon of Dro1
-/-
 and control mice (n=3/ group). (C) Mean 
number of cleaved caspase-3-positive cells in the small intestine and colon of Dro1
-/-
 
and control mice, counted in 50 crypt-villus units in the small intestinal and 100 crypts 
in the colon per mouse (n=3/ group).  
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4.2.2 Spontaneous intestinal tumor formation  
DRO1 was postulated to be a putative tumor suppressor gene (Bommer et al., 2005). 
Since loss-of-function mutations in tumor suppressor genes are a key aspect of 
colorectal carcinogenesis (Fearon and Vogelstein, 1990; Arnold et al., 2005; Fearon, 
2011), we investigated whether loss of Dro1 initiates intestinal neoplasia. Dro1
-/-
 (n=13) 
and control mice (n=16) of both genders were killed at the age of 18 months and the 
intestines were examined for visible polyps under a dissecting microscope. 
Independently of the Dro1 status no intestinal tumors were observed.   
 
4.2.3 Intestinal tumor formation in Apc
+/Min
 mice 
Since Dro1
-/-
 mice showed no spontaneous tumor formation in the intestinal tract, we 
assumed that loss of Dro1 alone is not sufficient to initiate intestinal tumorigenesis. 
Therefore, Dro1
-/-
 mice were introduced into the Apc
+/Min
 background, a widely used 
intestinal tumor mouse model (Moser et al., 1990), to investigate the impact of Dro1 
deficiency in mice already predisposed to tumor formation. Apc
+/Min
 mice were 
genotyped by PCR analysis from genomic tail tip DNA using primers Apc33, Apc34 
and Apc758 (Fig. 4.7).  
 
 
 
Fig. 4.7 Detection of the Apc
+
 and Apc
Min
 allele by PCR analysis.  
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4.2.3.1 Morbidity and mortality 
Mice on the Apc
+/Min
 background were surveyed daily for symptoms of illness and 
sacrificed when moribund. Dro1
-/-
;Apc
+/Min
 mice exhibited significantly reduced 
survival when compared to Apc
+/Min
 controls (P=0.0004; Fig. 4.8). Whereas compound 
mutant mice were moribund at an average age of 92 d, Apc
+/Min
 control animals 
survived up to an average age of 142 d. Independently of the Dro1 status, morbidity was 
hallmarked by body weight loss, hypothermia, bloody faeces, severe anemia, intestinal 
prolapse, and lethargy. Necropsy showed that severe symptoms of distress were most 
probably due to intestinal obstruction by tumor and intestinal hemorrhage. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8 Kaplan-Meier survival curve for Dro1
-/-
;Apc
+/Min
 (knockout; n=20) and Apc
+/Min 
control mice (control; n=18).  
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4.2.3.2 Intestinal tumor number and size 
To investigate a possible effect of Dro1 deficiency on tumor formation in Apc
+/Min
 
mice, the intestines of Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 control mice were examined under 
a dissecting microscope for tumor number, size and localization at different ages. 
Because of uncertainty about the precise anatomic demarcation, the colon and rectum 
were scored as “colon”. Tumors of the caecum were not investigated in the present 
study. 
Moribund Dro1
-/-
;Apc
+/Min
 (n=14) as well as Apc
+/Min
 control mice (n=19) developed a 
multitude of tumors throughout the entire small intestine. Average small intestinal 
tumor multiplicity was similar in both groups (Fig. 4.9A). Evaluation of mean tumor 
frequency between different sites of the small intestine showed that the vast majority of 
small intestinal polyps localized to the middle and distal segment regardless of the Dro1 
status (Fig 4.9B). Likewise, no differences in small intestinal tumor size distribution 
were recorded (Table 4.2).  
        
 
  
 
 
 
Fig. 4.9 Small intestinal tumor number (A) and distribution of tumors between the 
proximal, middle and distal section of the small intestine (B) in moribund Apc
+/Min
 
control (control; n=19) and Dro1
-/-
;Apc
+/Min
 (knockout; n=14) mice.  
Table 4.2 Size distribution of all tumors recorded in the small intestines of moribund 
Apc
+/Min
 control (control) and Dro1
-/-
;Apc
+/Min
 (knockout) mice. 
Genotype Control (n=19) Knockout (n=14) 
No. of tumors recorded 2547 2057 
Thereof ≤ 2.5 mm (%) 2230 (87.6%) 1848 (89.9%) 
>2.5 mm (%) 317 (12.4%) 208 (10.1%) 
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By contrast, differences in colonic tumor frequency between moribund Dro1
-/-
;Apc
+/Min 
(n=17) and Apc
+/Min
 control mice (n=16) were visible to the unaided eye at necropsy 
(Fig. 4.10). Microscopic analysis revealed a more than 3-fold increase in average 
colonic tumor number in Dro1
-/-
;Apc
+/Min 
mice as compared to Apc
+/Min 
controls (Fig. 
4.11A). Whereas all Dro1
-/-
;Apc
+/Min 
mice were affected by tumors of the colon, only 
75% of the Apc
+/Min 
control mice developed colonic polyps. The maximum colonic 
tumor number presented by a Dro1
-/-
;Apc
+/Min 
mouse was 31, in Apc
+/Min
 controls it was 
12 (Fig. 4.11A). To analyze mean distribution of tumors between different sites, the 
colon was divided into a proximal and distal section. Independently of the Dro1 status, 
the majority of colonic tumors localized to the distal section (Fig. 4.11B) and the 
percentage distribution of polyps between the proximal and distal colon was unchanged 
by Dro1 loss (Dro1
-/-
;Apc
+/Min
: 10% proximal, 90% distal; Apc
+/Min
 control: 6% 
proximal, 94% distal). Notably, a significant rise in mean tumor number in both the 
proximal and distal colon was observed in Dro1
-/-
;Apc
+/Min
 mice as compared to 
Apc
+/Min
 controls (Fig. 4.11B). Average tumor size (Fig. 4.11C) and tumor size 
distribution (Table 4.3) were similar in Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 control mice. 
Frequently, tumors of different sizes were observed in the same animal. No visible 
lymph node or distant metastases were recorded at necropsy, independently of the Dro1 
status. 
 
 
 
 
 
 
Fig. 4.10 Representative examples of longitudinally opened distal colon sections of a 
moribund Apc
+/Min 
control (control) and a moribund Dro1
-/-
;Apc
+/Min
 (knockout) mouse. 
Black arrowheads indicate neoplastic lesions. 
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Fig. 4.11 Number of colonic polyps (A), number of tumors recorded for the proximal 
and distal colon (B), and tumor size (C) in moribund Dro1
-/-
;Apc
+/Min
 (knockout; n=17) 
and Apc
+/Min 
control (control; n=16) mice. *: P ≤ 0.05; **: P ≤ 0.01. 
Table 4.3 Size distribution of all colonic polyps recorded in moribund Apc
+/Min
 control 
(control) and Dro1
-/-
;Apc
+/Min
 (knockout) mice. 
Genotype Control (n=16) Knockout (n=17) 
No. of tumors recorded 50 201 
Thereof ≤ 2.5 mm (%) 34 (68.0%) 138 (68.7%) 
> 2.5 mm (%) 16 (32.0%) 63 (31.3%) 
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To obtain insight into developmental aspects of tumor formation, Dro1
-/-
;Apc
+/Min
 and 
Apc
+/Min
 control mice were sacrificed at 5 and 10 weeks of age and the intestines were 
carefully examined.  
Small intestinal lesions were already present in 5-week-old animals of both groups. In 
the cohort of 8 Dro1
-/-
;Apc
+/Min
 mice, 3 animals exhibited a total of 4 small intestinal 
lesions which were all localized to the proximal section. In age-matched Apc
+/Min
 
controls (n=7), a total of 8 tumors developed in 4 mice, thereof 5 localized to the 
proximal, 1 to the middle and 2 to the distal segment. By 10 weeks of age the mean 
frequency of tumors of the small intestine was reduced in Dro1
-/-
;Apc
+/Min
 mice when 
compared to Apc
+/Min
 controls but statistical significance was not reached (P=0.40; Fig. 
4.12A). Consistent with findings in moribund animals, no differences in mean tumor 
frequency between different sites of the small intestine were observed (Fig. 4.12B).  
At the age of 5 weeks, mice were free of colonic polyps independently of the Dro1 
status. However, by 10 weeks of age, colonic tumors were frequently observed in 
Dro1
-/-
;Apc
+/Min
 mice (in 9 out of 10 mice) but were rather rarely present in Apc
+/Min
 
controls (in 3 out of 8 mice). A significant increase in mean colonic tumor multiplicity 
was recorded in 10-week-old Dro1
-/-
;Apc
+/Min
 mice (n=10) compared to similarly aged 
Apc
+/Min
 controls (n=8; Fig. 4.12C). Analysis of tumor distribution between the 
proximal and distal colon showed that lesions were solely committed to the distal 
section. The proximal colon was tumor free in both groups.  
   
   
 
 
 
 
 
 
Fig. 4.12 Small intestinal tumor number (A) and distribution of tumors between the 
proximal, middle and distal section of the small intestine (B) in Apc
+/Min
 control 
(control; n=10) and Dro1
-/-
;Apc
+/Min
 mice (knockout; n=8) at the age of 10 weeks. (C) 
Intestinal colonic tumor number in Apc
+/Min
 control (control; n=8) and Dro1
-/-
;Apc
+/Min
 
mice (knockout; n=10) at the age of 10 weeks. **: P ≤ 0.01.  
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4.2.3.3 Tumor histology 
A large number of representative small intestinal polyps and all colonic tumors > 2 mm 
in diameter were isolated from the intestines of moribund Dro1
-/-
;Apc
+/Min
 (n=21) and 
Apc
+/Min 
control (n=19)
 
mice and investigated by microscopic analysis of several H&E-
stained serial sections.   
Histologically, tumors (n=60) isolated from the small intestines of moribund Dro1
-/-
;Apc
+/Min
 mice corresponded to tubular adenomas with focal high grade 
dysplasia/intraepithelial neoplasia (IEN) of the epithelium (Table 4.4A). The same was 
true for the vast majority (49 of the 50) of lesions resected from the small intestines of 
moribund Apc
+/Min
 control mice (Table 4.4A). Noteworthy, a single lesion isolated from 
a control mouse euthanized at 144 d of age presented an invasive adenocarcinoma with 
infiltration of tumor cells into the tela submucosa.  
Microscopic evaluation of 83 colonic tumors resected from the colons of moribund 
Dro1
-/-
;Apc
+/Min 
mice revealed that 54 polyps (~65%) resembled tubular adenomas with 
focal high grade dysplasia/IEN and 29 lesions (~35%) had progressed to malignancy 
(adenoma/adenocarcinoma ratio of ~2: 1; Table 4.4A). Seventeen (~59%) of the 29 
adenocarcinomas featured intramucosal adenocarcinomas, the remaining (~41%) were 
characterized as invasive adenocarcinoma penetrating through the lamina muscularis 
mucosae. In the cohort of 21 Dro1
-/-
;Apc
+/Min
 mice, 10 animals (48%) harbored at least 
one colonic tumor with malignant growth features. Notably, 28 of the 29 
adenocarcinomas located to the distal colon. In contrast, colonic adenocarcinomas did 
not develop in the colons of Apc
+/Min
 control mice. Polyps isolated from the colons of 
Apc
+/Min
 control mice were classified, without exception, as tubular adenomas with 
focal high grade dysplasia/IEN of the epithelium (Table 4.4A). Small intestinal and 
colonic adenomas in Dro1
-/-
;Apc
+/Min
 mice were histologically similar to Apc
+/Min
 
control tumors. Representative pictures of H&E-stained sections from tumors from 
moribund Apc
+/Min
 control and Dro1
-/-
;Apc
+/Min
 mice are shown in Fig. 4.13. 
Tumor progression was investigated more closely by histopathologic analysis of tumors 
from 10-week-old Apc
+/Min
 control and Dro1
-/-
;Apc
+/Min
 mice. Assessment of a large 
number of small intestinal polyps showed that all lesions featured adenomas with high 
grade dysplasia/IEN of the epithelium regardless of the Dro1 status (Table 4.4B). 
Histopathologic analysis of 14 colonic tumors from Dro1
-/-
;Apc
+/Min
 mice revealed that 
10 lesions resembled adenomas with high grade dysplasia/IEN and 4 had progressed to 
intramucosal adenocarcinoma (adenoma/adenocarcinoma ratio 2.5: 1; Table 4.4B). By 
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contrast, 5 of the 6 colonic polyps from Apc
+/Min 
control mice were adenomas with high 
grade dysplasia/IEN and a single adenocarcinoma was observed (Table 4.4B). 
 
 
Fig. 4.13 Representative H&E-stained tissue sections from small intestinal and colonic 
tumors from moribund Dro1
-/-
;Apc
+/Min
 (knockout) and Apc
+/Min
 control (control) mice. 
Black arrowheads indicate invasion of tumor cells through the lamina muscularis 
mucosae into the tela submucosa. 
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Table 4.4 Histopathologic classification of tumors dissected from the small intestine and 
colon of moribund (A) and 10-week-old (B) Apc
+/Min 
control (control) and Dro1
-/-
;Apc
+/Min
 (knockout) mice. For histopathologic classification, small intestinal tumors 
were selected at random. Colonic polyps > 2.0 mm in diameter were analyzed 
A Moribund mice 
Genotype Control (n=19) Knockout (n=21) 
Small intestine 
No. of tumors analyzed 
 
60 
 
50 
Thereof    adenoma 59 (98.3%) 50 (100%) 
                adenocarcinoma 1 (1.7%) - 
   
Colon   
No. of tumors analyzed 15 83 
Thereof    adenoma 15 (100%) 54 (65.1%) 
                adenocarcinoma - 29 (34.9%) 
 
B 10 weeks of age 
Genotype Control (n=15) Knockout (n=16) 
Small intestine 
No. of tumors analyzed 
 
50 
 
50 
Thereof    adenoma 50 (100%) 50 (100%) 
                adenocarcinoma  - - 
   
Colon   
No. of tumors analyzed 6 14 
Thereof    adenoma 5 (83.4%) 10 (71.4%) 
                adenocarcinoma 1 (16.6%) 4 (28.6%) 
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4.2.3.4 Tumor proliferation rate 
The ability to sustain chronic proliferation constitutes the most fundamental hallmark of 
cancer cells (Hanahan and Weinberg, 2011). To investigate a probable effect of Dro1 
deficiency on the cellular proliferation rate in colorectal tumors of moribund Apc
+/Min
 
mice, immunohistochemical staining of Ki-67, a cell cycle related protein, was 
performed on tissue sections of Apc
+/Min
 adenomas (n=11), Dro1
-/-
;Apc
+/Min
 adenomas 
(n=15) and Dro1
-/-
;Apc
+/Min
 adenocarcinomas (n=14). Compared to normal intestinal 
epithelium, cellular proliferation was disorganized and profoundly increased in all 
categories of lesions analyzed (Fig. 4.14A). Quantification of the number of Ki-67-
positive cells revealed that, on average, the percentage of proliferating cells was 
unchanged between Dro1
-/-
;Apc
+/Min
 adenomas, Dro1
-/-
;Apc
+/Min
 adenocarcinomas and 
Apc
+/Min
 control adenomas (Fig. 4.14B). Furthermore, no differences in the distribution 
of Ki-67 cells throughout neoplastic lesions were observed (Fig. 4.14A).   
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Fig. 4.14 (A) Immunohistochemical staining of Ki-67 in colorectal tumors isolated from 
moribund Apc
+/Min 
control (control) and Dro1
-/-
;Apc
+/Min
 (knockout) mice. (B) 
Quantification of Ki-67-positive cells in colonic tumors of moribund Apc
+/Min
 control 
and Dro1
-/-
;Apc
+/Min 
mice (n=11 for Apc
+/Min
 control adenomas, n=15 for Dro1
-/-
;Apc
+/Min
 adenomas, n=14 for Dro1
-/-
;Apc
+/Min
 adenocarcinomas).  
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4.2.3.5 Nuclear β-catenin accumulation 
To investigate whether loss of Dro1 impacts accumulation of nuclear β-catenin within 
colonic tumors of moribund Apc
+/Min
 mice, immunohistochemical staining of β-catenin 
was performed on Apc
+/min
 control adenomas (n=12), Dro1
-/-
;Apc
+/Min
 adenomas (n=11) 
and Dro1
-/-
;Apc
+/Min
 adenocarcinomas (n=14).  
Elimination of Dro1 had no influence on β-catenin staining patterns in morphologically 
normal intestinal epithelium, in which β-catenin was distributed to the cell membrane 
and was rarely observed in cells located at the crypt base (Fig. 4.15A).  
Within neoplastic tissue nuclear β-catenin staining was strongly increased compared to 
normal intestinal epithelium independent of the Dro1 status and malignant progression 
(Fig. 4.15A). The mean percentage of tumor cells exhibiting positive nuclear β-catenin 
staining was similar in Dro1
-/-
;Apc
+/Min
 adenomas when compared to adenomas derived 
from Apc
+/Min
 control mice (Fig. 4.15B). Furthermore, no significant differences in the 
mean percentage of β-catenin positive nuclei were observed between adenomas and 
adenocarcinomas from Dro1
-/-
;Apc
+/Min
 mice (Fig. 4.15B).  
The staining intensity within the nucleus was evaluated by scoring changes in the 
intensity of staining relative to normal epithelium within the same section. Nearly all 
lesions were characterized by strong nuclear β-catenin staining. Noteworthy, low levels 
of nuclear staining were only observed within an Apc
+/Min 
control adenoma.  
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Fig. 4.15 (A) Immunohistochemical staining of β-catenin in the normal intestinal 
epithelium, in colorectal adenoma and in adenocarcinoma from moribund Apc
+/Min 
control (control) and Dro1
-/-
;Apc
+/Min
 (knockout) mice. (B) Percentage of β-catenin-
positive nuclei in colonic tumors from moribund Apc
+/Min
 (co) and Dro1
-/-
;Apc
+/Min
 (ko) 
mice (n=12 for Apc
+/Min
 control adenomas, n=11 for Dro1
-/-
;Apc
+/Min
 adenomas, n=14 
for Dro1
-/-
;Apc
+/Min
 adenocarcinomas).  
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4.2.3.6 ACF formation 
ACF are putative precursor lesions of colorectal adenomas in humans and some mouse 
strains of intestinal cancer (McLellan and Bird, 1988a; Fenoglio-Preiser and Noffsinger, 
1999; Boivin et al., 2003; Gupta and Schoen, 2009). To investigated whether Dro1 loss 
regulates the development of ACF in Apc
+/Min 
mice, Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 
control mice were sacrificed at the age of 5 (n=5/ group) and 10 (n=5/ group) weeks and 
whole-mount colon preparations were investigated for early morphologic changes of 
colonic crypts by methylene blue staining and trans-illumination. No ACF were 
observed in Apc
+/Min
 mice independently of the Dro1 status. Representative pictures of 
methylene blue stained whole-mount colon samples are displayed in Fig. 4.16. 
 
 
Fig. 4.16 Representative pictures of whole-mount distal colon samples from 10-week-
old Apc
+/Min
 control (control) and Dro1
-/-
;Apc
+/Min
 (knockout) mice stained with 
methylene blue. 
4.2.3.7 Mom1 status 
As the genetic background strongly influences tumor burden in Apc
+/Min
 mice (Gould et 
al., 1996; McCart et al., 2008), the Mom1 allele status of Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 
control mice was examined (n=15/ group). In order to detect a BamHI restriction site 
present in the resistant Mom1
 
allele (Mom1
R
) but absent in the sensitive Mom1 allele 
(Mom1
S
), a Mom1 PCR product was generated from tail tip genomic DNA, digested 
with BamHI and separated by gel electrophoresis. Dro1
-/-
;Apc
+/Min
 as well as Apc
+/Min
 
control mice were found to carry the Mom1
S
 allele homozygously (Fig. 4.17). 
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Fig. 4.17 Evaluation of the Mom1 allelic status of Dro1
-/-
;Apc
+/Min
 (knockout) and 
Apc
+/Min
 control (control) mice. Representative gel electrophoresis of Mom1 PCR 
products digested with BamHI. The 500 bp fragment indicates absence of a BamHI 
restriction site and is characteristic for the Mom1
S
 allele. The 400 bp and 100 bp 
fragments are characteristic for the Mom1
R
 allele. 
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4.3. Effects of Dro1 loss on body growth  
Since Dro1 has been implicated in energy homeostasis, body weight regulation, and 
obesity (Aoki et al., 2002; Okada et al., 2008; Tremblay et al., 2009) a possible effect 
of Dro1 deficiency on body growth was investigated under standard feeding conditions 
and when mice were exposed to a high-fat diet.  
 
4.3.1 Standard feeding conditions 
4.3.1.1 Body weight 
To ascertain whether inactivation of Dro1 affects body weight gain, selected litters of 
Dro1
-/-
 parents or control parents were weighted weekly from the 11
th
 day of life until 
15 weeks of age. Dro1
-/-
 mice of both genders showed normal development until 10 
(males) and 12 (females) weeks of age after which a significant increase in body weight 
was observed when compared to gender-matched controls (Fig. 4.18A). Examination of 
6- and 18-month-old mice also revealed profound differences in body weight between 
Dro1
-/-
 and control mice (4.18B and 4.18C).  
 
 
 
 
 
 
 
Fig. 4.18 (A) Body weight gain in Dro1
-/-
 (knockout) and control males (n=9 for Dro1
-/-
 
males and n=13 for control males) and females (n=10 for Dro1
-/-
 females and n=8 for 
control females) fed a standard diet. Dro1
-/-
 males exhibited significantly enhanced body 
weight from week 10 as compared to control males. Increase in body weight in Dro1
-/-
 
females as compared to control females was significant from week 12. P ≤ 0.001 for 
males and P ≤ 0.01 for females at 15 weeks of age. (B, C) Body weight in Dro1-/- 
(knockout) and control mice of both genders at 6 (B) and 18 (C) months of age (n=5/ 
group for males and n=6/ group for females at 6 months, n=7/ group for males at 18 
months and n=6/ group for females at 18 months). Legend displayed in (B) applies to 
(C). *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001. 
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4.3.1.2 Longitudinal growth 
Since changes in longitudinal body growth may account for differences in body weight, 
the length of the femora and the nose-rump-length (NRL) were investigated in 6-month-
old Dro1
-/-
 and control mice. Both parameters were found to be similar in Dro1
-/-
 and 
control mice (Fig. 4.19A and 4.19B). Notably, by 6 months of age relative nose-rump-
length calculated as body weight divided by NRL (g/cm) was significantly increased in 
Dro1
-/-
 mice of both genders as compared to gender-matched controls (Fig. 4.19C). 
  
 
 
 
 
 
 
 
Fig. 4.19 Femur length (A), nose-rump-length (NRL) (B), and relative nose-rump-
length (RNRL) (C) in 6-month-old Dro1
-/-
 (knockout) and control animals of both 
genders (n=5/ group for males and n=6/ group for females). Legend displayed in (A) 
applies to all figures. *: P ≤ 0.05; ***: P ≤ 0.001. 
4.3.1.3 Organ growth 
To determine a possible effect of Dro1 ablation on organ and carcass weight, Dro1
-/- 
and 
control mice were sacrificed at various stages of life. The weight of the following 
organs was examined: heart, lungs, liver, spleen and kidneys.  
Necropsy of 2-month-old animals revealed similar heart, lung, liver, kidney and carcass 
weight in Dro1
-/-
 and control mice of both sexes. Absolute and relative spleen weight 
was significantly increased in 2-month-old Dro1
-/-
 males as compared to age and 
gender-matched controls; females showed an increase in spleen weight but statistical 
significance was not reached.  
At the age of 6 months a significant rise in liver, spleen and carcass weight was detected 
in both genders of Dro1
-/-
 mice as compared to age- and gender-matched controls. 
Moreover, the weight of lungs and kidneys was profoundly increased in 6-month-old 
Dro1
-/-
 males. The absolute heart weight was increased but statistical significance was 
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not reached. When related to body weight, changes in the weight of lungs, liver, spleen, 
kidneys and carcass did not persist. Notably, the relative weight of heart and kidneys 
was significantly decreased in Dro1
-/-
 females but was unchanged in Dro1
-/-
 males as 
compared to age- and gender-matched control mice. Absolute and relative organ 
weights are presented in Table 4.5 and Table 4.6. Microscopic evaluation of H&E-
stained histological sections of heart, lung, spleen, liver and kidney from 2 (n=3) and 6 
(n=6) months old Dro1
-/-
 mice revealed no obvious pathologic alterations in organ 
architecture.  
 
Table 4.5 Absolute organ weight in male (A) and female (B) Dro1
-/-
 (knockout) and 
control mice at the age of 2 (n=3/ group) and 6 months (n=5/ group for males and n=6/ 
group for females at 6 months). Values are presented as means and corresponding 
standard deviations are displayed in brackets. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001. 
(-) indicates the absence of significant differences.  
A Organ weights (mg), males 
 
2 months 
Δ 
6 months 
Δ 
Control Knockout
 
Control Knockout 
Heart 144 (9) 159 (31) - 176 (19) 235 (64) - 
Lungs 156 (11) 162 (6) - 189 (33) 240 (39) * 
Liver 1233 (100) 1387 (39) - 1634 (144) 2492 (274) ** 
Spleen 59 (13) 91 (9) * 73 (11) 118 (23) * 
Kidneys 295 (11) 338 (43) - 397 (53) 548 (14) ** 
Carcass 11324 (836) 11297 (607) - 14172 (532) 16791 (415) *** 
 
B Organ weights (mg), females 
 
2 months 
Δ 
6 months 
Δ 
Control Knockout
 
Control Knockout 
Heart 127 (12) 110 (12) - 140 (6) 152 (20) - 
Lungs 159 (13) 143 (6) - 181 (20) 214 (48) - 
Liver 1065 (137) 1110 (77) - 1376 (186) 1811 (327) ** 
Spleen 86 (14) 110 (20) - 82 (12) 125 (17) *** 
Kidneys 262 (9) 257 (24) - 308 (22) 326 (21) - 
Carcass 9977 (319) 9292 (392) - 11003 (703) 13881 (568) *** 
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Table 4.6 Relative organ weight in male (A) and female (B) Dro1
-/-
 (knockout) and 
control mice at the age of 2 (n=3/ group) and 6 months (n=5/ group for males and n=6/ 
group for females at 6 months). Values are presented as means and corresponding 
standard deviations are displayed in brackets. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001. 
(-) indicates the absence of significant differences.  
A Relative organ weights (% of body weight), males 
 
2 months 
Δ 
6 months 
Δ 
Control Knockout
 
Control Knockout 
Heart 0.55 (0.05) 0.60 (0.10) - 0.52 (0.05) 0.57 (0.18) - 
Lungs 0.59 (0.07) 0.61 (0.03) - 0.56 (0.08) 0.57 (0.07) - 
Liver 4.65 (0.17) 5.23 (0.35) - 4.86 (0.82) 5.99 (1.08) - 
Spleen 0.22 (0.04) 0.34 (0.04) * 0.22 (0.02) 0.29 (0.07) - 
Kidneys 1.12 (0.10) 1.28 (0.18) - 1.18 (0.10) 1.33 (0.24) - 
Carcass 42.68 (0.26) 42.57 (1.35) - 42.21 (1.57) 40.5 (1.48) - 
 
B Relative organ weights (% of body weight), females 
 
2 months 
Δ 
6 months 
Δ 
Control Knockout
 
Control Knockout 
Heart 0.56 (0.06) 0.51 (0.09) - 0.52 (0.04) 0.44 (0.07) * 
Lungs 0.70 (0.05) 0.66 (0.07) - 0.67 (0.07) 0.62 (0.16) - 
Liver 4.68 (0.47) 5.13 (0.09) - 5.12 (0.61) 5.23 (1.05) - 
Spleen 0.35 (0.08) 0.51 (0.06) - 0.30 (0.06) 0.36 (0.06) - 
Kidneys 1.15 (0.05) 1.09 (0.05) - 1.15 (0.08) 0.94 (0.08) *** 
Carcass 43.95 (0.19) 42.99 (1.08) - 40.98 (2.26) 40.01 (2.89) - 
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4.3.1.4 Total body fat and lean mass 
To evaluate changes in body composition, total body fat content and lean mass were 
determined weekly in Dro1
-/-
 and control males from 4 to 15 weeks of age by MRI. 
Dro1
-/-
 males exhibited a significant increase in lean mass compared to controls by week 
9 onwards (Fig. 4.20A). Total body fat tended to be higher in Dro1
-/- 
males but 
statistical significance was not reached (Fig. 4.20B). 
     
 
 
 
 
 
 
 
Fig. 4.20 Lean mass (A) and total body fat (B) gain in Dro1
-/-
 (knockout; n=9) and 
control males (n=13). Increase in lean mass in Dro1
-/-
 males was significant from week 
9 onwards as compared to control males (P ≤ 0.001 at 15 weeks of age). No significant 
differences in total body fat were observed (P=0.32 at 15 weeks of age). Legend 
displayed in (A) applies to both figures. 
4.3.1.5 Fat pad growth 
To investigate changes in fat pad growth the main white adipose tissue depots of 2- and 
6-month-old Dro1
-/-
 and control mice of both genders were weighted and their relative 
contribution to body weight was calculated. Analyses involved the epididymal, 
abdominal and subcutaneous fat pads in males and the abdominal (including ovarian 
and periovarian fat) and subcutaneous fat pads in females. At 2 months of age, when 
body weight of Dro1
-/-
 mice was not significantly different from that of control mice, no 
significant differences in white adipose tissue mass were recorded between Dro1
-/-
 and 
control mice (Fig. 4.21A and 4.21B).  
By 6 months of age when profound differences in body weight were present, substantial 
changes in fat pad weight were observed (Fig. 4.21C and 4.21D). Dro1
-/-
 males 
exhibited significantly enlarged epididymal, abdominal and subcutaneous fat pads when 
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compared to age- and gender-matched controls (Fig. 4.21C). In Dro1
-/-
 females a 
significant rise in abdominal fat was recorded and the weight of the subcutaneous fat 
pad tended to be increased but statistical significance was not reached (Fig. 4.21D). 
Substantial changes in fat pad weight between Dro1
-/-
 and control mice persisted when 
fat pad weight was related to body weight (Fig. 4.21). Evaluation of H&E-stained 
histological sections of the cranial tip of epididymal white adipose tissue from 2- and 6-
month-old Dro1
-/-
 males revealed no obvious pathologic changes.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Fig. 4.21 Absolute and relative weights of the subcutaneous (subc), abdominal (abd) 
and epididymal (epid) white fat pads in Dro1
-/-
 (knockout) and control males (A, C) and 
females (B, D) at 2 (A, B) and 6 (C, D) months of age. Relative fat pad weight was 
calculated as percent of body weight. (n=3/ group for both genders at 2 months, n=5/ 
group for males and n=6/ group for females at 6 months). Legend displayed in (A) 
applies to all figures. *: P ≤ 0.05; **: P ≤ 0.01. 
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4.3.1.6 Glucose metabolism 
To detect possible changes in glucose metabolism, intraperitoneal glucose tolerance test 
was performed in 14-week-old Dro1
-/-
 (n=9) and control (n=12) males. At this age body 
mass was significantly enhanced in Dro1
-/-
 males when compared to control males 
(32.12 g ± 1.99 g in Dro1
-/-
 males compared to 29.46 g ± 1.45 g in control males. P ≤ 
0.01). Fasted blood glucose levels were similar in Dro1
-/-
 and control mice and Dro1
-/-
 
mice cleared the administrated glucose as efficiently from the blood as controls (Fig. 
4.22). 
 
 
 
 
 
 
 
 
Fig. 4.22 Intraperitoneal glucose tolerance test in 14-week-old Dro1
-/-
 (knockout; n=9) 
and control males (n=12). 
4.3.1.7 Serum triglycerides and free fatty acids 
To elucidate a possible effect of Dro1 deficiency on serum lipids, triglycerides and free 
fatty acids were measured in the serum of 2- and 6-month-old Dro1
-/-
 and control mice. 
At 2 months of age serum triglycerides tended to be lower in Dro1
-/-
 mice as compared 
to controls and by 6 months of age the decrease reached significance (Fig. 4.23A). 
Serum free fatty acid levels were unchanged in Dro1
-/-
 mice when compared to controls 
at 2 as well as 6 months of age (4.23B).  
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Fig. 4.23 Serum triglycerides (A) and free fatty acids (FFA) (B) in Dro1
-/-
 (knockout) 
and control mice at the age of 2 (n=3/ group) and 6 months (n=6/ group). Legend 
displayed in (A) applies to (B). *: P ≤ 0.05. 
4.3.2 High-fat diet feeding conditions 
Since Dro1
-/-
 mice of both sexes exhibited an overweight phenotype under standard 
feeding conditions, the impact of Dro1 elimination on the development of diet-induced 
obesity was investigated. Thus, Dro1
-/-
 and control mice (n=9/ group) were fed a high-
fat diet in which the majority of caloric intake (60%) is from fat for 16 weeks beginning 
at 11 days of age (first day of solid food intake). The following experiments were 
conducted in male mice as changes in adipose tissue mass were more pronounced in 
Dro1
-/-
 males than in females when fed a standard diet.  
 
4.3.2.1 Body weight, body fat and lean mass 
To investigate the effect of Dro1 deficiency on body weight gain in mice maintained on 
a high-fat diet, body weight was measured weekly starting from the 11
th
 day of life until 
17 weeks of age. No significant differences in weight curves were found between 
Dro1
-/-
 and control mice in the first 7 weeks of life. However, from week 8 onwards 
Dro1
-/-
 mice were significantly heavier than controls (Fig. 4.25A). After being exposed 
to a high-fat diet for 16 weeks Dro1
-/- 
mice exhibited 43.9% more body weight than 
controls. Fig. 4.24 demonstrates the dramatic phenotype.  
To analyze how changes in body weight correlate with changes in total body fat and 
lean mass in high-fat diet-fed mice, MRI measurement was performed weekly starting 
from the 4
th
 week of life. By week 8 onwards Dro1
-/-
 mice exhibited a significant 
increase in lean mass (Fig. 4.25B) and body fat (Fig. 4.25C) as compared to controls. 
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Throughout the whole time-course a severe rise in body fat was detected in Dro1
-/-
 mice 
whereas body fat only slightly increased in controls after week 9 (Fig. 4.25C).  
At the age of 15 weeks body weight, body fat and lean mass were significantly 
increased in high-fat diet-fed Dro1
-/-
 mice compared to their normal-fed counterparts. 
Control mice also exhibited higher body weight and body fat under high-fat diet than 
under normal diet but the difference was statistically significant only for body fat. Lean 
mass in controls was unchanged by high-fat diet. Changes in body weight, body fat and 
lean mass in knockout and control mice under normal diet and high-fat diet are 
displayed in Table 4.6. 
 
 
 
Fig. 4.24 Representative picture of a control and Dro1
-/-
 (knockout) mouse after exposed 
to a high-fat diet for 16 weeks. 
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Fig. 4.25 Body weight (A), lean mass (B) and total body fat (C) gain in Dro1
-/-
 
(knockout) and control males (n=9/ group) maintained on a high-fat diet for 16 weeks 
beginning at the 11
th
 day of age. Increases in body weight, body fat and lean mass were 
continually significant after week 8. P ≤ 0.001 for body weight and body fat and P ≤ 
0.05 for lean mass at 17 weeks of age. Legend displayed in (A) applies to all figures.  
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Table 4.6 Comparison of body weight, body fat and lean mass between normal-fed (n=9 
for Dro1
-/-
 males and n=13 for control males) and high-fat diet-fed (n=9/ group) control 
mice and Dro1
-/-
 (knockout) mice at 15 weeks of age. Values are presented as means 
and standard deviations (brackets). *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001. (-) 
indicates the absence of significant differences. 
 Normal diet High-fat diet Δ Increase (%) 
Body weight     
     Control 30.82 (1.94) 31.56 (3.47) - + 2.39 
Knockout
 
33.06 (1.85) 40.92 (5.70) ** + 23.41 
Body fat     
     Control 3.40 (0.53) 4.04 (0.79) * + 18.78 
Knockout 3.41 (0.50) 7.55 (2.11) *** + 121.24 
Lean mass     
     Control 27.42 (1.43) 27.51 (2.8) - + 1.04% 
Knockout 29.65 (1.36) 33.37 (4.05) * + 12.53% 
 
4.3.2.2 Glucose metabolism  
To assess the response to glucose administration under high-fat diet feeding, an 
intraperitoneal glucose tolerance test was performed in 14-week-old Dro1
-/-
 and control 
mice (after they had been exposed to a high-fat diet for 13 weeks). Dro1
-/-
 mice showed 
significantly higher levels of blood glucose after fasting for 16 h when compared to 
controls. Moreover their ability to clear glucose from the blood was substantially 
decreased (Fig. 4.26A). 
An intraperitoneal insulin tolerance test was accomplished one week later to investigate 
the role of insulin resistance in the glucose response. Fasted blood glucose levels tended 
to be higher in Dro1
-/- 
mice but statistical significance was not reached. In addition, 
knockout mice showed a markedly attenuated glucose lowering rate after insulin 
injection when compared to controls (Fig. 4.26B). 
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Fig. 4.26 Intraperitoneal glucose tolerance (A) and insulin tolerance (B) tests in Dro1
-/-
 
and control mice (n=9/ group) after being fed a high-fat diet for 13 and 14 weeks, 
respectively. Legend displayed in (A) applies to (B). *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 
0.001.  
4.3.2.3 Organ growth 
After knockout and control mice had been exposed to a high-fat diet for 16 weeks they 
were sacrificed and the organs and carcass were weighted. In accordance with our 
findings in normal-fed mice, Dro1
-/-
 mice exhibited significantly increased absolute 
weight of lungs, liver, spleen, kidneys and carcass when compared to controls (Table 
4.7). When related to body weight, the weight of heart, lungs, kidneys and carcass was 
over-proportionally decreased in Dro1
-/-
 mice as compared to controls (Table 4.7). 
Noteworthy, the liver was remarkably pale and saffron-colored in all Dro1
-/-
 mice but in 
none of the controls (Fig. 4.27).  
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Table 4.7 Absolute and relative organ weight in Dro1
-/-
 (knockout) and control (n=9/ 
group) males maintained on a high-fat diet for 16 weeks starting from the 11
th
 day of 
life. Values are presented as means. Corresponding standard deviations are displayed in 
brackets. *: P ≤ 0.05; **: P ≤ 0.01; ***: P ≤ 0.001. (-) indicates the absence of 
significant differences. 
 
Organ weights (mg) Relative organ weights 
(% of body weight) 
 Control Knockout
 Δ Control Knockout Δ 
Heart 173 (21) 204 (63) - 0.54 (0.05) 0.44 (0.11) * 
Lungs 193 (23) 218 (15) * 0.66 (0.03) 0.48 (0.06) *** 
Liver 1491 (192) 2105 (479) ** 4.65 (0.33) 4.55 (0.69) - 
Spleen 92 (63) 199 (81) ** 0.28 (0.16) 0.45 (0.19) - 
Kidneys 398 (43) 468 (71) * 1.24 (0.07) 1.02 (0.12) *** 
Carcass 14012 (1113) 16849 (2116) ** 43.23 (0.90) 37.14 (3.13) *** 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.27 Representative picture of a liver from a Dro1
-/-
 (knockout) and control mouse 
after fed a high-fat diet for 16 weeks starting from the 11
th
 day of life. 
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4.3.2.4 Fat pad growth 
To investigate the effect of Dro1 loss on fat pad weight under high-fat diet feeding 
conditions, the epididymal, abdominal and subcutaneous fat pads of Dro1
-/-
 and control 
mice were weighted after mice had been exposed to a high-fat diet for 16 weeks. 
Consistent with profound changes in body weight and total body fat content, these fat 
compartments were dramatically enlarged in Dro1
-/-
 males as compared to controls (Fig. 
4.28A and Fig.4.29). These changes persisted when fat pad weight was related to body 
weight (Fig. 4.28B). Microscopic examination of H&E-stained histological sections of 
the cranial tip of epididymal white adipose tissue from 17-week-old high-fat diet-fed 
Dro1
-/-
 males revealed no obvious pathologic changes  
 
  
 
 
 
 
 
 
Fig. 4.28 Absolute (A) and relative (B) weight of the subcutaneous (subc), abdominal 
(abd) and epididymal (epid) white fat pad in Dro1
-/-
 (knockout)  and control mice (n=9/ 
group) after fed a high-fat diet for 16 weeks starting from the 11
th
 day of life. Relative 
fat pad weight was calculated as percent of body weight. Legend displayed in (A) 
applies to (B). **: P ≤ 0.01; ***: P ≤ 0.001. 
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Fig. 4.29 Representative pictures of epididymal white fat pads from a control and 
Dro1
-/-
 (knockout) mouse after fed a high-fat diet for 16 weeks starting from the 11
th
 
day of life.  
4.3.2.5 Liver histology 
At necropsy, livers of high-fat diet-fed Dro1
-/-
 mice were substantially increased and 
exhibited a pale appearance. Microscopic evaluation of H&E-stained Dro1
-/-
 liver 
sections revealed severe mixed steatosis with microvesicular and medium sized fat 
vacuoles in more than 80% of hepatocytes of the centrilobular region in 4 of 9 Dro1
-/-
 
mice (Fig. 4.30A). The remaining cases exhibited macrovesicular or mixed steatosis 
with fat vacuoles in 20 to 40% of hepatocytes. In contrast, hepatocellular steatosis was 
not observed in liver sections from control animals (Fig. 4.30A). Colorimetric 
quantification of triglycerides in homogenized liver samples confirmed significantly 
elevated triglyceride levels in Dro1
-/-
 mice as compared to controls (Fig. 4.30B). 
Noteworthy, a slight pericellular and perisinusoidal fibrosis with chicken wire pattern 
could be demonstrated by EvG staining (Fig. 4.30A). Furthermore, a minor Kupffer cell 
aggregation was observed. 
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Fig. 4.30 (A) H&E- and EvG-stained liver sections from a control and Dro1
-/-
 
(knockout) mouse at 17 weeks of age after maintained on a high-fat diet for 16 weeks 
starting from the 11
th
 day of age. (B) Mean triglyceride content in livers of control and 
Dro1
-/-
 mice (n=9/ group). *: P ≤ 0.05. 
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4.3.2.6 Serum triglycerides and free fatty acids 
To investigate changes in circulating triglycerides and free fatty acids, blood of high-fat 
diet-fed Dro1
-/-
 and control mice was collected after they had been exposed to a high-fat 
diet for 16 weeks and the serum was isolated. No significant differences were recorded 
between Dro1
-/-
 and control mice in serum triglycerides (Fig. 4.31A) and free fatty acids 
(Fig. 4.31B). 
  
  
 
 
 
 
 
 
Fig. 4.31 Serum triglycerides (A) and free fatty acids (FFA) (B) in Dro1
-/-
 and control 
mice (n=7/ group) at the age of 17 weeks after exposed to a high-fat diet for 16 weeks.  
4.3.3 Analysis of adipogenesis in SV cells 
Since down-regulation of Dro1 in 3T3-L1 cells was demonstrated to impair adipocyte 
differentiation (Tremblay et al., 2009), a possible impact of Dro1 loss on adipogenesis 
in white adipose tissue SV cells containing primary preadipocytes (Hausman et al., 
2008; Poulos et al., 2010) was investigated in vitro. For this purpose, Dro1
-/-
 and control 
mice were sacrificed at the age of 21 days and SV cells were isolated from the inguinal 
white fat pads, grown confluent and differentiated. Confluence was reached at day 14 
after isolation independently of the Dro1 status and SV cells were differentiated for 
additional 14 days. Oil red O staining revealed that the accumulation of lipids was 
severely increased in differentiated Dro1
-/-
 SV cells as compared to control SV cells 
(Fig. 4.32A), with a significant increase in the mean number (Fig. 4.32B) and size (Fig. 
4.32C) of lipid droplets. 
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Fig. 4.32 (A) Representative pictures of undifferentiated and differentiated oil red 
O-stained control and Dro1
-/-
 (knockout) white adipose tissue SV cells. Mean number 
(B) and mean size (C) of lipid droplets in control and Dro1
-/-
 (knockout) white adipose 
tissue SV cells. Multiplicity and size of lipid droplets were investigated for areas 
showing a high grade of differentiated cells (n=10 areas for Dro1
-/-
 and n=8 areas for 
control SV cells). **: P ≤ 0.01. 
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5. Discussion 
Previous in vitro studies suggested DRO1 to be a putative tumor suppressor (Bommer et 
al., 2005) and modulator of adipogenesis (Tremblay et al., 2009). Until today, 
investigation of Dro1 function in vivo was restricted to expression analysis, offering 
evidence for involvement in colorectal, mammary and thyroid carcinogenesis 
(Marcantonio et al., 2001; Visconti et al., 2003; Bommer et al., 2005), obesity (Aoki et 
al., 2002; Okada et al., 2008), eye development (Mu et al., 2003) and skeletogenesis 
(Liu et al., 2004; Wilson et al., 2011). The aim of the present study was to elucidate the 
function of Dro1 in colorectal carcinogenesis and body growth in vivo. We therefore 
generated the first knockout mouse model in which the Dro1 gene is constitutively 
inactivated using a Cre/loxP strategy. 
  
5.1 Generation of Dro1
-/-
 mice 
In Dro1
-/-
 mice, genetic deletion of Dro1 by Cre-recombinase was demonstrated by 
Southern blot analysis with liver genomic DNA from 8-week-old animals. Loss of the 
targeted exon 2 was further confirmed by PCR analysis from genomic tail tip DNA. As 
expected from the ubiquitous expression of Cre-recombinase under control of the CMV 
promoter, no significant Dro1 expression was detected in various tissues of Dro1
-/-
 
mice, including white adipose tissue and intestinal epithelium, suggesting a high 
efficiency of Dro1 depletion. In accordance with previous findings (Aoki et al., 2002; 
Liu et al., 2004; Bommer et al., 2005; Okada et al., 2008; Tremblay et al., 2009), 
control mice expressed Dro1 in all tissues tested. Unfortunately, it was not possible to 
investigate Dro1 expression by Western blot analysis since antibodies raised against 
human DRO1 were inappropriate to detect the mouse DRO1 protein. This observation is 
rather surprising considering the high sequence homology between human and mouse 
DRO1/Dro1 (Mu et al., 2003; Liu et al., 2004; Bommer et al., 2005).  
Dro1
-/-
 mice were viable and fertile and showed no changes in mortality as compared to 
controls, indicating that Dro1 expression is dispensable for survival. Depletion of Dro1 
was not observed to cause embryonic lethality since the litter size from Dro1
-/-
 parents 
was unchanged as compared to litters from control animals.  
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5.2 Effects of Dro1 loss on intestinal tumor formation 
Quantitative analysis of length and wet weight of small intestine and colon revealed no 
changes in 2-month-old Dro1
-/-
 mice, indicating normal intestinal growth. Microscopic 
evaluation of H&E-stained histologic sections of the intestine from 4-month-old Dro1
-/-
 
mice revealed no obvious pathologic alterations in the architecture of the intestinal 
epithelium. As demonstrated by PAS staining, the number and distribution of goblet 
cells along the crypt-villus-axis was unchanged. In addition, a normal localization of 
Paneth cells at the bottom of the crypt was observed. These findings offer strong 
evidence that Dro1 expression is dispensable for cell maturation and positioning in the 
intestinal epithelium.  
To investigate cell proliferation in the intestinal epithelium, 4-month-old Dro1
-/-
 and 
control mice were injected with BrdU 1 h prior to sacrifice. Immunohistochemical 
detection of BrdU incorporation revealed no effect on the number of BrdU-positive 
cells per crypt, suggesting an unchanged proliferative activity. Furthermore, a normal 
distribution of proliferating cells was observed, with BrdU-positive cells being localized 
close to the crypt base. As demonstrated by immunohistochemical staining for cleaved 
caspase-3, the number of apoptotic cells in the intestinal epithelium was also unaffected. 
Restoration of DRO1 expression in cancer cell lines has been described to result in 
sensitization to various apoptotic stimuli (Bommer et al., 2005; Ferragud et al., 2011), 
however, no pro-apoptotic effect of DRO1 was observed under standard adherent 
growth conditions (Bommer et al., 2005). In summary, our data suggest that Dro1 gene 
expression is dispensable for the maintenance of the intestinal epithelium. 
 
In vitro studies have implicated DRO1 to be a candidate tumor suppressor gene 
(Bommer et al., 2005). To investigate a possible effect of Dro1 deficiency on 
spontaneous tumor formation in the intestinal tract, Dro1
-/-
 and control mice were 
sacrificed at the age of 18 months and the intestines were examined. Regardless of the 
Dro1 status, no spontaneous tumors of the intestine were observed. It is known that 
inactivation of a tumor suppressor gene alone is often not sufficient to cause 
tumorigenesis, and additional mutation events that result in perturbation of other critical 
signaling pathways are necessary (Berger et al., 2011).  
 
To study the consequences of Dro1 deficiency on intestinal tumorigenesis in a tumor-
prone background, Dro1
-/- 
mice were intercrossed with Apc
+/Min
 mice, a well-established 
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intestinal tumor mouse model (Moser et al., 1990). Mice on the Apc
+/Min
 background 
were monitored daily for symptoms of distress and sacrificed when moribund. Survival 
was significantly reduced in Dro1
-/-
;Apc
+/Min
 mice as compared to Apc
+/Min
 controls, 
demonstrating a profound effect of Dro1 deficiency on morbidity and mortality in 
Apc
+/Min
 mice.  
Microscopic examination of whole-mount colon preparations from moribund and 10-
week-old mice revealed that Dro1
-/-
;Apc
+/Min
 mice were characterized by a striking 
increase in mean colonic tumor multiplicity as compared to Apc
+/Min
 controls, 
suggesting a critical role for Dro1 in suppressing tumor initiation in the colon of 
Apc
+/Min
 mice. The dramatically reduced survival observed in Dro1
-/-
;Apc
+/Min
 mice is 
most probably due to the severe rise in mean colonic polyp frequency implicating an 
early onset of morbidity. In cancer cell lines, DRO1 expression has been shown to 
impair growth (Bommer et al., 2005) and induce sensitization to various apoptotic 
stimuli (Bommer et al., 2005; Ferragud et al., 2011). Moreover, overexpression of 
DRO1 in mammary cancer cells has been shown to result in up-regulation of B-cell 
lymphoma 2-associated transcription factor 1 (BCLAF1), a death-promoting 
transcriptional repressor (Ferragud et al., 2011). Resistance to cell death by apoptosis-
avoiding mechanisms constitutes one of the hallmarks of cancer cells (Hanahn and 
Weinberg, 2011). It is therefore tempting to suggest that loss of Dro1 function supports 
the survival of nascent tumors in Apc
+/Min
 mice, resulting in an increase in the final 
number of polyps. The hypothesis that Dro1 deficiency may promote tumor 
establishment by providing a survival benefit for adenomas with Apc inactivation is 
further supported by the fact that the primary localization of colonic polyps was 
unchanged in Dro1
-/-
;Apc
+/Min
 mice as compared to Apc
+/Min
 controls, indicating that 
tumorigenesis is primarily initiated by loss of Apc function. Although Dro1
-/-
;Apc
+/Min
 
mice showed a profound increase in mean tumor multiplicity throughout the colon, the 
percentage distribution of polyps between the proximal and distal colon was unchanged 
when compared to Apc
+/Min
 control mice. Interestingly, Dro1 loss did not change the 
mean size of colonic polyps in Apc
+/Min
 mice.  
 
Histopathologic analysis of tumors isolated from the colon of moribund and 10-week-
old animals revealed that Dro1
-/-
;Apc
+/Min 
mice developed adenomas, intramucosal 
adenocarcinomas and invasive adenocarcinomas, whereas tumors from Apc
+/Min
 
controls overall resembled tubular adenomas (a single adenocarcinoma was observed in 
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the colon of a 10-week-old Apc
+/Min
 control animal). Approximately one third of colonic 
tumors from moribund Dro1
-/-
;Apc
+/Min
 mice had progressed to malignancy and 
adenocarcinomas arose in about 50% of Dro1 knockout mice. Although local invasion 
of colonic adenocarcinomas through the lamina muscularis mucosae into the tela 
submucosa was regularly observed in moribund Dro1
-/-
;Apc
+/Min
 mice, no visible 
metastatic tumors were recorded at necropsy. This may be explained by the rather early 
onset of morbidity in Dro1
-/-
;Apc
+/Min
 mice at an average of 94 d, with insufficient time 
for tumors to generate detectable metastases. Our results also demonstrate that ablation 
of Dro1 in Apc
+/Min
 mice leads to the regular formation of colonic adenocarcinomas in 
young animals, suggesting a critical role for Dro1 as negative regulator of malignant 
progression in adenomas with Apc inactivation. In accordance, DRO1 expression has 
been shown to reduce malignant growth properties (colony formation and anchorage 
independent growth) in various cancer cell lines (Bommer et al., 2005).  
 
Interestingly, analysis of colonic adenocarcinoma distribution between the proximal and 
distal colon in moribund Dro1
-/-
;Apc
+/Min
 mice revealed that only a single malignant 
lesion located to the proximal colon. This asymmetric distribution pattern may be due to 
differences in the timing of tumor development between the proximal and distal colon. 
Dro1
-/-
;Apc
+/Min
 mice at the age of 10 weeks had developed no tumors of the proximal 
colon, but exhibited plenty of lesions in the distal segment. In moribund Dro1
-/-
;Apc
+/Min
 
mice, a small number of tumors located to the proximal colon and tumor multiplicity in 
the distal colon was strongly increased as compared to 10-week-old mice. One can 
conclude from this that polyps in Dro1
-/-
;Apc
+/Min
 mice arise first in the distal colon 
before extending to the proximal segment. Therefore, tumors of the distal colon have 
more time to progress to malignancy than tumors in the proximal segment. Another 
possibility is a non-requirement of Dro1 expression for prevention of tumor progression 
specifically in the proximal colon. Previous studies on human colorectal cancer have 
shown major genetic differences between tumors of the proximal and distal colon 
(Distler and Holt, 1997; Iacopetta, 2002; Nawa et al., 2008). It was suggested that 
differences in gene expression patterns between the proximal and distal colon may 
underlie site-specific differences in carcinogenesis (Glebov et al., 2003), however, the 
molecular mechanisms underlying this observation are poorly understood. The 
development of tumors along different tumorigenic pathways may partly be due to 
differences between the normal proximal and distal colon, e.g. in the embryonic origin, 
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vascularization, crypt length, apoptosis rate and metabolism (Iacopetta, 2002). The 
Dro1
-/-
;Apc
+/Min
 mouse model may provide further evidence that cancers of the proximal 
and distal colon are under the influence of different molecular pathways. 
 
To investigate a possible effect of Dro1 loss on Wnt signaling activation and 
proliferation in tumors from Apc
+/Min
 mice, immunohistochemical staining for β-catenin 
and Ki-67 were performed on a subset of tumors from moribund Dro1
-/-
;Apc
+/Min
 and 
Apc
+/Min
 control mice. As expected from Apc inactivation in tumors from Apc
+/Min
 mice 
(Luongo et al., 1994; Shoemaker et al., 1997), pronounced nuclear β-catenin staining 
was observed in all tumors analyzed, independently of the Dro1 status. Dro1 loss did 
not impact the mean percentage and distribution of cells with nuclear β-catenin 
accumulation within the neoplastic tissue. In addition, β-catenin localization in adjacent 
normal intestinal epithelium was unaffected by Dro1 deficiency. As nuclear β-catenin 
accumulation is viewed as a hallmark of canonical Wnt signaling activation 
(MacDonald et al., 2009), these results offer strong evidence that changes in colonic 
tumor multiplicity and neoplastic progression in Dro1
-/-
;Apc
+/Min
 mice are most 
probably mediated by pathways other than Wnt/β-catenin signaling. 
Ki-67 immunohistochemical staining showed that cellular proliferation indices were not 
significantly different between colonic tumors from moribund Dro1
-/-
;Apc
+/Min
 and 
Apc
+/Min
 control mice, indicating that alterations in cellular proliferation are likely to 
play only a minor role, if any, in the observed phenotypic alterations.  
 
Elimination of Dro1 was not found to impact ACF formation in Apc
+/Min
 mice. ACF, 
putative precursors of adenomas (McLellan and Bird, 1988a; Fenoglio-Preiser and 
Noffsinger, 1999; Boivin et al., 2003), have been observed in some mouse models of 
intestinal cancer (Reitmair et al., 1996; Pretlow et al., 2003) and have been 
demonstrated to be a regular event after treatment with colon carcinogens (McLellan 
and Bird, 1988a; McLellan and Bird, 1988b). In the untreated Apc
+/Min
 mouse ACF are 
known to be rare or absent (Reitmair et al., 1996; Song et al., 2000; Boivin et al., 2003). 
 
The Mom1 allele is known to exert a strong influence on tumor burden in Apc
+/Min
 mice 
(Gould et al., 1996; McCart et al., 2008). It has been previously shown that Apc
+/Min
 
mice carrying the Mom
R
 allele exhibit a significant decrease in tumor multiplicity 
compared to animals on the Mom
S/S
 background (Gould et al., 1996). Analysis of the 
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Mom1 allelic status in Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 control mice revealed that both 
lines carried the Mom
S
 allele homozygously. This finding clearly demonstrates that 
differences in colonic polyp numbers between Dro1
-/-
;Apc
+/Min
 and Apc
+/Min
 control 
mice are not modulated by differences in the Mom1 allelic status. 
  
Another important observation is that Dro1 deficiency did not result in obvious effects 
on number, size or histopathologic quality of polyps in the small intestine of Apc
+/Min
 
mice, indicating that the Dro1 tumor suppressor gene function in the intestinal tract is 
confined to the colon. Recent investigations on the gene expression in the murine 
intestinal tract have uncovered site-specific differences between the small intestine and 
colon (Klostermeier et al., 2011). It is therefore conceivable that differences in gene 
expression pattern between small and large intestine are responsible for the restriction 
of the tumor suppressor activity of Dro1 to one compartment.  
 
In summary, the analysis of the first Dro1 knockout mouse model clearly demonstrates 
Dro1 to be an important colonic tumor suppressor gene that suppresses polyp initiation 
and particularly prevents tumor progression towards malignancy in Apc
+/Min
 mice. 
Further studies are needed to clarify the underlying mechanisms for the phenotypic 
alterations observed in Dro1
-/-
;Apc
+/Min
 mice.  
Human colorectal cancer is assumed to develop from adenomatous precursor lesions by 
the accumulation of multiple independent somatic alterations in oncogenes and tumor 
suppressor genes (Fearon, 2011). Inactivating mutations of the APC tumor suppressor 
gene are viewed as an early if not initiating event in up to 80% of human sporadic 
colorectal cancers and implicate the development of a multitude of adenomas in the 
colon and rectum of FAP patients (Giles et al., 2003; Fearon, 2011). Our findings 
strongly suggest that loss of DRO1 may be a critical step in colorectal cancer 
development by promoting progression to malignancy in adenomas with APC 
inactivation. This role of DRO1 is supported by the fact that DRO1 expression has been 
shown to be highly reduced in the majority of primary colorectal cancer specimens and 
in numerous colorectal cancer cell lines (Bommer et al., 2005).  
 
5.3 Effects of Dro1 loss on body growth 
Under standard feeding conditions, Dro1
-/-
 mice showed normal development until 10 
(males) and 12 (females) weeks of age, after which a significant increase in body weight 
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was observed as compared to gender-matched controls. Analysis of body composition 
in young males from weeks 4 to 15 by MRI showed that Dro1 loss causes a mild 
increase in total body fat by week 14. At the age of 6 months, the observed differences 
in body weight primarily originated in substantially enlarged epididymal, subcutaneous, 
and abdominal white fat pads. Our findings demonstrate that loss of Dro1 causes 
spontaneous, widespread late-onset obesity, indicating a crucial role for Dro1 in energy 
homeostasis and body weight regulation.  
 
When exposed to a high-fat diet for 16 weeks (starting from the 11
th
 day of age), 
increases in body weight and body fat developed earlier, and remained significantly 
higher after week 8 as compared to diet-matched controls. Moreover, high-fat diet-fed 
Dro1
-/-
 mice exhibited a significant increase in body mass and body fat when compared 
to age-matched, normal-fed counterparts. These findings show that the overweight 
phenotype under standard feeding conditions was not maximal but can further be 
enhanced by diet.  
 
Femur and nose-rump-length were unchanged in 6-month-old Dro1
-/-
 mice, 
demonstrating that longitudinal growth was not affected by disruption of the Dro1 gene. 
This finding offers clear evidence that the observed changes in body mass do not result 
from alterations in body length. The overweight in Dro1
-/-
 mice was further confirmed 
by a significant increase in relative nose-rump-length, calculated as body weight per cm 
body length.  
 
Six-month-old normal-fed and 17-week-old high-fat diet-fed Dro1
-/-
 mice exhibited a 
significant increase in the absolute and relative weight of the major white fat pads. 
Examination of H&E-stained tissue sections from the cranial tip of epididymal white 
adipose tissue revealed no pathologic alterations, regardless of the feeding condition. 
During the development of obesity, white adipose tissue expansion can be accomplished 
by an increase in adipocyte size as well as by the addition of new adipocytes by 
adipogenesis (Hausman et al., 2001; Vazquez-Vela et al., 2008). White adipose tissue 
stromal vascular (SV) cells, a fraction enriched for preadipocytes, are often used as a 
model system to investigate adipogenesis (Gregoire et al., 1998; Hausman et al., 2008; 
Poulos et al., 2010). SV cells were isolated from inguinal white fat pads from 3-week-
old Dro1
-/-
 and control mice, grown confluent and differentiated into mature adipocytes. 
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The differentiated Dro1
-/-
 SV culture exhibited a significant increase in multiplicity and 
size of accumulated oil red O-stained lipid droplets, demonstrating that Dro1 loss 
promotes lipid accumulation in SV cells after the induction of adipocyte differentiation. 
As the number of preadipocytes was not investigated in the freshly isolated SV cell 
fraction, it cannot be excluded that the observed rise in lipid droplet frequency may 
partly be due to an increase in the initial number of adipocyte progenitor cells. Lipid 
accumulation represents one of the hallmarks of adipocyte differentiation (Gregoire et 
al., 1998; Hausman et al., 2001). It is therefore probable that Dro1 loss enhances the 
differentiation potential in SV cells, offering evidence that Dro1 exerts an inhibitory 
effect on the maturation of preadipocytes to adipocytes. It is also tempting to suggest 
that excess body fat in Dro1
-/-
 mice may partly result from deregulated adipogenesis, 
increasing the total number of adipocytes in white adipose tissue. The enhanced 
adipocyte quantity would be available for additional lipid deposition resulting in 
obesity. This hypothesis is supported by the fact that 6-month-old normal-fed Dro1
-/-
 
mice showed a significant decrease in the level of serum triglycerides. White adipose 
tissue is the primary site for the metabolism of circulating triglyceride-rich lipoproteins 
by releasing non-esterified fatty acids by the action of the adipocyte-derived lipoprotein 
lipase (Bamba and Rader, 2007). It can also be speculated that an increase in adipocyte 
multiplicity would imply more cells for lipoprotein lipase synthesis and triglyceride 
uptake, leading to a decrease in the level of circulating triglycerides. Future work is 
needed to investigate the effect of Dro1 loss on adipose tissue cellularity and 
triglyceride turnover in detail.  
 
Our results are in sharp contrast to previous findings that noted impaired adipogenesis 
and lipid accumulation in 3T3-L1 cells following down-regulation of Dro1 by siRNA 
(Tremblay et al., 2009). The 3T3-L1 preadipocyte cell line was isolated from Swiss 3T3 
mouse cells derived from disaggregated 17- to 19- day embryos and contains a single 
cell type (Gregoire et al., 1998; Poulos et al., 2010). In contrast, primary SV cells 
include mesenchymal stem cells, T regulatory cells, endothelial precursor cells, 
preadipocytes and macrophages (Hausman et al., 2008; Poulos et al., 2010). It has been 
noted that the patterns and models of adipogenesis derived from established cell lines 
can dramatically differ from those seen with primary cells (Gregoire et al., 1998; Poulos 
et al., 2010). It is therefore most probable that the contrasting results obtained from 
3T3-L1 and SV cells upon down-regulation/loss of Dro1 may be due to metabolic and 
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physiologic differences between the adipogenic cell models employed. As SV fractions 
contain various cell types, the in vitro conditions may mimic in vivo conditions of 
adipose tissue complexity more closely than cultures of a single cell type (Poulos et al., 
2010).  
 
An important finding is that loss of Dro1 function causes a profound rise in lean mass 
from week 9 onwards, demonstrating the contribution of non-adipose tissue mass to the 
overweight phenotype. In Dro1
-/-
 mice, maintenance on a high-fat diet for 16 weeks 
starting from the 11
th
 day of age caused a substantial increase in lean mass as compared 
to age-matched, normal-fed counterparts. In accordance to previous data on diet-
induced obesity in C57BL/6 mice (Park et al.; 2005; Matyskova et al., 2008), high-fat 
diet feeding had no effect on lean mass in control mice.  
At the age of 2 months, when body weight of Dro1
-/-
 mice was not significantly 
different from that of control mice, absolute and relative spleen weight was significantly 
increased in Dro1
-/-
 males. At the age of 6 months a significant rise in liver, spleen and 
carcass weight was detected in both genders of Dro1
-/-
 mice as compared to age- and 
gender-matched controls. Moreover, the weight of lungs and kidneys was profoundly 
increased in 6-month-old Dro1
-/-
 males. In 17-week-old high-fat diet-fed Dro1
-/-
 mice, 
the absolute weight of lungs, liver, spleen and kidneys was significantly increased. 
These findings indicate an important role for Dro1 in the growth of these organs. 
Changes in absolute weight did not persist when related to body weight, demonstrating 
that increases in organ weight were proportional to the rise in body mass. In 6-month-
old normal-fed females, the relative weight of heart and kidneys was significantly 
decreased. The same was true for heart, lungs and kidneys under high-fat diet feeding, 
demonstrating that increases in absolute weight were insufficient to follow the increase 
in body weight. Furthermore, 6-month-old normal-fed and 17-week-old high-fat diet-
fed Dro1
-/-
 mice exhibited a significant rise in the absolute weight of carcass. Under 
high-fat diet feeding conditions, the increase was disproportional to the increase in body 
weight. The carcass is a complex structure composed of muscle, bone, connective tissue 
and fat. Thus, further studies are needed to clarify the effects of Dro1 loss on carcass 
composition.  
Examination of H&E-stained tissue sections of various organs from normal-fed 2- and 
6-month-old Dro1
-/-
 mice showed no histopathologic changes. When exposed to a high-
fat diet for 16 weeks Dro1
-/-
 mice exhibited severe hepatosteatosis that was 
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accompanied by a minor Kupffer cell aggregation and a slight pericellular and 
perisinusoidal fibrosis. Hepatosteatosis did not progress to steatohepatitis. No 
histopathologic changes were observed in the livers from diet-matched controls. 
Increased lipid deposition was further confirmed by a significant rise in the level of 
triglycerides in homogenized liver samples. In Dro1
-/-
 mice, maintenance on a high-fat 
diet implicated a profound rise in total body fat compared to normal-fed counterparts 
and high-fat diet-fed controls. As excess body fat is known to be a major risk factor for 
the development of fatty liver disease (Hebbard and George, 2010; Cohen et al., 2011), 
it is reasonable to suggest that lipid deposition in livers from high-fat diet-fed Dro1
-/-
 
mice develops secondary to the severe obesity caused by Dro1 loss.  
 
As demonstrated by intraperitoneal glucose tolerance test, 14-week-old standard-fed 
Dro1
-/-
 mice showed normal fasted blood glucose and cleared glucose from the blood as 
efficiently as controls, offering strong evidence that glucose metabolism is unaffected 
by Dro1 loss. However, 14-week-old high-fat diet-fed Dro1
-/-
 mice exhibited glucose 
intolerance characterized by a significant increase in fasted blood glucose and a 
substantially decreased ability to eliminate glucose from the blood as compared to diet-
matched controls. The impaired glucose tolerance was associated with insulin 
resistance, characterized by a significantly decreased glucose lowering rate after insulin 
injection as compared to controls. Excess body fat accumulation is known to be a major 
risk factor for the development of type 2 diabetes (Bays et al., 2008). It is therefore 
likely that changes in glucose metabolism in high-fat diet-fed Dro1
-/-
 mice are 
secondary to obesity. 
 
Free fatty acid serum levels were unchanged in 2- and 6-month-old normal-fed Dro1
-/-
 
mice as compared to diet-matched controls. The same was true after maintenance on a 
high-fat diet for 16 weeks. In general, circulating free fatty acids are a net result of the 
amount of free fatty acids released from adipose tissue and free fatty acids taken up by 
liver, skeletal and cardiac muscle (Karpe et al., 2011). These results therefore indicate 
that Dro1 is most probably not involved in the turnover of free fatty acids. 
 
In summary, our results demonstrate that Dro1 plays a crucial role in body growth as 
Dro1 loss causes the development of general late-onset obesity and stimulates the 
growth of lungs, liver, spleen, kidneys and carcass. Moreover, we identified Dro1 as a 
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putative inhibitor of adipogenesis in vitro, suggesting that Dro1 might control fat cell 
multiplicity in white adipose tissue depots. In the development of obesity, excess energy 
is initially stored by an increase in fat cell size, however, once a critical cell size has 
been reached, further energy storage is accomplished by the addition of new adipocytes 
by adipogenesis (Hausman et al., 2001; Guilherme et al., 2008). Impaired adipogenesis 
implicates excessive adipocyte hypertrophy which is thought to be one of the major risk 
factors for the development of metabolic disease (Bays et al., 2008). As Dro1 
expression impairs the maturation of preadipocytes to adipocytes in SV cells, our 
findings suggest that down-regulation of Dro1 in adipose tissue might be a critical step 
to allow an increase in the number of adipocytes for further energy storage. This 
suggestion is supported by the fact that Dro1 was shown to be down-regulated in 
epididymal white adipose tissue of several obese mouse models (Okada et al., 2008). 
 
Previously, DRO1 was demonstrated to be secreted from 3T3-L1 mature adipocytes and 
was therefore supposed to be a novel adipokine that might influence whole body energy 
homeostasis (Tremblay et al., 2009). In the future, a detailed analysis of energy 
homeostasis in Dro1
-/-
 mice could improve our understanding of Dro1 functions in the 
development of obesity and provide valuable information on potentially involved 
signaling pathways. 
 
5.4 Final considerations 
The Apc
+/Min
 mouse represents a widely used, well-characterized mouse model of 
intestinal neoplasia. However, the usefulness of Apc
+/Min
 mice for the study of 
colorectal carcinogenesis is limited since Apc
+/Min
 mice mainly develop adenomas of the 
small intestine and only few lesions in the colon. Moreover, progression to malignancy 
is rare, a fact that is probably due to the short lifespan of Apc
+/Min
 mice (Shoemaker et 
al., 1997; McCart et al., 2008). In the present study, we demonstrate that inactivation of 
Dro1 on the Apc
+/Min
 background strongly enhances tumor multiplicity in the colon and 
frequently leads to the development of colonic adenocarcinomas. Thus, Dro1
-/-
;Apc
+/Min
 
mice recapitulate the characteristics of human sporadic colorectal cancer and inherited 
FAP more closely than Apc
+/Min
 animals. The Dro1
-/-
;Apc
+/Min
 mouse model described 
here may therefore facilitate the study of colorectal tumorigenesis, the role of other 
genes in adenoma-carcinoma transition, and potential cancer prevention and treatment 
strategies.  
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There is accumulating evidence suggesting that greater body fatness and greater 
abdominal fatness are associated with an increased risk to develop cancer of the 
colorectum (World Cancer Research Fund, 2007). However, until today, the 
mechanisms underlying this observation remain widely unknown. As Dro1 loss results 
in the development of general late-onset obesity characterized by significantly enlarged 
epididymal, abdominal and subcutaneous white fat pads, the Dro1
-/-
 mouse model could 
provide a valuable tool to investigate the correlation between obesity and colorectal 
cancer. 
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6. Summary  
Effects of Dro1 loss on colorectal carcinogenesis and body growth in a constitutive 
knockout mouse model 
Previous studies suggested DRO1 to be a putative tumor suppressor gene that is down-
regulated in various colorectal and pancreatic cancer cell lines, in the majority of 
colorectal cancer specimens (Bommer et al., 2005) and in thyroid neoplastic cell lines 
and carcinomas (Visconti et al., 2003). Re-expression of DRO1 in several cancer cell 
lines reduced their malignant growth properties (Bommer et al., 2005) and induced their 
sensitization to pro-apoptotic stimuli (Bommer et al., 2005; Ferragud et al., 2011).  
DRO1/Dro1 is a gene predominantly expressed in white adipose tissue with 
considerably lower expression levels in other tissues (Aoki et al., 2002; Liu et al., 2004; 
Bommer et al., 2005; Okada et al., 2008; Tremblay et al., 2009). Dro1 was 
demonstrated to be profoundly decreased in epididymal white adipose tissue of several 
obese mouse models (Okada et al., 2008). In 3T3-L1 cells, Dro1 was implicated as a 
bidirectional modulator of adipogenesis (Tremblay et al., 2009). Moreover, DRO1 was 
found to be a secreted protein from 3T3-L1 adipocytes, indicating a role as novel 
adipokine that might influence adipose tissue homeostasis and whole body energy 
metabolism and might be involved in the development of obesity (Tremblay et al., 
2009).  
The aim of the present study was to investigate the effects of Dro1 loss on colorectal 
carcinogenesis and body growth in vivo. We therefore generated the first knockout 
mouse model in which the Dro1 gene is constitutively inactivated (Dro1
-/-
) using a 
Cre/lox-P strategy. Genetic deletion of Dro1 by Cre-recombinase was demonstrated by 
Southern blot and further confirmed by PCR analysis. RT-PCR demonstrated no 
significant Dro1 expression in various organs from Dro1
-/-
 mice, suggesting a high 
efficiency of Dro1 depletion. Dro1
-/-
 mice were viable and fertile and showed no 
changes in lifespan. 
Loss of Dro1 had no effects on length and wet weight of the intestine. Moreover, no 
changes in cell maturation, positioning and the rate of proliferation and apoptosis were 
observed in the intestinal epithelium. Dro1
-/-
 mice did not develop intestinal tumors 
spontaneously. To investigate the effects of Dro1 loss on intestinal tumor formation, 
Dro1
-/-
 mice were crossed into the Apc
+/Min
 background, a widely used intestinal tumor 
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mouse model (Moser et al., 1990). Dro1
-/-
;Apc
+/Min
 mice were characterized by 
significantly reduced survival and a striking increase in colonic tumor multiplicity as 
compared to Apc
+/Min
 controls. Specifically, Dro1 loss promoted progression to 
malignancy in colonic tumors from Apc
+/Min
 mice. Approximately one third of colonic 
tumors from moribund Dro1
-/-
;Apc
+/Min
 mice had progressed to malignancy whereas 
colonic lesions from Apc
+/Min
 controls resembled tubular adenomas.  
Changes in colonic tumor multiplicity and neoplastic progression in Dro1
-/-
;Apc
+/Min
 
mice are most probably mediated by pathways other than Wnt/β-catenin signaling and 
alterations in cellular proliferation are likely to play only a minor role, if any, in the 
observed phenotypic alterations. Dro1 deficiency did not result in obvious effects on 
number, size or histopathologic quality of polyps in the small intestine of Apc
+/Min 
mice, 
suggesting a site-specific tumor suppressor role in the colon. Our findings clearly 
demonstrate Dro1 to be an important colonic tumor suppressor gene that suppresses 
polyp initiation and particularly prevents tumor progression towards malignancy in 
Apc
+/Min
 mice. 
Dro1
-/-
 mice showed normal development until 10 (males) and 12 (females) weeks of 
age, after which a significant increase in body weight was observed that was not 
mediated by changes in longitudinal growth. At the age of 6 months, Dro1
-/-
 mice 
exhibited substantially enlarged major white fat pads and a significant rise in the weight 
of lungs, liver, spleen, kidneys and carcass. The effects of Dro1 loss on body, organ and 
fat pad growth could further be enhanced by high-fat diet feeding conditions. Isolation 
and differentiation of white adipose tissue stromal vascular (SV) cells revealed that 
ablation of Dro1 significantly enhances the differentiation potential of these cells. Our 
results demonstrate a significant role for Dro1 in whole body growth. Moreover, we 
identified Dro1 to be a putative inhibitor of adipogenesis in primary SV culture, 
indicating a probable role in controlling fat cell multiplicity in white adipose tissue 
depots. 
The Dro1
-/-
;Apc
+/Min
 mouse model described here is likely to facilitate efforts to study 
colorectal tumorigenesis mechanisms, the role of other genes in adenoma-carcinoma 
transition and potential cancer prevention and treatment strategies. In addition, the 
Dro1
-/-
 mouse model may provide a valuable tool to investigate the correlation between 
obesity and colorectal cancer. 
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7. Zusammenfassung 
Auswirkungen des Verlustes von Dro1 auf die kolorektale Karzinogenese und das 
Körperwachstum in einem  konstitutiven Knockout-Mausmodell 
Vorangehende Untersuchungen konnten zeigen, dass die DRO1 Expression in 
verschiedenen Kolonkarzinom- und Pankreaskrebszelllinien und in der Mehrzahl 
kolorektaler Primärkarzinome stark vermindert ist (Bommer et al., 2005). 
Entsprechendes wurde für Schilddrüsenkrebszelllinien und -karzinome berichtet 
(Visconti et al., 2003). Eine Reexpression von DRO1 in verschiedenen Krebszelllinien 
reduziert deren maligne Wachstumseigenschaften (Bommer et al., 2005) und erhöht 
deren Sensitivität gegenüber pro-apoptotischen Stimuli (Bommer et al., 2005; Ferragud 
et al., 2011). Ausgehend von diesen Befunden, wurde vermutet, dass DRO1 ein 
potentielles Tumorsuppressorgen ist (Bommer et al., 2005). 
Es ist bekannt, dass DRO1/Dro1 ubiquitär, vor allem jedoch im weißen Fettgewebe 
exprimiert wird (Aoki et al., 2002; Liu et al., 2004; Bommer et al., 2005; Okada et al., 
2008; Tremblay et al., 2009). Eine starke Verminderung der Dro1 Expression wurde im 
epididymalen weißen Fettgewebe verschiedener Adipositas-Mausmodelle nachgewiesen 
(Okada et al., 2008). Untersuchungen in 3T3-L1 Zellen weisen darauf hin, dass Dro1 
ein bidirektionaler Modulator der Adipogenese ist (Tremblay et al., 2009). Es konnte 
gezeigt werden, dass DRO1 von 3T3-L1 Adipozyten sezerniert wird (Tremblay et al., 
2009). Dies lässt vermuten, dass DRO1 ein neues Adipokin sein könnte, das eine 
wichtige Funktion in der Homöostase des weißen Fettgewebes, in der Regulation des 
Energiehaushaltes und in der Entwicklung von Adipositas übernimmt (Tremblay et al., 
2009). 
Das Ziel der vorliegenden Studie war es, die Folgen eines Verlustes von Dro1 auf die 
kolorektale Karzinogenese und des Körperwachstums in vivo zu untersuchen. Aus 
diesem Grund haben wir unter Verwendung des Cre/lox-P-Systems das erste 
Mausmodell generiert, in welchem Dro1 konstitutiv inaktiviert ist. Southern blot und 
weiterführende PCR Analysen bestätigten die korrekte Rekombination durch die Cre-
Rekombinase im Dro1 Gen. Zudem konnte mit RT-PCR keine signifikante Dro1 
Expression in verschiedenen Organen der Dro1
-/-
 Maus nachgewiesen werden. Dro1
-/-
 
Mäuse waren lebensfähig, fertil und zeigten keine Veränderung in der 
Lebenserwartung. 
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Der Verlust von Dro1 hatte keinen Einfluss auf die Länge und das Nassgewicht des 
Darms. Im intestinalen Epithel konnten keine Veränderungen in der Zellausreifung und 
-positionierung sowie in der Proliferations- und Apoptoserate beobachtet werden. Da 
Dro1
-/-
 Mäuse keine spontanen Darmtumoren bilden, wurden sie in den Apc
+/Min
 
Hintergrund eingekreuzt, ein gut etabliertes intestinales Tumormausmodell (Moser et 
al., 1990). Im Vergleich zu Apc
+/Min 
Kontrolltieren zeigten Dro1
-/-
;Apc
+/Min 
Mäuse eine 
signifikant reduzierte Lebenserwartung und eine bedeutende Erhöhung der Tumorlast 
im Kolon. Im Besonderen fördert der Verlust von Dro1 die Progression vom Adenom 
zum Karzinom im Kolon von Apc
+/Min
 Mäusen. Ungefähr ein Drittel der untersuchten 
Kolontumoren aus moribunden Dro1
-/-
;Apc
+/Min
 Mäusen wurden als Adenokarzinome 
identifiziert, wohingegen alle Tumoren aus dem Kolon der Apc
+/Min
 Kontrollmäuse 
Adenome waren.  
Die beobachteten Veränderungen in der Tumorzahl und Tumorprogression in Dro1
-/-
;Apc
+/Min
 Mäusen werden höchstwahrscheinlich durch andere Signalwege als den 
kanonischen Wnt/β-catenin Signalweg vermittelt. Auch spielen Veränderungen der 
Proliferationsrate im Tumorgewebe keine oder nur eine untergeordnete Rolle für die 
Ausbildung des Darmphänotyps in Dro1
-/-
;Apc
+/Min
 Mäusen. Der Verlust von Dro1 hatte 
keinen Einfluss auf die Anzahl, Verteilung und Histologie der Tumoren im Dünndarm 
von Apc
+/Min
 Mäusen. Dies weist darauf hin, dass die Tumorsuppressorfunktion von 
Dro1 spezifisch für das Kolon ist. Unsere Befunde zeigen deutlich, dass Dro1 ein 
wichtiges Tumorsuppressorgen im Kolon in vivo ist, das die Tumorinitiation 
unterdrückt und im Besonderen die Tumorprogression in Apc
+/Min
 Mäusen verhindert.   
Dro1
-/-
 Mäuse entwickelten sich normal bis zur 10. (Männchen) bzw. 12. (Weibchen) 
Lebenswoche. Danach wurde eine signifikante Erhöhung des Körpergewichts 
beobachtet, die nicht mit Veränderungen des Längenwachstums einherging. Im Alter 
von 6 Monaten zeigten Dro1
-/-
 Mäuse stark vergrößerte weiße Fettdepots und eine 
signifikante Erhöhung des Gewichts von Lunge, Leber, Milz, Niere und Karkasse. Das 
Füttern einer fettreichen Diät verstärkte die Auswirkungen des Verlusts von Dro1 auf 
die Körpergewichtsentwicklung und das Wachstum der Organe und Fettdepots. 
Isolierung und Differenzierung von primären Stromazellen (stromal vascular (SV) cells) 
aus weißem Fettgewebe zeigten, dass der Verlust von Dro1 zu einer Steigerung des 
Differenzierungspotentials in diesen Zellen führt. Unsere Ergebnisse demonstrieren, 
dass Dro1 eine bedeutsame Rolle im Körperwachstum spielt. Des Weiteren wurde Dro1 
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in primären SV Zellen als potentieller Inhibitor der Adipogenese identifiziert. Dies 
weist darauf hin, dass Dro1 die Anzahl der Adipozyten im weißen Fettgewebe 
kontrollieren könnte. 
Das hier beschriebene Dro1
-/-
;Apc
+/Min
 Mausmodell sollte die zukünftige Erforschung 
der kolorektalen Karzinogenese, der Funktion weiterer Gene in der Adenom-Karzinom-
Sequenz sowie potentieller Krebsvorsorge und -behandlungsmethoden vorantreiben. 
Des Weiteren könnte die Dro1
-/-
 Maus ein wertvolles Modell sein, um den 
Zusammenhang zwischen Adipositas und der Entstehung des Kolonkarzinoms 
aufzuklären. 
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